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Over the past decades the face of medicine has changed radically for patients with cardiac 
disease. Advances in research and developments in technology, coupled with a significant 
global increase in spending on health-related issues has caused a significant improvement 
in life expectancy [1-3]. This positive trend has impacted the lives of many, but especially of 
those suffering from congenital heart disease (CHD) (figure 1) [4]. The introduction of the 
heart-lung machine and other advance in the second half of the 20th century had a 
dramatic impact on the outcome of patients with severe congenital heart disease, where 
previously only 15% of patients reaching adulthood, now more than 90% of patients reach 
adulthood [5]. 
The Bicuspid aortic valve (BAV) is the most frequent congenital heart defect [6], with a 
prevalence of approximately 2% in the general population [6, 7]. Despite its frequent 
occurrence, we know relatively little about its etiology, natural history and optimal 
treatment. Importantly, in 50% of BAV patients dilatation of the ascending aorta occurs, 
adding to the elevated risk of aortic dissection. Turner syndrome (TS) is a genetic syndrome 
that is often associated with many different forms of CHD including a bicuspid aortic valve 
[8]. The risk of aortic dissection is elevated in patients with TS and reported to be 6 times or 
even 20 times higher compared with the normal population [9, 10]. 
A third group at risk of aortic dissection are the patients with a SMAD3 genetic mutation. 
This specific mutation was first described by our group in 2011 and the clinical entity was 
called the Aneurysm-Osteoarthritis syndrome. Recently, it became clear that there is 
overlap with other genetic syndromes and currently this syndrome is classified as Loeys-
Dietz syndrome (LDS) type III.  In this thesis we expand upon earlier efforts and describe 
long-term outcome and quality of life in these patients. 
Figure 1. Trends in the 
percentage of all 
congenital heart defect–
related deaths that 
occurred in England and 
Wales between 1959 
and 2009, assessed at 
different ages. CHD 
indicates congenital 
heart disease (Knowles 
et al, 2012). Reprinted 
with permission from 
BMJ Publishing Group 






TS is a genetic disorder that is 
caused by a partial or complete 
monosomy of the X-chromosome, 
which occurs in 1 per 2500 live 
born females [11]and was first 
described by Henry Turner in 
1938 [12]. TS patients may suffer 
from a multitude of disorders 
including short stature, estrogen 
deficiency, infertility and a 
‘webbed neck’ [13]. Additionally, 
Diabetes, hypertension, ischaemic 
heart disease and stroke are 
prevalent and autoimmunity is 
increased, leading to thyroiditis 
(figure) 2 [8]. Care for Turner 
syndrome patients is generally 
provided by a multidisciplinary 
team in a tertiary centre; the 
standard composition of this 
team includes, at a minimum, a 
gynaecologist, endocrinologist-
internist and cardiologist. Recently, the cardiovascular aspects of the syndrome have 
received more attention. Accordingly, current guidelines [14]dictate that every patient 
should consult a cardiologist specialized in congenital cardiology at least once every five 
years. This is especially important as an estimated 50% of women with TS will suffer from 
either congenital or acquired [15, 16]cardiovascular disease. These congenital 
abnormalities complicate care and are the main causes of morbidity and mortality in 
patients suffering from TS [8]. 
Often, these congenital heart defects (CHD) are left-sided, the most prevalent are: a 
bicuspid aortic valve (BAV, 15-30%), elongation of the transverse aortic arch (ETA, 49%) and 
coarctation of the aorta (CoA, 17%) [8, 16]. Additionally, bovine aortic arch, arteria lusoria 
may occur figure 3 [8]. Associated venous lesions frequently include partial abnormal 
pulmonary venous return (PAPVR) and persistent left superior vena cava (LSVC) [16, 17]. 
Other defects, such as a ventricular septal defect  (VSD), are seen less often in TS [18]. 
Women with Turner syndrome also suffer from acquired heart diseases which mainly 
comprise hypertension, aortic dilatation, and dissection [9, 10]. 
Figure 2. Differentiated mortality in TS for all ages and according 
to age groups. Categories were defined according to 
International Classification of Diseases. Numbers are adapted to 
express the percentage of total absolute excess risk caused by 
the group of disorders in question (8). Reprinted with permission 




Genetics of the cardiovascular pathology in TS  
On a genetic level TS and 
Bicuspid aortic pathology 
appear to exhibit some 
interesting similarities. Turner 
syndrome is an ‘aneuploid’ 
condition resulting from the 
complete or partial loss of the 
second sex chromosome [19]. It 
seems that the resulting 
‘deficiency’ of sex chromosome 
genes predisposes individuals 
with Turner syndrome to 
diseases that are known to have 
a sex bias in the general 
population. Such a male 
predisposition is also present in 
patients with a bicuspid aortic valve. Together, the combination of the high incidence of 
BAV in women with Turner syndrome and the substantial sex bias towards males in the 
general ‘euploid’ population together suggest that there is a certain measure of 
‘protection’ conferred by having a second X chromosome [19]. However, while all women 
with TS are by definition ‘aneuploid’ to a degree, certainly not all have a BAV. 
Consequently, one might deduce that a ‘second hit’,  other than this monosomy, is 
necessary to cross the disease threshold (figure 4). Such a second hit, necessary for the 
aortic disease in TS women could be either environmental or epigenetic. 
Recently an important role in 
BAV pathology has been 
described for matrix 
metalloproteinases (MMP’s) 
and their inhibitor (tissue 
inhibitor of 
metalloproteinase, TIMP) 
enzymes that regulate 
extracellular matrix 
breakdown [20]. Especially 
interesting is TIMP-3, which 
was associated with BAV and 
aortic dilatation [21]. 
Downstream, MMP’s, are 
Figure 3.  The most common congenital cardiovascular 
malformation seen in TS.PAPVR, Partial anomalous pulmonary 
venous return; SVC, superior vena cava (8).Reprinted with 
permission from Oxford University Press. (Licence number: 
4676511219970) 
Figure 4. TS genetic hypothesis. The horizontal line represents a 
theoretical threshold of disease. In TS the loss of an X-chromosome 
alone is not sufficient alone to breach the disease threshold for BAV 




inhibited by TIMPs, where TIMP3 specifically controls MMP-2 and 9, which are highly 
expressed in thoracic aneurysm tissue. An unbalance between TIMPs and MMPs has been 
associated with aortic dilatation and dissection, as MMP activity in the tunica media of the 
aorta disrupts the elastin-based extracellular matrix [22-25].  
This theory is supported by a recent study by Corbitt et al., which describes that TIMP3 
exceeds genome-wide significance for the association with BAV and aortic root 
enlargement. However, the TIMP3 gene is located on chromosome 22, whereas previous 
literature suggested that a genetic factor would most likely be located on the short arm of 
the X chromosome (Xp), which has been associated with BAV and aortic aneurysms [26, 
27]. Therefore Corbitt et al. hypothesize a second gene that has a pathogenic interaction 
with TIMP3, is unique to Xp, without a homolog elsewhere, escapes X-inactivation and is 
expressed in the developing aortic valve [19].  
Corbitt el al., find that TIMP1, a functionally redundant paralogue of TIMP3, meets these 
criteria. Additionally, hemizygosity for TIMP 1 increased the chance of BAV aortoparthy, as 
its copy number is associated with BAV and dissection. This hemizygosity for TIMP 1 is 
exacerbated by TIMP3 risk alleles and subsequent loss of inhibition of MMP-2 and MMP-9 
causes degradation of the extra cellular matrix (ECM) of the aortic wall. Subsequently ECM 
degradation leads to a release of active TGF-β which increases TGF-β signalling. In turn this 
increase in TGF-β signalling creates a positive feedback loop by increasing MMP expression 
and thereby aggravating the TIMP/MMP imbalance (29) and, eventually, aneurysm 
formation [19].This feedback loop may be the ‘second hit’ needed to progress from 
progenitor stages to the aortopathy often seen in Turner syndrome. This hypothesis 
provides an important foundation on which further studies can build.  
Aortic dissection and dilatation 
The frailty of the aortic wall that develops via the supposed pathophysiological mechanism 
described above may cause aortic dilatation, or even aortic dissection. This potential 
dilatation and dissection pose a serious clinical concern in patients with TS. The estimated 
prevalence of aortic dissection in women with TS varies greatly in literature, [9, 10] where 
the most recent and only prospective study estimates the incidence at 354 cases per 100 
000 person-years. This is up to 12 times higher compared to the general female population 
[28]. And in TS aortic dissection is not exclusive to patients of old age, as peak incidence is 
observed  in the third to fifth decade of life and dissection may even occur in the first 
decade of life [10, 29]. Additionally, in women with TS the diameter of the ascending aorta, 
where the dissection often originates [9, 10, 30], may be smaller on average than in those 





Even more challenging than estimating the incidence of dissection, is discerning risk factors 
for dissection. Some classic risk markers include: hypertension, karyotype 45,X, and left-
sided obstructive lesions including bicuspid aortic valves, coarctation of the aorta, and 
other obstructive arch lesions [8]. Aortic size is another important risk factor for dissection 
and aortic dilatation is quite common in TS women. As described above, the aetiology of 
the dilatation in TS is not yet fully understood. However, the histological changes such as 
cystic medial degeneration are reported in 42 to 72% of aortic dissections in TS [10, 32]. 
Additionally, collagen fiber composition may also be affected [10]. These changes in 
vascular smooth muscle cells, elastin, collagen, and other extracellular matrix components 
are not exclusive to TS as they are also encountered in other thoracic aneurysm diseases 
[32]. However, it is hard to discern a primary genetic cause from an environmental cause as 
aortic disease in TS is attenuated by common risk factors such as hypertension and 
hyperlipidaemia which end in mechanical and elastic failure of the aortic wall [33-35]. 
The Bicuspid aortic valve and aortic coarctation 
Leonardo da Vinci first described the bicuspid 
aortic valve [36], the most prevalent congenital 
heart defect in humans that affects 1-2% of the 
population [6, 7](BAV; figure 5), some five 
hunderd years ago. The number of publications 
on the bicupsid aortic valve increased 
exponentially over the past century (figure 6). A 
normal aortic valve consists of three leaflets and 
is therefore called tricuspid. Conversely, a 
bicuspid aortic valve exists in different 
configurations (figure 7) and consists of two 
leaflets. Depending on the raphe, different types can be discerned. The commissural fusion 
between the left and right coronary cusp (Type 1, 
LR-BAV) is the most common [37]. While the BAV 
anatomy may not intrinsically hamper valvular 
function, it is commonly associated with several 
adverse outcomes such as: valve dysfunction, 
(either stenotic or insufficient, requiring surgical 
intervention), bacterial endocarditis, and aortic 
dilatation and dissection [38-40]. The outcome 
differs substantially on a patient level and clinical 
predictors are difficult to discern, which is why 
the treatment of BAV patients is so challenging. 
Therefore discovering the etiology of BAV and 
Figure 5. Sketch of the aortic valve by 
Leonardo da Vinci 
Figure 6. Research interest as measured by 
number of publications on the bicuspid 




















































discerning moderators from disease mediators is paramoount in accurately predicting 
these morbidities and improving clinical outcome.  
Aortic dilatation in bicuspid aortic valve  
There is much controversy 
around the aortic dilatation that 
is often seen in BAV patients. 
Generally three patterns of aoric 
dilatation can be discerned in 
BAV patients. Aortic dilatation of 
the aortic root and the tubular 
ascending aorta (type 1) has 
been associated with diagnosis at 
older age, aortic valve stenosis, 
and RL-fusion pattern of the 
aortic valve [41-43]. The second 
pattern, where only the tubular 
ascending aorta is involved, is 
often seen in co-occurrence with 
RN-fusion type [41-43]. The third 
type, where only the aortic root is affected is often considered the type where a genetic 
cause is most likely as it is associated with dilatation at young age, male sex, and aortic 
valve inssufficiency [41, 44, 45]. With respect to the etiology, two hypotheses exist. The 
first assumes the existence of common genetic defect that could potentially cause both the 
bicuspid leaflet configuration and the aortic wall frailty and subsequent dilatation. And 
indeed many genes have been associated with the occurence of BAV [46, 47]. More 
recently, MMP’s and their inhibitor proteins TIMP’s have been demonstraded to be of 
influence [20, 22]. The second hypothesis suposes a haemodynamic cause of the dilatation; 
abnormal BAV dynamics may cause perturbations on blood flow patterns and 
hemodynamic stress on the aortic wall, leading to aortic dilation [41, 48, 49].  
The genetic hypothesis is supported by studies showing higher prevalence of aortopathy in 
relatives of BAV patients [50] and autosomal dominant, X-linked, and familial inheritance 
has been described [47]. However, no single gene model can clearly explain BAV 
inheritance. For example, difference in severity of aortic dilatation persist, even in BAV 
patients with normally functioning aortic valves or when aortic diameter is corrected for 
known risk factors such bloodpressure, peak aortic-jet velocity, and left ventricular ejection 
time [40]. Further histological changes, which are often erronously termed ‘cystic medial 
necrosis’ (seeing that they are neither cystic nor necrotic) are frequently found in BAV 
patients and negatively influence the structural integrity and flexibility of the aorta.  
Figure 7. Classification of the bicuspid valve according to Sievers 
(39), Red lines indicate raphe between fused leaflets. Reprinted 





The hemodynamic theory is mainly supported by studies demonstrating regionally 
increased shear stress of the aortic wall depending on the type of bicuspid valve [41, 51, 
52]. This hemodynamic hypothesis is gaining ground and is a promising area of research, 
especially 4D flow MR. However, mapping aortic wall stress is not without its difficulties, 
given that apart from technical challenges, data from healthy control populations is 
necessary in order to identify abnormal flow patterns [53].  
SMAD3  
In 2011 a new genetic mutation was found, these mutations appeared to cause a 
syndromic form of familial osteoarthritis and thoracic aortic aneurysms and dissections 
(TAAD) [54]. The SMAD3 gene encodes for a protein that is part of the transforming growth 
factor (TGF) β pathway. Nowadays, AOS is recognized by most to be a subtype of the Loeys-
Dietz syndrome (LDS) [55]. Oftentimes patients first present with early-onset joint 
abnormalities, while other features include arterial aneurysms and tortuosity [54]. 
Mutations in the SMAD3 gene are thought to be responsible for 2% of familial TAAD [54, 
56]. The underlying SMAD3 variant is responsible for some variation in the age of onset and 
penetrance [57]. Lower age of onset of the first aortic event is observed in individuals with 
a missense mutation in the MH2 domain than in those with halpoinsufficiency variants [57]. 
The aggressive aortic dilatation nessecitates vigilant follow-ups using yearly advance cardio-
vascular imaging in these patients according to a dedicated AOS protocol that was devised 
in the Erasmus MC. However, the longterm outcomes of these patients and how their 
quality of life is affected by their affliction is unknown as of yet. Therefore, Part III of this 
thesis discusses those matters in two separate chapters. 
Figure 8.  
TGF-β binds to the TGF-
β receptor complex 
(TGFBR1 and 2). 
TGFBR1 then activates 
SMAD2 and SMAD3, 
which trimerize with a 
SMAD4. This SMAD 
trimer promote cell 
growth and survival 
after entering the 
nucleus and activating 








This thesis: the BAV-study  
This thesis covers aortic pathology in a broad perspective, but focusses on the pathology 
found in women with Turner syndrome and patients, with a SMAD3 mutation or a bicuspid 
aortic valve.  
It centers around the BAV-study, funded by the Dutch Heart foundation, which was 
designed to find clinical risk markers that predict decline of cardiac function or 
complications in patients with BAV or TS. For that purpose, 187 patients with Turner 
syndrome or a bicuspid aortic 
valve were consecutively 
included in this prospective 
multicenter cohort study; a 
collaboration between the 
Radboud UMC, Leiden UMC 
ande the Erasmus MC. They 
either had a bicuspid aortic 
valve or Turner syndrome. The 
inclusion criteria for the BAV-
patients were age ≥ 18 year and one of the following: [1] aortic stenosis (gradient 
>2.5 m/s), [2] aortic regurgitation (at least moderate) or [3] ascending aortic dilation 
≥40 mm and/or aortic size index >2.1 cm/m2. At baseline and at three-year follow-up the 
study protocol included: blood sampling, cardiopulmonary exercise testing (CPET), twelve-
lead electrocardiogram (ECG), trans thoracic echocardiography (TTE), CT and CMR on the 
same day (figure 8).  
This thesis aims to elucidate the etiologies and pathogenic mechanisms leading to BAV or 
aneurysm formation and find risk factors for disease progression. Furthermore, this thesis 
aims to explore the myriad of cardiovascular abnormalities associated with TS and to study 
their impact on the quality of life of the individual patient in addition to comprehensively 
describing the TS cardiovascular phenotype. This is done with a view to enabling the 
eventual individualization of current treatment protocols and to derive novel therapeutic 
strategies. 
Part I focuses on Turner syndrome, its associated pathologies and the quality of life of TS 
women. The combination of imaging findings and clinical outcomes in patients with a 
bicuspid aortic valve is described in Part II. Finally, in Part III long-term follow-up of aortic 
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Turner syndrome is a complex and divers clinical entity that requires the cooperation of a 
myriad of specialist and allied health professions. One of the first concerns in these patients 
are the congenital and acquired cardiac and aortic pathologies. The cardiac pathology in 
these women ranges from benign to severe and life threatening disease. This chapter 
provides a narrative review of the known cardiovascular disease in women with Turner 
syndrome and describes several theories regarding its origin. Moreover, several of most 







Turner syndrome (TS), a partial or complete monosomy of the X-chromosome, is a genetic 
disorder that occurs in 1 per 2500 live born females [1] and was originally described by 
Henry Turner in 1938 [2]. Patients may suffer from a multitude of disorders including short 
stature, estrogen deficiency,  infertility and a ‘webbed neck’ [3]. The morbidity and 
mortality is significantly higher in these patients [1, 4]. Turner patients’ care is given by a 
multidisciplinary team in a tertiary centre; such a team often comprises of a paediatrician, 
gynaecologist, endocrinologist-internist and cardiologist. In complex patients it may also be 
necessary to involve E.N.T. specialists, clinical-geneticists, ophthalmologists, psychologists, 
orthodontologists and orthopaedic surgeons. Recently the cardiovascular aspect of the 
syndrome has received more attention and according to current guidelines [5] every 
patient should be advised to visit a cardiologist specialized in congenital cardiology at least 
every five years. Due to increasingly complex patient care it is important that all patient 
care providers are aware of the cardiovascular phenotype associated with Turner 
syndrome. In this chapter the various cardiovascular manifestations that may occur in 
patients with Turner syndrome will be presented and the latest insights into the genetic 
aspects of the syndrome will be discussed. 
Genetics 
Females typically have two X-chromosomes, one paternally derived (Xp) and one maternally 
derived (Xm). However, in Turner Syndrome a de novo nondisjunction of the X-chromosome 
can lead to a female with a completely or partially absent X-chromosome, most often the 
paternal X-chromosome. This nondisjunction results in a diverse spectrum of karyotypes, of 
which the non-mosaic 45,X0 monosomy is the most well-known. Other Turner syndrome 
associated karyotypes known to cause are different forms of mosaicism (e.g. 45X/46XX) and 
structurally abnormal X-chromosomes such as iso-chromosomes (e.g.  46X,i(Xq)),  ring 
chromosomes (e.g. 46X,r(X)), deletions (e.g. 46,X,del(X)) and even karyotypes with Y-
chromosomal DNA (e.g. 45,X/46XY).  
The suggestion that the non-disjunction in TS is the result of meiotic factors is unlikely since 
the number of 45,X conceptions is too high to be explained solely by the frequency of 
gametes hypo haploid for a sex chromosome. [6] A loss of sex chromosome after 
conception (a mitotic loss) would better explain the unequal ratio of the parental origin of 
the X-chromosome (male:female, 1:3). Due to the fact that a 46,XX conception would 
generate, upon loss of one X-chromosome during mitosis, a 45,X line with equal paternal 
and maternal origin of the remaining X-chromosome, whereas a 46,XY conception would  




An estimated 1 in every 100 pregnancies start as a Turner syndrome (45,X0) pregnancy. 
However, 99% of these pregnancies do not make it to full term [6]. In about 50% of the 
cases, analysis of peripheral lymphocytes indicates the complete loss of one X-
chromosome, most often the paternal X-chromosome. However, most studies will have an 
inherent bias because 45,X0 will be over-represented in clinical populations since they are 
more prone to display the Turner phenotype. The frequency of the chromosomal pattern 
varies depending on the reason for karyotyping [7]. Karyotype determination that is carried 
out because of prenatal echo findings show a 45,X0 karyotype in 90% of cases, whereas it is 
only 63% in accidental findings.[5]  
In addition, with the use of more sensitive genetic techniques such as fluorescence in situ 
hybridization (FISH) and reverse transcriptase polymerase-chain-reaction (PCR) assays, non-
mosaic 45,X0 prevalence rises to 60% and 74% respectively. This may suggest that the 
survival of non-mosaic karyotypes is an even rarer event than previously assumed. Thus, 
the hypothesis by Hook and Warburton that all Turner syndrome females might actually be 
‘cryptic mosaics’ gains ground. 
However, the question of why the (in 
part) absence of an X-chromosome 
should be so invalidating when 
approximately 50% of the world 
population seems to do fine with one 
X-chromosome still remains. 
 Two main theories exist that try to 
explain the phenotypes found in 
Turner syndrome. A visual depiction of 
both theories is provided in figure 1.  
For the first theory, the X-inactivation 
theory, it is important to understand 
the concept of X-inactivation: when 
fully transcribed somatic cells in 46,XX 
females would result in a surplus of 
transcriptional product. Therefore one 
X-chromosome has to be 
transcriptionally silenced to effectively 
reduce the transcriptional product to 
that of males. However, approximately 
25% of genes on the inactive X-
chromosome escape silencing [8]. 





These genes are predominantly located in two regions called pseudo-autosomal region 1 
and -2 (PAR1 and -2). Of which PAR1 (2.6 Mbp) is located on the end of the p-arms of both 
X and Y chromosomes and PAR2 (320 kbp) is located on the q-arms end. Pseudo autosomal 
regions contain genes that normally escape X-inactivation have a Y-chromosome homolog 
and are inherited like autosomal genes.  
The X-inactivation theory postulates [9] that the haploinsufficiency of these ‘pseudo-
autosomal genes’ on the X-chromosome results in an insufficient dosage to ensure normal 
expression. Which exact genes are contributing to the Turner phenotype is not yet clear, 
but the diverse spectrum of features in TS suggests that multiple genes may contribute. 
Genes located in PAR-1, have already been found; the short-stature-homeobox (SHOX) 
gene is an example. Haploinsufficiency for this gene, one which escapes X-inactivation, 
appears to cause the short stature in TS. More recently a study by Urbach and Benvenitsy 
[10] discovered a gene necessary for placental function (PSF2RA), located in the pseudo 
autosomal region. According to this study deletion of this gene may cause placental 
malfunction leading to high fetal mortality in non-mosaic TS.  
The second theory [11] suggests TS might be the effect of imprinted genes, expressed in a 
mono-allelic fashion, depending on a parental origin cause . Parental imprinting is a form of 
epigenetic regulation that results in parent-of-origin differential gene expression.[12]  It has 
a crucial role in prenatal growth and placentation and will affect the development the 
musculoskeletal system and the brain. Hence, as displayed in figure 1, there is no 
expression when the X-chromosome containing the expressed allele is lost. The loss of 
these active alleles has also been implicated in Prader-Willi syndrome [13]. In non-mosaic 
TS it is often the maternal X-chromosome that is retained [14]. Phenotypical traits in TS 
have been associated with the parental origin of the remaining X-chromosome. 
In conclusion, the genetic aspects of Turner syndrome are not yet fully unravelled. The role 
of imprinting and x-inactivation will have to be investigated further.  
Cardiovascular disease 
Introduction 
An estimated 50% of women with TS will suffer from cardiovascular disease, be it 
congenital or acquired [15, 16]. Various congenital abnormalities complicate care and are 
likely to cause significant morbidity. The congenital heart defects (CHD) are mainly left-
sided, of which a bicuspid aortic valve (BAV, 15-30%), elongation of the transverse aortic 
arch (ETA, 49%) and coarctation of the aorta (CoA 17%) are most prevalent [8, 16]. 
Associated venous lesions include partial abnormal pulmonary venous return (PAPVR) and 




defect  (VSD), common in Down syndrome, are seen less often in TS [18]. The acquired 
heart diseases mainly comprise of hypertension, aortic dilatation, and dissection [19, 20]. 
Etiology 
Genetic disorders such as TS are sometimes first noticed by a pre-natal ultrasound after 
detection of nucheal translucency. This collection of fluid under the skin in the neck region 
is supposed to be a precursor of the webbed neck, one of the classical traits of TS. Sixty-
eight percent of infants with a webbed neck is affected by a genetic syndrome such as 
Down- (37%), Noonan- (5%) or Turner-syndrome (13%)[21]. CHD is detected in sixty 
percent of patients with a webbed neck and in TS a high prevalence of cardiac 
abnormalities, such as aortic coarctation, has also been observed [18, 21-23].  
Therefore, a common causal mechanism from which the multiple CHDs arise has been 
suggested to lie in the disturbance of early lymphangiogenesis [24]. This co-occurrence 
does not necessarily imply a causal relation, since a single gene causing both lymphedema 
and CHDs could theoretically confound this causal relation [23]. And indeed haplo-
insufficiency for the autosomal gene FOXC2;16q seems to cause lymphedema and cardiac 
defects independent of each other [22]. An attempt to further elucidate a causality, genetic 
or otherwise, between lymphangiogenesis and CHD will have to start with a thorough 
understanding of the cardiovascular phenotype.  
Congenital Abnormalities 
As noted above, a large number of cardiovascular malformations exist in TS. For some 
abnormalities the evidence is anecdotal and may not bear any particular association with 
TS. However, as the accuracy of imaging modalities and genetic techniques rises, an 
increasing number of abnormalities are detected in TS and genotype-phenotype 
correlations may become more evident.  
Bicuspid Aortic Valve 
 The earliest description of the BAV dates back to the 15th century when Leonardo da Vinci 
sketched different variants of the aortic valve [25].  Furthermore, the association with 
aortic regurgitation and stenosis has been known for 150 years [26]. With a prevalence in 
the general population of about 0,5% to 2% [27] (males:females, 3:1), it is the most 
prevalent CHD. Approximately one third of these patients will develop serious 
complications that require treatment [28] since a BAV is likely to become stenotic or 
insufficient [29]. From a developmental viewpoint BAV is thought to be more than the mere 
fusion of two cusp leaflets; it is seen as a part of a developmental defect ranging from uni- 
to quadri-cuspid valves [6]. A true bicuspid valve is very rarely seen. More often it is a 




fusion. In this chapter we will focus on the BAV within Turner syndrome and we will discuss 
the BAV in the general population in more detail in a separate chapter. 
The prevalence of BAV in Turner Syndrome ranges quite spectacularly, from as low 10% to 
as high as 39,2% [30], depending on the imaging modality and study population. Autosomal 
dominant, X-linked, and familial modes of inheritance have been reported in the general 
population [27]. BAV is associated with a monosomy 45,X0 and is often seen in combination 
with a coarctation of the aorta[31], but is also associated with acquired diseases, dilatation, 
aneurysm and dissection. Two dimensional and Doppler echocardiography is currently the 
most widely used and least demanding technique to assess valvular function. However, 
some studies suggest it underestimates the prevalence of BAV when compared to MRI [22]. 
Valves that are hard to asses seem to be bicuspid more often, resulting in an 
underestimation by echocardiography. [22] 
Treatment for BAV in TS does not differ from normal, but it is important to note that the 
aorta of BAV patients dilates more quickly than in TAV in the general population, especially 
at the level of the ascendens and sinus [17]. Dilatation does clearly predict dissection, [19] 
however dissection may also occur at normal aortic diameters and it is therefore advisable 
to pay extra attention to TS patients when symptoms occur. The risk of dissection will be 
discussed further below.  
Aortic coarctation 
Aortic coarctation (CoA) is a congenital narrowing of the aorta, distal to the aortic annulus, 
that occurs in 3.4 per 10.000 live births and constitutes 5% of all CHD in the general 
population [32]. It is often seen in combination with a BAV, especially a left and right 
coronary cusp fusion.[22] In TS it is also seen very frequently, ranging from 12% to 17% 
[16].  
The first successful surgical correction was performed in 1945 [33]. Nowadays, aortic 
coarctation is still preferably repaired surgically at an early age. However, lifelong 
surveillance is a necessity since patients remain at risk for re-coarctation and aneurysm 
formation [34-36]. Turner Syndrome (TS) has been associated with CoA and 17% of TS 
patients have a coarctation of the aorta [8]. Moreover, CoA in TS patients is often 
associated with the presence of a bicuspid aortic valve (BAV (RR, 4.6)) [22, 37].  Ho et al. 
recently found that aortic coarctation appeared to be associated with an elongated 
transverse aortic arch (ETA) [16] 
Shinebourne and Elseed [38] hypothesize a haemodynamic pathogenesis of CoA. The 
altered flow patterns could be caused by a left-sided blockage within the fetal circulation, 
resulting in elevated pulmonary pressure and blood flow over the ductus arteriosus. They 




hypoplasia, tortuosity, or coarctation of the aorta in the juxtaductal region. These are all 
abnormalities that also appear in TS and some are predicted to be the result of left-sided 
lymphatic compression of the aortic arch, as hypothesized by Clark [24]. These 
abnormalities also include some right-sided defects (PAPVR, PLVCS), due to backpressure. 
However, we cannot rule out the contribution from genetic regulatory mechanisms to 
these malformations [8].   
Stent implantation has been introduced as a treatment for CoA in the late 1980’s [39], with 
good gradient relief and a low complication rate [39-41]. More recently the aortic arch and 
aortic wall composition in TS have received increasing attention. Changes in vascular 
smooth muscle cells, elastin and collagen fibre appear to contribute to the cardiovascular 
problems in TS [42].  Cystic medial wall necrosis, similar to what can be found in Marfan 
syndrome, has been described in TS and is suggested to be a causative factor of aortic 
dissection [43-45]. The aortic wall certainly appears to be fragile in TS as well.  Stent 
implantation may therefore be associated with a higher risk of complications, especially 
aortic dissection. However, data on the ideal corrective technique of coarctation repair for 
patients with TS is limited, since it is largely based on small case series or case reports and 
are often contradictory [46, 47].  
A recent study [48] has shown that stenting of aortic coarctation may be associated with 
increased risk of especially short term complications, such as aortic dissections. 
Aortic arch abnormalities 
Aortic Arch   
Recently an elongated transverse arch (ETA) has been added to the Turner syndrome 
cardiac phenotype. It is defined by two criteria, firstly an origin of the left subclavian artery 
and secondly an inward indentation of the lesser curvature or kinking at the aortic isthmus. 
[16] It has been reported to occur in approximately half of the patients and is associated 
with a higher blood pressure, aortic coarctation an aberrant right subclavian artery and a 
left superior vena cava. 
Aberrant right subclavian artery 
The aberrant right subclavian artery, or arteria lusoria, is the most common anomaly of the 
aortic arch, which may occur in 0.4% to 2% of the population[49]. In TS however it can 
occur in as much as 8% in women. Its clinical significance lies in the fact that it can cause 
dysphagia [50] and mask the presence of a coarctation by altering the upper to lower blood 
pressure ratio, when measured at the right upper extremity [16]. Little is known about the 







A common origin of the innominate artery and the left common carotid, also known as a ‘bovine 
aortic arch’, is seen in 8% of TS females, but has not yet been correlated with the syndrome [16]. It 
has been described in 13% of the general population 
Venous abnormalities 
In TS the cardiac defects are often left-sided and not many venous abnormalities are 
associated with the syndrome. As stated before, with more advanced imaging techniques, 
anatomy can be mapped in more detail, leading to the discovery of rarer cardiovascular 
malformations.  
PAPVR 
Partial anomalous pulmonary venous return (PAPVR), first described by Winslow in 1739 
[51, 52], is often found by chance during routine check-up and can cause a 
hemodynamically significant left-to-right shunt. Significant shunts (Qp:Qs>1.5:1.0) can 
manifest as right heart volume overload, the onset of pulmonary hypertension [53]  and 
can eventually result in right ventricular hypertrophy or failure [54]. Therefore, this 
necessitates early diagnosis and treatment. The prevalence of PAPVR in TS might be 
underestimated because it is difficult to diagnose via echocardiography. Previously, venous 
abnormalities in TS were relatively unknown and their occurrence was grossly 
underestimated due to this inadequate method of diagnosis. Prandstaller et al. reported in 
a study using echocardiography a PAPVR prevalence of 2.9% [55], however, since MRI and 
CT came in to regular use over the last 5 years, a prevalence of PAPVR in TS has been 
suggested to be as high as 15,7% by Ho et al. [16, 17]. And more recently detailed analyses 
finds PAPVR in almost 25% of Turner syndrome patients [56]. 
Persistent Left vena cava superior 
 A persistent left sided superior vena cava (PLVCS) is seen in 0.3–0.5% of the normal 
population, and in 4,4% of those with CHD [57, 58]. Most often, it is seen incidentally 
during CT scan of the thorax. In addition to the PLVCS (82%-90%), a normal VC can also be 
found[58]. Left to right shunting can be present, as the vein drains into the left atrium in 8% 
of cases, but is often not clinically significant. During fetal development the left anterior 
cardinal vein normally disintegrates, but in some cases this fails to take place. The failure of 
the left anterior cardinal vein to disintegrate results in connections with either the coronary 
sinus (92%) or the left atrium (8%) [58]. 
Interrupted inferior vena cava with azygous continuation 
This venous malformality has been described anecdotally in case reports [59]and has been 
associated with CHD in the past. Very few cases are known in literature, but it can present 




lead to problems during surgical procedures or percutaneous interventions. It is however 
unclear whether any causal relation is present since the prevalence in the general 
population is not known exactly. Larger cohorts with a control population will have to 
specifically be examined for this defect before we can draw any conclusions on its link with 
TS 
Acquired Heart Disease 
Acquired heart disease is a significant cause of morbidity and mortality in TS, as was 
revealed in an article by Mortensen et al [8]. Aortic dilation and dissection are for a large 
part the cause of absolute excess mortality amongst the TS population (SMR 23.6). 
Ischemic heart disease (SMR 2.8) is also a significant contributor to mortality in TS patients 
especially at older age.[8].  
Aortic Dissection 
Acute aortic dissection often presents with a sharp pain, but its clinical presentation is 
often more diverse [61]. The incidence is estimated at 36 per 100.00 TS-years, compared to 
6 per 100.000 patient years in the general population (male:female, 2:1) [20]. Dissection 
also occurs much earlier than in the general population, with 56% of dissections between 
the age of 20 and 40 years, an incidence of 14 per 100.000 before 19 and an average 
dissection age of 35 years (4-64) [20]. However, it remains an infrequent event since TS 
occurs only in 1 per 2500 live-born females and only 1 or 2 of  100  females will develop a 
dissection over their lifetime [8]. Risk factors for dissection in TS include hypertension, 
karyotype 45,X0, BAV, CoA, age and pregnancy [8, 62]. It remains unclear however, 
whether this high rate of dissection can occur separately from the aforementioned risk 
factors, as it does in connective tissue disorders such as Marfan, Loeys-Dietz-syndrome or 
Aneurysms-Osteoarthritis syndrome. Some articles do suggest TS to be a separate risk 
factor for aortic dilatation [62]. 
There is no data on the outcome of the dissection in TS, but there is no reason to suspect it 
to be less severe than in the general population where mortality varies depending on the 
type: 26% for the type A dissection and 10,7% for a type B dissection respectively [61].  
Aortic Dilatation 
Aortic dilatation is very prevalent in TS and is estimated to occur in up to 42% percent of 
patients [15, 18, 43, 63]. Body size and age are the primary determinants of aortic size in TS 
[19] and since patients with TS are generally smaller and have a ‘barrel shaped’ chest, it is 
important to correct their aortic dimensions for body surface area (BSA). Several factors 
such as BAV, hypertension and vessel wall structure contribute to aortic dilatation. 
Presence of a BAV is associated with dilatation of the aortic root and proximal ascending 




aortic media. Recent studies show a clear role for cellular mechanisms underlying the 
dilatation and its prevalence in first-degree relatives of BAV patients [64].  
Therefore, it is particularly important to closely monitor aortic dimensions in females with 
TS. These dimensions should be corrected for body surface, because these females 
generally have a shorter height. Annual intensive follow-up may be justified when absolute 
ascending aortic diameters exceed 40 mm or 2.1cm/m2 [27] and early surgical intervention 
might be necessary in this population. Dutch guidelines advise the use of MRI for the 
follow-up of the aortic diameters in these patients [5] and to use aortic size index  (ASI) to 
determine correct therapy. The guidelines also state that frequent follow-up (1 per 1-2 
years) is justified when ASI >2.0 cm/m2. It is also advisable to consider medicinal treatment 
with beta-blockers and angiotensin receptor blockers to control blood pressure. Elective 
surgery might even be considered when the ASI exceeds 2,5 cm/m2 or when rapid 
progression of the aortic diameter (0,5cm/y) is observed. 
Hypertension 
Aortic root dilatation is closely associated with blood pressure and left ventricular thickness 
and valve type, but does not seem to be affected by atherosclerosis [63]. Hypertension 
occurs in 7-17% of young girls with TS and in 50% of young adults, it can be secondary to an 
aortic coarctation or kidney disease but it is often primary [65]. Since it is a risk factor for 
dissection, guidelines advise  blood pressure measurement 1-2 times per year and strive for 
a target blood pressure of <140mmHg and in case of a bicuspid valve for <120mmHg [5]. 
Hormone substitution therapy appears to positively influence blood pressure, or at least 
have no negative influence [65] 
Pregnancy  
Infertility is one of the important complications of TS affecting woman’s life (ref). Patients 
with some mosaic karyotypes (45,X/46,XX) may be able to achieve spontaneous 
pregnancies (2-6%) [66], while others will only be able to conceive by oocyte donation. 
However, these assisted reproductive technologies may increase the risk of adverse events 
in TS patients , such as aortic dissection or rupture [67]. This risk seems to be augmented by 
hormonal influences on the vascular wall [67, 68]. Maternal death from aortic dissection in 
TS pregnancies is estimated at 2%, a 100-fold increased risk as compared to the general 
population. [68, 69]. The presence of hypertension, BAV and CoA are associated with an 
increased risk and pregnancy itself seems to be an additional, separate risk factor [70]. 
Therefore, treatment of hypertension, associated with poor fetal outcome such as 
prematurity and fetal growth retardation [71],  is of great importance for both women and 




Special attention should also be given to the aortic diameter as an aortic size index (ASI) 
>2cm/m2 and/or a significant abnormality is a strict contraindication for attempting 
pregnancy [68]. Aortic diameters should be measured at least once every four to eight 
weeks [72]. Consequently, deliveries should be in a medical center with cardiothoracic 
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Objectives. The aim of this study is to describe the prevalence, anatomy, associations 
and clinical impact of partial abnormal pulmonary venous return (PAPVR) 
in the Turner population. 
Methods.  All Turner patients who presented at our Turner clinic, between January 
2007 and October 2015 were included in this study and underwent ECG, 
echocardiography and advanced imaging such as cardiac magnetic 
resonance or computed tomography as part of their regular clinical 
workup. All imaging was re-evaluated and detailed anatomy was 
described.  
Results.  Partial anomalous pulmonary venous return was diagnosed in 24 (25%) 
out of 96 Turner patients included and 14 (58%) of these 24 partial 
anomalous pulmonary venous return had not been reported previously. 
Right atrial or ventricular dilatation was present in 11 (46%) of 24 partial 
anomalous pulmonary venous return patients.  
Conclusions.  When studied with advanced imaging modalities and looked for with 
specific attention, PAPVR is found in 1 out of 4 Turner patients. Half of 
these patients had right atrial and/or ventricular dilatation. Evaluation of 
pulmonary venous return should be included in the standard protocol in 





Turner syndrome (TS) is a partial or complete monosomy of the X-chromosome, and was 
originally described by Henry Turner in 1938. It occurs in 1 per 2500 live born females (1-3). 
Turner syndrome is nowadays often diagnosed prenatally or during early childhood and 
patients present with a broad variety of disorders, including short stature, estrogen 
deficiency and cardiovascular abnormalities (4). Aside from a higher risk profile for ischemic 
heart disease, often congenital cardiac defects, located  mainly on the left side, can be 
found in these patients. The most common lesions are: elongation of the aortic arch (49%), 
bicuspid aortic valve (14 - 30%), coarctation (7 - 18%), persistent left superior vena cava 
(13%), and atrial and ventricular septal defect (0-8%) (2, 5-9). PAPVR has been described to 
be more prevalent in TS patients, however knowledge about detailed anatomy and precise 
prevalence is scarce, partly because it is not routinely looked for at first recognition of the 
syndrome (6-9). However, PAPVR can cause an hemodynamically significant left-to-right 
shunt and subsequently, right chamber dilatation, arrhythmias and even pulmonary 
hypertension (10). This necessitates early diagnosis and, in case of a large shunt, treatment. 
In our tertiary centre for Turner syndrome all adult patients undergo a CT scan, while 
children and adolescents will have an MRI (11).  
The aim of this study is to describe the prevalence, anatomy and clinical significance of 
PAPVR, in patients with Turner syndrome. Furthermore, factors, possibly related with 
PAPVR were studied. 
Methods 
Every Turner patient is enrolled into a prospective surveillance program according to a local 
standardized clinical protocol. This protocol includes clinical assessment by a cardiologist, 
ECG, echocardiography and cardiac CT (adults) or MR imaging (children and adolescents). 
For this study all adult patients,  who were evaluated at the department of congenital 
cardiology between January 2007 and October 2015 with genetically proven Turner 
syndrome were included. We excluded patients with insufficient CT or MR imaging quality. 
The study was approved by the medical ethical committee of our center. Informed consent 
was waived. 
Imaging 
For this study all CT and MR-images were re-evaluated by two independent investigators 
(A.H. and R.C.), blinded to each other. When more than one scan (CT or MR) was available 
per patient, the most recent CT scan was used. Evaluation was done by multi planar 
reconstruction, using the AquariusNet (TeraRecon, Inc, San Mateo, CA) software. The 




into the systemic venous system. At this location vessel diameter and area were measured; 
perpendicular to the anomalous vein, as proximal to the vessel it feeds into as possible but 
where it was still discernable as a separate vessel (figure 1.) The anomalous vessel was then 
traced back to the lung lobe or lobes from which it originated; the site of origin.  Right atrial 
and right ventricular dilatation was visually assessed on echocardiography images by two 
observers (A.T. and J.R.), blinded to CT/MR data, on apical 4-chamber view, parasternal 
long-axis and parasternal short-axis according to the latest guidelines (12). To assess global 
RV systolic function the right ventricular fractional area change (RV  FAC) was calculated, 
where a RV FAC <32% was considered impaired (12).  
Electrocardiography 
ECG’s were scored for signs of right atrial or ventricular abnormalities. Right atrial dilatation was 
defined as: a P-wave in lead II >0.25mV. Right ventricular hypertrophy was defined as: an R/S ratio in 
V1>1, R in V1>7mm, or a right bundle branch block RV1>15mm. Right axis deviation was defined as a 
QRS-axis of more than 90˚.  
Karyotype analysis 
For purpose of statistical analysis karyotypes were divided into one of seven different 
categories; monosomy (e.g. 45,X0), mosaicism for monosomy (e.g.  45,X/46,XX [9/41]), full 
or mosaic isochromosomes (e.g. 45,X0/46,i(Xq)), polyploidy (e.g.  45,X0/47,XXX (100/2)), 
ring chromosomes (e.g. 45,X0/46X,+r(X) [36/14]) and karyotypes with Y-material (e.g. 
45,X0/46,XY/46,XX/47,XY [8/3/2/37]).  
Statistical analysis 
Continuous variables with a normal distribution were reported as mean ± standard 
deviation. We reported a median and range in case of non-normal distribution, checked 
using the Shapiro-Wilk test. Categorical variables were summarized as frequencies and 
percentages.  The Chi squared test was used to detect associations between patient 
characteristics and imaging data, in case of an expected value <5 a Fischer’s exact test was 
conducted. Independent sample t-tests and one-way ANOVA were used to compare means. 
A p-value of less than 0.05 was considered statistically significant. All statistical analyses 
were performed using the Statistical Package for Social Sciences (Released 2012. IBM SPSS 







Figure 1. Measurement of 
PAPVR. Panel A) 3D volume 
rendered reconstruction 
showing a PAPVR (*), the Aorta 
(Ao), Pulmonary Artery (PA), 
innominate vein (IV). Panel B 
and C) Sagittal and coronal 
oblique views of how the 
connecting site area of the 
PAPVR (*) was measured. D) 
Cross section of the PAPVR (*) 
perpendicular to the vessel. 
Figure 2. PAPVR as seen on CT. 
Panel A)  Right upper 
pulmonary vein connecting to 
superior vena cava (*); Panel 
B,D,F) corresponding volume 
rendered image of the same 
patient.  C) Coronal oblique 
view of the left upper 
pulmonary vein connecting to 
the innominate vein (*):  E,F) 
Sagittal oblique image showing 
the right upper pulmonary vein 
connecting to the superior 






Between January 2007 and October 2015, 104 patients with TS were referred to the 
outpatient clinic of our center for routine cardiac screening. In eight patients the image 
quality of the CT/MR was insufficient and these patients were excluded from further 
analysis. No differences in baseline characteristics were found between included and 
excluded patients. The baseline characteristics of the 96 patients included in our study are 
presented in table 1. At least one PAPVR was found in 24 of the 96 patients (25%) and had 
not been reported before in 14 (58%). In the majority of the patients a CT scan (n= 79, 82%) 
was performed, PAPVR was detected on 21 of these (27%). In the remaining 17 patients, an 
MR was performed and in 3 (18%) a PAPVR was found. 
Echocardiographic imaging was of sufficient or good quality in all 96 patients. Right atrial 
(RA) and ventricular (RV) dimensions were measured and are reported in table 2. RA 
dilatation was found in 22 of the 96 patients (23%), and associated with the presence of 
PAPVR. In 7 of the 24 PAPVR patients the right ventricle was dilated compared to 7 of 72 in 
the non-PAPVR group (29% vs 10%, p=0.039). Adequate measurement of the RV FAC was 
possible in 73 patients and was considered impaired in 13 patients (19%). RA and RV area 
were measured in 75 patients, from which RV fractional area change was calculated (table 
2). Both the RV end-diastolic area (EDA) and the end-systolic area (ESA) were enlarged in 
the PAPVR group (p<0.001 and p=0.001). The RV fractional area change (RV FAC) did not 
differ significantly between the groups. 
The ECGs showed right axis deviation (6%) in 6 patients, all 6 had a PAPVR (p<0.001). Two 
ECG’s showed signs of right atrial enlargement, one of the patients had a PAPVR, no signs 
of right ventricular hypertrophy or dilatation were found. 
Anatomy 
Details of the anatomy of the PAPVRs are presented in Table 3. The lung lobe of origin and 
the site where the PAPVR connects to the circulation could be determined in all 24 PAPVR 
patients. The most common site of origin was the left upper lung lobe (n=14, 58%) and the 
most common connecting site was the innominate vein (n=14, 58%). All PAPVRs were of 
the supra cardiac type, i.e. none of the PAPVRs connected to the coronary sinus or inferior 
caval vein. The median area of PAPVR was 38mm2 (inter quartile range: 83, range; 3-
391mm2) with a median diameter of 8mm (inter quartile range: 8.7, range; 2-25mm). The 
vessel area correlated with the RV EDA (r=0.49, p=0.014). BAV was found in 18 (18.8%) 
patients and CoA in 10 patients (10.4%). 
An arteria lusoria and a common origin of innominate and left carotid artery were found in 
4 (4.2%) and in 1 (1%) patient respectively. BAV occurred more frequently in combination 






The information on the exact karyotype was available in 88 (92%) patients and shown in 
table 4. The most prevalent karyotype was a monosomy of the X-chromosome (45,X0), 
followed by a mosaic monosomy pattern . PAPVR was observed more frequently in patients 
with a 45,X0 monosomy or mosaic monosomy (19 in 55) when compared to the other 
karyotypes (3 in 33; 35% vs. 9%, p=0.008). Remarkably, PAPVR was not seen in any of the 
seventeen patients with an isochromosome (0% vs. 31%, p=0.005). Of the isochromosome 
karyotypes in this cohort all had deletion of the shorter p-arm (isochromosome-q), 11 were 
a mosaic form (e.g. 45,X0/46-X,i(X)(q10) [24/5]), the other were of the non-mosaic type 
(e.g. 46,X,i(Xq)). 
Discussion 
In this large group of Turner syndrome patients a surprisingly high prevalence of PAPVR 
(25%) was found. This percentage is markedly higher than in previous studies, where PAPVR 
prevalence, when reported at all, is found to be between 2.9 and 18% (2, 6, 7, 9, 13). The 
higher incidence may be explained by the careful attention in our study, but also by 
differences in imaging techniques. Echocardiography is probably less sensitive to 
pulmonary vein abnormalities than CT or MR, explaining a possible underestimation of  
Patient characteristics (N=96)  
 
Mean ± sd 
 Age, y 35 ±13 
 Height, cm 155 ±14 
 Weight, kg 65 ±17 
 Systolic BP, mmHg 124 ±19 
 Diastolic BP, mmHg 76 ±13 
 Body Surface Area, m2 1.6 ±0.25 
 Body Mass Index, kg/m2 27 ±6 
 Saturation,%O2 (N=49) 99 ±1.4 
Table 1. Baseline characteristics, *saturation was available in 49 patients 




PAPVR prevalence in earlier studies. Contrast-enhanced CT and contrast-enhanced 3D MR 
angiography are both adequate techniques to assess the presence of a PAPVR (14) where 
CT of course carries the disadvantage of radiation.  
In this cohort none of the newly diagnosed PAPVRs needed immediate surgical 
intervention, but adequate follow-up of these patients is warranted to assess changes in 
right heart dimensions and pressures over time. PAPVR can become clinically relevant as 
adult-onset pulmonary hypertension has been reported in PAPVR patients (10, 15). We 
found some degree of right heart dilatation in half of the PAPVR patients. Therefore, we 
would like to stress the importance of including advanced imaging in the clinical protocol of 
Turner syndrome patients with specific attention for possible PAPVR and right heart 
dilatation. 
 






Right Atrial Dilatation   P=0.004 
     No  13 (54.2) 61 (84.7) 74 (77.1) 
     Yes 11 (45.8) 11 (15.3) 22 (22.9) 
Right Ventricular Dilatation   P=0.039 
     No 17 (70.8) 65 (90.3) 82 (85.4) 
     Yes 7 (29.2) 7 (9.7) 14 (14.6) 
Right Ventricular measurements N=22 N=51 p-value 
     EDA 22.5±6.3 16.4 ±6.8 <0.001 
     ESA 12.6±4.2 9.2 ±4.1 0.001 
     RV FAC 43.7±9.7 44.1±9.1 0.86 
Table 2. Echocardiographic measurements. 
Table 2. Presented as N= (%) and mean ±sd, EDA: End diastolic Area, ESA: END systolic Area, RV 





In addition to the clinical implications of having PAPVR , also some pathophysiological 
aspects warrant further investigation. This study was not designed to examine the PAPVR 
from a developmental aspect, but it is remarkable that only PAPVR of the ‘supra cardiac 
type’ (i.e. pulmonary veins draining into the superior caval vein or innominate vein) were 
observed, in concurrence with another study in a TS population (2). This is in contrast to 
what may be expected based on findings in non-Turner patients (16). It seems that the 
“supracardiac type” of PAPVR is an inherent part of the Turner cardiac phenotype, where in 
non-Turner cohorts this supracardiac type is  relatively uncommon (17). Another 
remarkable observation is the absence of atrial septal defects, which are supposedly 
associated with PAPVR in the non-TS population, predominantly with right-sided PAPVR 
(17, 18). A single underlying cause for the wide spectrum of left-sided cardiac defects in TS, 
genetic or otherwise, has not yet been established. There are however several theories; 
cardiac abnormalities could be caused by either haemodynamical changes in utero or could 
have a multifactorial or genetic origin. It is suggested that either a jugular lymphatic 
obstruction may lead to compression of outflow structures (19), or that a left-sided 
blockage of the fetal circulation forms the explanation for the defects(20). The association  




  Lung segments SVC IV Left Subclavian Vein PLVCS Total 
Right  Upper Lobe 2 
  
 2 
 Upper Lobe/Middle Lobe 1 
  
1 2 
 Middle Lobe 2 2 
 
 4 
 Middle Lobe/ Lower Lobe 2 
  
 2 
 Lower Lobe 0 
  
 0 
Left  Upper Lobe 
 
10 1 1 12 










  Total 7 14 1 2 24 
Table 3. IVC: Inferior Vena Cava,  IV: Innominate Vein, SCV: superior Vena Cava, PLVCS: Persistent 
Left Vena Cava 




Table 4. Presented as N= (%) and mean ±sd, PAPVR:  partial abnormal pulmonary venous return 
between TS genotype and PAPVR phenotype needs further study and knowledge about the 
various cardiac abnormalities and their interrelation might play a meaningful role in 
unravelling the etiology of the ‘Turner cardiac phenotype’. 
Limitations 
A possible inclusion bias may have been in place as only TS patients from a tertiary center 
were included. However, we feel that this effect is likely to be very small as all TS patients 
are referred for follow-up irrespective of complaints or symptoms and follow-up is done 
according to a standard protocol. 
Conclusion 
PAPVR is present in one quarter of patients with Turner syndrome, and often missed at first 
diagnosis of the syndrome. Medical specialists involved in the care for TS patients, should 








(Mosaic) Monosomy X 19 (79,2) 36 (50) 55 (57.3) 0.008 
Isochromosomes 0 (0) 17 (23.6) 17 (17.7) 0.005 
Deletions 1 (4.2) 3 (4.2) 4 (4.2) 1 
Polyploidy 1 (4.2) 4 (5.6) 5 (5.2) 1 
Ring chromosomes 1 (4.2) 3 (4.2) 4 (4.2) 1 
Y material 0 (0) 3 (4.2) 3 (3.1) 0.570 
Missing 2 (8.3) 6 (8.3) 8 (8.3) - 
Total 24 72 96 (100.0) - 
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Objective:  As part of the value-based health care program in our hospital a set of 
patient reported outcome measures was developed together with 
patients and implemented in the dedicated Turner Syndrome (TS) 
outpatient clinic. This study aims to investigate different aspects of health 
related quality of life (HR-QoL) and psychosocial functioning in women 
with TS in order to establish new possible targets for therapy. 
Methods:   A comprehensive set of questionnaires (EQ-5D, PSS-10, CIS-20, Ferti-QoL, 
FSFI) was developed and used to capture different aspects of HR-QoL and 
psychosocial functioning in a large cohort of adult women with Turner 
syndrome. All consecutive women, ≥18 years, who visited the outpatient 
clinic of our tertiary center were eligible for inclusion. 
Results:   Of the eligible 201 women who were invited to participate, 177 women 
(age 34 ±12 years, mean±SD) completed at least one of the validated 
questionnaires (88%).  Women with TS reported a lower health-related 
quality of life (EQ-5D: 0.857 vs. 0.892, p=0.003), perceived more stress 
(PSS-10: 14.7 vs. 13.3; p=0.012) and experienced increased fatigue (CIS-
20: p<0.001) compared to the general Dutch population. A relationship 
between non-cardiac comorbidities (e.g. diabetes, orthopedic complaints) 
and HR-QoL was found (R=0.508). 
Conclusions:   We showed that TS women suffer from impaired HR-QoL, more perceived 
stress and increased fatigue compared to healthy controls. A relationship 
between non-cardiac comorbidities and HR-QoL was found. Especially 
perceived stress and increased fatigue can be considered targets for 






Turner syndrome (TS), first described by Henry Turner in 1938, is caused by a partial or 
complete monosomy of the X-chromosome, and occurs in 1 per 2500 live born females.[1, 
2] Classic characteristics of TS include: short stature, webbing of the neck, estrogen 
deficiency and decreased fertility.[3-5] Moreover, significant morbidity in these patients is 
caused by the cardiovascular abnormalities of heart and thoracic vessels, which affect an 
estimated 50% of women with TS.[6] Of these congenital defects the bicuspid aortic valve 
(BAV: 15-30%), coarctation of the aorta (CoA 12-17%) and partial anomalous pulmonary 
venous return (PAPVR: 18-25%) are most prevalent.[2, 6-8] Additionally diabetes, obesity 
and hypertension are often seen in these women, adding to their cardiovascular risk.[9] 
Although cardiovascular and other physical morbidities of women with TS have already 
been described in detail, literature is still inconclusive or contradictory on the impact of TS 
on HR-QoL.[10] In addition to the physical factors, HR-QoL in these women is also affected 
by the mild neuropsychological deficits these patients may encounter, such as the relative 
weakness in visual–spatial, executive, and social cognitive domains.[11-13] Additionally, 
other factors such as lower socioeconomic status or impaired ability to work may affect 
QoL. Finally, fertility issues may also have impact on QoL in TS women. Since the phenotype 
is so multi-dimensional and heterogeneous, traditional psychometric tools, such as the SF-
36, cannot completely capture the broad range of psychosocial problems in these 
patients.[14] Moreover, the importance of psychometrically sound disease-specific tools 
has been stressed in other chronic illnesses, where more generic tools often fail to capture 
loss of quality of life on disease specific domains.[15]  In this study we describe the 
development and first results of a set of clinician and patient reported outcome set in 
Turner syndrome as part of the value-based health care programs in our hospital.[16] We 
aim to provide a comprehensive evaluation of HR-QoL and different domains of 
psychosocial functioning in women with TS in order to identify individual and disease-
specific targets for effective improvement of their HR-QoL. 
Methods 
Development of the outcome set 
For the development of such a set, out organization works according to a so called 
blueprint which is adapted to the specific situation of a disease team. This way of working is 
described in detail elsewhere. [16] In brief, a disease team is formed consisting of the most 
important disciplines involved in the treatment, in this case the departments of internal 
medicine, gynecology and cardiology.  A representation of patients is invite to participate in 
this process. In our situation we had a 24 year old patient and the mother of a patient being 
also member of the national patient organization, they are volunteers for the Turner 




With this group and technically supervised by a value based healthcare expert, the team 
discussed in 4 sessions the following items: current care path, possible outcome measures 
from literature and complemented with topics from the patients that really matter to them. 
Consensus based this long list of outcome topics was decreased to a more discrete based 
on frequency and impact. Finally, the outcome topics were translated into validated 
outcome measures and built into our data capture tool in order to measure them 
electronically. Before every outpatient clinic visit, patients receive an email with a web link 
to the questions, so they were able to answer them at home before the visit. During the 
visit the result were discussed with them. Our tertiary care center has developed a 5- year 
VBHC-strategy to transform the institute into a true value innovator. An integrated, 
multidisciplinary Turner syndrome-care unit was already in place within our institute. The 
Turner team is composed of a cardiologist, endocrinologist, gynecologist, physiotherapist, 
psychologist and ENT specialist and other specialists are consulted upon indication.  
For women with Turner syndrome, navigating the complex health-care pathway involving 
many specialties can be daunting. Therefore this path-way was redesigned analogous to 
the breast cancer-care path-way described earlier [ref 16]. A critical step within VBHC is 
defining an outcomes set, this was done with the described multi-disciplinary team. After 
both a literature survey and from experience, all participants worked on a long list of 
outcome domains and ranked based on prevalence, impact for the patient and relevance 
for quality of care. For sake of feasibility the final list was discussed and selected using a 
modified Delphi method, see figure. The PROMS selected are described below under 
‘instruments’ and in more detail in the supplementary material.  
As described earlier, PROMS in the VBHC-pathways in our institution are captured using an 
in-house developed open source electronical data collection tool, which allows the 
construction of data collection-forms and automatic distribution of PROMs. [16] Emails are 
sent to the patients in order to activate the distribution of PROMs. After the right 
treatment pathway is selected by the physician, all the following PROMs will be sent 
automatically by the tool at the right time-point. The tool was linked to the EHR enabling 
the review of the collected data for individual patients at the (outpatient) clinic. The secure 
platform is build up by two software programs, LimeSurvey[17] and GemsTracker[18]. The 
development team simultaneously developed a user-friendly interface to display the 
collected data. Longitudinal PRO data and data from the caregivers is collected in these 
pathways. 
Setting and study design 
All patients in our center of expertise are seen according to a new value-based healthcare 
clinical pathway which includes annual visits to the dedicated Turner outpatient clinic.[5, 




December 2015 and October 2018 were prospectively included. Cardiovascular 
examination was performed including electrocardiography (ECG) and transthoracic 
echocardiogram (TTE) and advanced cardiac imaging (CT or CMR). Karyotype was taken 
from the clinical genetics report. The study complied with the Declaration of Helsinki and 
was approved by the medical ethical committee of the Erasmus Medical Centre. Written 
informed consent was waived. 
Instruments 
As a part of a hospital wide value-based healthcare program patients were asked to 
complete 12 questionnaires: 5 standardized questionnaires: the EuroQol-5D (EQ-5D), 
Hospital Anxiety and Depression Scale (HADS), Checklist Individual Strength (CIS-20), 
Perceived Stress Scale (PSS-10), Fertility Quality of Life (Ferti-QoL), 4 questionnaires on 
sexual functioning (sexual activity question, brief sexual symptom checklist for women 
(BSSC-W), female sexual functioning index (FSFI) and the female sexual distress scale - 
revised (FSFD-R)) and 3 questionnaires on body image and the perceived burden 
questionnaires.[20-22] The questionnaires have been  described in more detail in the 
supplementary methods. The sexuality questionnaires were offered  to the women with TS 
aged 20 and 45 years because sexuality starts later in women with TS [23-26] and end 
earlier because of hormonal changes.  
Statistics 
Continuous variables were presented as mean ± standard deviation (SD) or as median with 
an interquartile range. Categorical variables were presented as frequencies and 
percentages. We examined distributions by visually assessing histograms of the data by 
calculating Z-values of skewness and kurtosis, and by tested for normality using the 
Shapiro-Wilk test. For comparison of normally distributed continuous variables between 
two groups the Student’s t-test was used. Univariate linear regression analysis was 
performed. Subsequently, multivariate linear regression analysis was performed to identify 
patient characteristics that were significantly associated with different measures of HR-QoL 
or other psychosocial outcomes. In case of collinearity we entered the variable with the 
strongest correlation with the outcome into the multivariate linear regression analysis. As 
previously described the tri-modal distribution of the EQ-5D outcome measure hampers 
ordinary least squares (OLS) regression, three-part regression methods seem to have better 
prediction power than OLS with EQ-5D data, although OLS seems quite robust.[27] 
Therefore we conducted separate linear regression for the 0.5-0.99 range as an additional 
‘sensitivity analysis’. The statistical tests were two sided and a p-value below 0.05 was 






The questionnaires were offered to all 201 women with TS who visited our outpatient clinic 
between December 2015 and September 2018, of which 177 women completed at least 
one of the questionnaires (response rate: 88%) and were included in this study. Baseline 
characteristics of the 177 women are presented in table 1. The mean time to complete the 
questionnaires was 15 minutes. All women seen in our outpatient clinic between the age of 
18 and 52 use HRT.  
Table 1. Baseline characteristics.  
Baseline characteristics  Women with TS 
Median [IQR] 
Age, y 33 [18] 
Height, cm 157 [11] 
Weight, kg 64 [19] 
Systolic BP, mmHg 125 [21] 
Diastolic BP, mmHg 76 [17] 
Body Surface Area, m2 1.65 [0.22] 
Body Mass Index, kg/m2 25.4 [6.4] 
Sinus Rhythm, n=167 167 (100) 
Heart rate, bpm 75 (15) 
Karyotype 171 (97) 
Monosomy X 93 (52.5) 
Mosaic 25 (14) 
Isochromosomes 25 (14) 
Deletions 6 (3.4) 
Polyploidy 9 (5.1) 
Ring chromosomes 5 (2.8) 
Y material 8 (4.5) 
  






















Demographics and morbidity  
Many women indicated  living with a partner (table 2; n=50, 28%). Of the women living with 
parents or family (n=51), 15 (29%) were older than 25 years of age. In total 29 women 
(16%) raised a total of 30 children. The highest level of educational attainment was known 
in 123 (69%) participants; most of who had finished intermediate vocational education in 
51 (29%). Women were often employed, either fulltime (n=23, 13%) or part-time (n=26, 
20%). Of the 90 participants less than half indicated to practice sports regularly, on average 
3hours (median, IQR 3 hours) per week.  
Demographics (N=177) n= % 
Living situation 174 98 
 
With a partner 50 29 
 
Alone 47 27 
 
Living with parents 44 25 
 
Family 7 4 
 
Friends 2 1 
Children 30 16 
 
Biological children  12 40 
 
Foster or adopted children  11 37 
 After oocyte donation 7 23 
Highest level of educational attainment 123 69 
 
Pre-vocational secondary 14 11 
 
Senior general secondary/pre-university 17 14 
 
Intermediate vocational  51 41 
 Higher vocational  19 15 
 University education 13 11 
Current occupation 90 51 
 
Fulltime employed 23 26 
 
Part-time employed 36 40 
 
Still attend educational services 16 18 
 
Unemployed 12 13 
Sports participation 73 41 
 
Jogging  19 26 
 
Cycling  17 23 
 
Fitness  16 22 
 
Team sports  1 1 
Table 2. Demographics. Completeness per domain (e.g. living situation) is presented as n (%) 





Noticeably all but 1 participant practiced individual sports. Data on morbidity is presented 
in table 3. Most frequently encountered problems included: ear and/or hearing problems 
(n=57; 32%) and cardiovascular disease (n=56; 32%). In the 56 women with cardiac disease 
several different structural heart defects were identified; of which a bicuspid aortic valve 
(BAV) was the most frequent (19%). Aortic dilatation was found in 10 patients (6%) and 1 
patient had suffered from dissection (0.6%). 

















The EQ-5D was completed by nearly all patients (n=175, 99%). Women with TS scored 
lower compared to the general Dutch population (0.857 vs. 0.892; p=0.003) as shown in 
figure 1.[28] Women with TS scored significantly higher on the ‘problems with daily activity’ 
(p<0.001) and the ‘fear and anxiety’ (p<0.001) compared to healthy controls 
(supplementary figure 1). Finally the EQ-5D included a subjective ‘health score’ (EQ-VAS; 
supplementary figure 2), where the women with TS (n=176) scored significantly lower than 
healthy women (76.8 versus 82, p<0.001).  
Morbidity (n=177) n= % 
Otological problems 57 32 
Cardiovascular disease 56 32 
 
BAV 34 19 
 
PAPVR 12 7 
 
CoA 9 5 
 bovine aortic arch 2 1 
 Persistent duct  2 1 
 PLSCV 2 1 
 ASD 1 0.6 
 VSD 1 0.6 
Hypothyroidism 30 17 
Dento-facial malformations 26 15 
Orthopedic problems 21 12 
Liver dysfunction 20 11 
Renal malformations  13 7 
Diabetes 6 3 
Coeliac disease 3 2 
Hyperthyroidism 1 1 








Figure 2. Total CIS-20 (fatigue) scores in TS-women versus different non-Turner syndrome reference 
populations from literature. 
 
  
Figure 1. EQ-5D scores per decade of life. The red line depicts scores in women with TS.  
Blue line depicts scores in a cohort of healthy Dutch non- women with TS. *: average 
age groups (p<0.003).  
Figure 2. Total CIS-score per patient group colors indicates different subdomains, total 






Of the 176 women (99%) who completed the PSS-10 questionnaire more than half (n=90, 
51%) indicated low or average stress (<13points), while 23% (n=41) experienced stress 
levels above average (between 13-20 points), and 25% (n=45) reported high stress levels 
(>20 points). Women with TS scored significantly higher than their non-TS peers, indicating 
a higher level of perceived stress. Especially women in the age group 45 to 59 years scored 
higher compared to their peers(n=45: 16.18 vs 12.99, p-value: 0.002), whereas higher but 
non-statically significant values where observed in the other age groups (18-39 years, 
n=124: 14.2 vs 13.34, p-value: 0.084) (≥60 years, n=7: 13.71 vs. 12.82, p-value: 0.403).   
CIS-20 
The CIS-20 was completed by 175 participants (99%). In our cohort 32% of patients (n=56) 
scored 76 or higher indicating increased fatigue. In figure 2 we compare our cohort of 
women with TS to reference populations from literature, showing that women with TS are 
significantly more fatigued than healthy controls, indicated by a higher total score (67 vs 
55; p<0.001). They also score significantly worse on the sub scores of ‘fatigue’ and 
‘concentration’ subscales compared to controls (29 vs 23; p<0.001 and 17 vs 12; p<0.001 
respectively, figure 2) 
HADS  
The HADS measures fear and depression in patients under medical treatment. This 
questionnaire was offered to 27 who showed indications of emotional suffering on the EQ-
5D and was completed by 20/27 eligible participants (74%). One of whom scored between 
8 to 10 points, indicating a ‘possible depression or anxiety disorder’ while 19 women (95%) 
scored above 10 points, indicative of a ‘probable depression or anxiety disorder’. Since this 
questionnaire was offered only to a subset of patients no comparison to a reference 
population could be made. 
Fertility and Sexuality 
The fertility-related quality of life (Ferti-QoL) was completed by 57 of the 140 eligible 
patients (41%).  Women with TS scored significantly lower on the relational subscale (78 vs. 
71; p=0.009) indicating more impact of fertility problems on the marriage or partnership 
(supplementary figure 3) compared to a reference population of women who underwent 
medically assisted reproduction.[29] Conversely, they scored better on the mind-body (90 
vs 71; p<0.001), social (82 vs 74; p<0.001) and emotional sub scores (81 vs 60; p<0.001), 
indicating less impact of negative emotions on quality of life and impact of fertility 
problems, cognitions and behavior on physical health. On the total Ferti-QoL women with 




Additionally, the four questionnaires on sexual activity and sexual functioning in women 
(sexual activity question, BSSC-W, FSFI and FSFD-R) were completed by 57/140 (41%), 
40/140 (29%), 8/9 (89%) and 2/5 (40%) participants respectively. On the ‘sexual activity 
question’ (mean age: 37.5±8.4years), 32 women (56%) indicated that they were sexually 
active. On the BSSC-W (mean age: 38±8.9years) 33 of the 40 respondents (82.5%) indicated 
that they were content with their sex life, 7 were not (17.5%). Causes for dissatisfaction 
with sex life included a lack of libido (n=3; 7%), reduced genital sensations (n=1; 2.4%), 
vaginal dryness (n=1; 2.4%) or pain during intercourse (n=2; 5%). As a part of the value-
based healthcare program these women were then referred to a sexologist. 
Body Image and Disease burden 
The BCS questionnaire on body-image was answered by 175 (99%) women, of who 66 
(37%) indicated to be discontent with their appearance. Scores of the body-image 
questionnaire on the 52 areas of physique are shown in supplementary figure 4.  Women 
with TS were least content with their waist, build, belly, weight, and figure. Also reflected in 
this questionnaire is the discontent with their energy level. The burden questionnaire was 
completed by 177 women (100%) Self-reported burden scored on six domains is shown in 
supplementary table 1. The question which asked how much these issues on the different 
domains affected the participant on a scale from 0-10 was answered (n=161; 91%) with a 
mean score of 4.6 (SD±2.6). Of the physical complaints, fatigue was especially frequently 
reported by women in our cohort. Other physical problems (12%) often concerned joint 
and muscle pain (4%). The most frequently reported emotional complaint in the ‘other 
emotional complaints’ category (4%) was work related stress (2%). Problems in social 
interaction concerned the connection with peers (15%) or engaging in a romantic 
relationship (16%). In the ‘work-related category’ issues reported often included mild 
neuropsychological problems such as memory (19%), and concentration (20%) issues. The 
majority of other complaints in the work category (5%) specifically described the feeling of 
being overburdened by work (4%). Women with TS also frequently reported concerns 
about the future, often related to their education or work (30%).  
Determinants of quality of life 
Univariate linear regression showed age, diabetes, liver dysfunction, orthopedic problem, 
fatigue (CIS-20) and stress (PSS) to be associated (p<0.2) with worse quality of life (EQ-5D). 
Subsequent backward multivariate linear regression analysis revealed that higher fatigue 
(β=-0.004, SE<0.001, p<0.001), orthopedic complaints, defined as physical problems (e.g. 
scoliosis, leg length discrepancy or Madelung’s deformity (β=-0.049, SE=0.027, p=.072) and 
diabetes (β=-0.090, SE=0.047, p=0.056) were associated with worse EQ-5D score (r-square: 
0.508). Moreover, both PSS-10 score and CIS-20 score were independently associated with 
a lower EQ-5D outcome (β=-0.014, p<0.001 and β=-0.005, p<0.001, respectively). However, 




since CIS-20 had the strongest correlation PSS was removed from the analysis. Additional 
piece-wise separate linear regression for the 0.5-0.99 EQ-5D range improved the 
correlation, but did not change the outcome. Notably, the presence of cardiac disease or 
hearing impairment did not influence quality of life (EQ-5D). No significant difference was 
found between the different levels of educational attainment forEQ-5D (p=0.9156), CIS-20 
(p=0.759) or PSS-10 (p=0.380) or for partnership status on EQ-5D (p=0.488), CIS-20 
(p=0.055) or PSS-10 (p=0.265) . A summary of the questionnaires and their results has been 
provided in supplementary figure 5.   
Discussion 
In order to analyze the added value of our care for patients with TS we developed together 
with a small patients representation a set of clinician and patient reported outcome 
variables related to items that really matter to them in daily life. Subsequently we 
measured these outcome variables in a group of TS patients. This study describes the 
results of these measurements. In this large cohort of women with TS we found an 
impaired health related quality of life (HR-QoL), correlated to higher stress and more 
fatigue compared to control populations. When considering determinants for these results 
we found that especially having comorbidities such as diabetes and orthopedic complaints 
were related to lower HR-QoL. This impaired quality of life was reported before, in which at 
least some domains of QoL were found to be decreased in women with TS.[26, 30-36] 
However, three studies found QoL in women with TS to be comparable to non-TS 
controls,[37-39] or found even better scores by  women with TS on some aspects such as 
social and emotional functioning.[38]  Our study further determined in which domains 
Turner patients are especially experiencing difficulties and which factors contributed to 
their reduced mental health.  
Moreover, in our cohort ‘fatigue’ as measured by the CIS-20 was strongly correlated with a 
lower quality of life. Fatigue is a complaint frequently encountered in the care for women 
with TS, often in absence of physical disease, with no clear cause for this debilitating 
complaint. We also found the increased score for fatigue to be correlated with high stress 
scores, and this was not sufficiently explained by any physical comorbidities. In literature it 
has been suggested that women with TS exhibit greater anaerobic stress during exercise, 
leading to increased muscle fatigue.[40] Also menopausal symptom may affect fatigue in TS 
women. However, such an effect cannot be determined from the results in the current 
study.  
Another remarkable finding was that almost all women with TS engaged in sports chose an 
individual sports activity (e.g. running or fitness). It might be that a team sport is too 
demanding for these women as they have impaired performance across both verbal and 




setting because of their lower satisfaction with their body image. This clearly warrants 
further study. 
We also consulted a ‘Turner life coach’ involved in the value-based health care program, for 
the interpretation of our results. Turner life coaches are women with TS who ‘coach’ Turner 
women in day-to-day problems. She suggested that the extreme fatigue may partially be 
explained by the mismatch that women with TS experience between what is expected of 
them by themselves and their environment and what they are capable of doing. This may 
result from the impaired concentration and attention leading to impaired executive 
function and subsequent fatigue. This is something that is also clearly reflected in the work 
domain of the burden questionnaire. Another potential explanation for these findings in 
women with TS is offered by Tancredi et al., who suggest that TS patients might have an 
overactive sympathetic nervous system (SNS).[42] Zuckerman et al. showed that TS 
patients have an increased resting norepinephrine level.[43] These TS women also had a 
lower response of catecholamines to exercise, which may be reflected in an increased basal 
tone of the SNS, resulting in high blood pressure, relative tachycardia, shorter conduction 
times and a decreased VO2max. This may culminate in the increased fatigue often 
experienced by these women.  
Stress in women with TS has been investigated by Fjermestad et al. (n=57, mean age 
40.6±11.1 years), showing that they experience more stress than healthy controls.[32] We 
also found an increased stress level in our cohort of Turner patients. In addition, we found 
that stress also negatively influenced HR-QoL. However, causality cannot be established 
based on this cross-sectional study, but stress reduction might be a tool for clinicians to 
improve QoL in women with TS.  
From literature it is well-known that fertility issues play an important role in women with 
TS.[10, 36] Indeed the questionnaire on fertility was not well-responded to, showing that 
this issue might by a difficult topic for TS women. The results showed a lower relational 
quality of life but a higher score on the mind-body and emotional sub scores compared to a 
retrospective cohort of Dutch women who underwent medically assisted reproduction. The 
questionnaires used in this study are well validated in other populations and have been 
used in clinical setting. We have not evaluated the burden of filling out the questionnaire 
itself, but it takes approximately 15 minutes and we feel this is a relatively small effort. We 
do aim to evaluate the acceptability in future studies. Conversely clinicians are often time-
pressed and the time it takes to fill in a questionnaire cannot be spent elsewhere. 
Therefore the set-up of automated sent questionnaires, providing so much important 
information is an important asset in the assessment for the clinician. In our study the 
feasibility was good as 177 out of the 201 women did fill in the questionnaires. An 
important hurdle is that some specific questionnaires such as the one on sexuality was only 




questionnaires just over half were sexually active and of these around 80% were content 
with their sex-life. There might be a selection bias of women feeling more comfortable 
completing these questionnaires being more positive on their sex-life, compared with 
women who feel uncomfortable, it may have been confronting or women may have 
considered questions not relevant.[44] Also, these questionnaires have not yet been 
validated specifically for the TS population which limits their interpretation. Therefore, 
future research should focus on developing disease specific tools, as previous studies show 
that disease specific HR-QoL instruments can contribute to more effective treatment 
interventions as they have more power to detect small differences and changes over 
time.[15, 45-47]  
Clinical implications 
We want to underline the need for screening with Turner specific questionnaires covering a 
broader range of HR-QoL and varying aspects of psychosocial functioning in women with 
TS. Reis et al. described 18 different instruments in a recent review, mostly the SF-36, used 
to assess QoL and related domains.[10] TS, however is a very heterogeneous syndrome that 
is not easily covered in a limited set of questions. However, a single validated TS specific 
questionnaire would in our opinion allow to more easily score QoL and act timely and 
appropriately. Considering our results, such a questionnaire would need to cover the HR-
QoL aspects of the EQ-5D, stress, fatigue and sexuality. Indeed if all women with TS would 
fill in this questionnaire, problems could be identified timely and possible therapy can be 
offered and initiated. Once a common methodology has been established to investigate 
QOL in these women other possible sources of bias, such as ascertainment bias due to the 
tendency of TS women to give expected responses, could studied further. For some women 
group sessions may provide useful support, while others clearly need individual coaching or 
psychological therapy. In addition, a well-structured exercise program may be useful in 
selected women with TS. Finally, attention for and information on sexual functioning and 
fertility should be organized for all women with TS. 
The main limitation of our study is that not all questionnaires were completed by all 
participants, which possibly introduced bias. Patient who experienced higher stress, more 
fatigue or lower QoL could have been less motivated to participate in this comprehensive 
set of questionnaires. A second limitation lies in the retrospective manner in which 
electronic patient records were searched for patient specific clinical information, which is 
sensitive to incompleteness. All women with TS are seen in our center and the current 
cohort should therefore be representative of the general TS population. Furthermore we 
had no data on the women who did not respond to the questionnaires, we were therefore 
unable to assess a potential difference between these groups. A final limitation is that there 




comparison on these aspects could be made. This would be an important aspect to take 
into account in designing future studies.  
Conclusion 
Value based healthcare means aiming at improving outcomes that really matter to patients. 
In order to do this, we should first measure these outcomes. By doing so, we showed that 
women with TS scored lower on HR-QoL and reported more stress and fatigue compared to 
healthy controls. Determinants which were found to affect HR-QoL were physical factors, 
such as diabetes and orthopedic complaints, but also stress and fatigue were clearly 



























Self-reported Burden (N=177) n= % 
Physical  
 
Obesity 59 33 
 
Hearing  67 38 
 
Fatigue 79 45 
Emotional 
 
Anger  32 18 
 
Sadness  34 19 
 Gloominess 48 27 
 loneliness 22 12 
 Low self-esteem 84 47 
 Anxiety 19 11 
Practical concerns 
 
Trouble taking medication 15 8 
 
Activities 21 12 
 
Transportation to work 7 4 
Social interaction 
 
Parents 18 10 
 
Brothers or sisters 14 8 
 
Family 6 3 
 
Friends 18 10 
 Connection with peers 27 15 
 Romantic relationship 29 16 
Work 
 
Absenteeism   3 2 
 
Memory 33 19 
 
Concentration 35 20 
 
Relation with colleagues 35 20 
 Being bullied or excluded  7 3 
Future  
 Education or work 53 30 
 Uncertainty about physique  23 13 
 Aging 25 14 
Supplementary table 1. 
Self-reported burden. 
Data per item is 





Supplementary figure 1. EQ-5D (HR-QoL) scores per subdomain:  TS  women vs. Dutch population. 
 
 Supplementary figure 1. EQ-5D scores per subdomain. Scores in a cohort of healthy Dutch 
non- women (blue). The scores of women with TS (red). P values are calculated over 




Supplementary figure 2. Euro-QoL visual analogue scale (VAS):  women with TS vs control population. 
 
 
Supplementary figure 3. Ferti-QOL scores in TS-women vs control population  
 
 
Supplementary figure 2. VAS-score per decade of life. Interpreted as a quantitative measure of 
health outcome as judged by the individual respondents. The red line depicts scores in women 
with TS. The blue line depicts scores in a cohort of healthy Dutch non- women with TS. *p-value 
significant below p<0.05. 
Supplementary figure 3. Ferti-QoL score per domain.  








Supplementary figure 4. Body-image score on 52 items. Scored on a five point Likert-scale (1-5). 





The HADS is an instrument to screen for anxiety and depression in patients under medical 
treatment using 14 statements on a four-point Likert scale.[48] The HADS was only offered 
after indication of emotional suffering on EQ-5D and therefore no comparison to a 
reference population can be made.  
Ferti-QoL 
The Ferti-QoL consists of 36 items that yield six subscales and three total scores, higher 
scores indicate a more favorable outcome.[49] It scores the fertility-related quality of life 
across the ‘Emotional’, ‘Mind-Body’, ‘Relational’, ‘Social’, ‘Treatment Environment’ and 
‘Treatment Tolerability’ subscales. The emotional subscale score shows the impact of 
negative emotions related to fertility problems on quality of life. The Mind-Body subscale 
score shows the impact of fertility problems on physical health, cognitions and behavior. 
The relational subscale measures the impact of fertility problems on the marriage or 
partnership. The social subscale assessed the extent to which social interactions have been 
affected by fertility.  The treatment environment subscale score covers the extent to which 
the accessibility and quality of treatment impacts quality of life. The treatment tolerability 
subscale score indicates the extent to which fertility medical services impact on daily life. 
We compare our data to a cohort of Dutch women who underwent screening for medically 
assisted reproduction.[29] 
Sexuality questionnaires 
All four questionnaires on sexual activity and sexual functioning in women (sexual activity 
question, BSSC-W, FSFI and FSFD-R) were offered to the women with TS aged 20 and 45 
years.[50] These questionnaires were offered in a stepwise fashion; the FSFI and FSDS-R 
were offered only to women who had indicated sexual discontent on the BSSC-W.  
Disease burden and body image 
Furthermore a ‘burden questionnaire’ was offered which scored problems on six domains; 
‘physical’, ‘emotional’, ‘practical concerns’, ‘home and environment’, ‘work’,  and ‘future’. 
And a separate score indicating how much they were bothered by the reported burden in 
their daily lives on a scale from 1-10. Finally, women who had indicated to be dissatisfied 
with their body were asked to fill out the Body Cathexis Scale (BCS),[51] a questionnaire 
about body image that assesses satisfaction on a five-point Likert-scale on 52 different 
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Objective:  This study aimed to describe the systolic left ventricular global 
longitudinal strain (LvGLS) and left ventricular peak early diastolic strain 
rate (Sre) in adult women with Turner syndrome (TS) and to determine its 
relationship with exercise capacity and clinical parameters. 
Methods:   In this cross-sectional cohort study, consecutively included adult TS 
women underwent an electrocardiogram, transthoracic echocardiogram 
(TTE) and cardiopulmonary exercise test (CPET) on the same day. LvGLS 
and Sre were measured using 2D speckle tracking analysis (STE) and 
compared with age-matched healthy female controls. 
Results:   Ninety-four adult women (age 36±13 years) with TS and 32 healthy age-
matched female controls were included. Women with TS had a 
significantly impaired/reduced systolic LvGLS (-17.82 ±2.98% vs. -21.80 
±1.85%, p<0.001) and Sre (0.98 ±0.32 s-1 vs. 1.27 ±0.19 s-1, p>0.001), 
compared to healthy female controls. Furthermore, TS women had 
reduced diastolic function as measured by conventional 
echocardiographic parameters: a higher A-wave (p<0.001), lower E/A-
ratio (p=0.001), longer deceleration time (p=0.006), and a higher E/E’-
ratio (p<0.001). Women with TS also had a significantly reduced maximal 
workload (p=0.033), reduced oxygen uptake (p<0.001) and a reduced 
maximal heart rate (p<0.001) during exercise. Multivariable linear 
regression analysis revealed that Age, karyotype and QT-duration were 
significantly associated with Sre, but not with LvGLS, in the TS population 
Conclusions:   Systolic and diastolic strain and exercise capacity were significantly 
reduced in TS women compared to healthy women. No correlation 
between strain itself and exercise capacity could be demonstrated, but 
correlations with conventional TTE parameters and baseline 







Turner syndrome (TS) is caused by a partial or complete loss of the X chromosome and 
affects approximately 1 in 2000 live-born girls [1]. Besides the classical features, such as 
short stature and gonadal dysgenesis, these women have an increased risk of 
cardiovascular disease which is an important cause of morbidity and mortality among TS 
patients [1, 2]. Common congenital heart defects are bicuspid aortic valve (BAV; 25-39%) 
[3, 4], coarctation of the aorta (CoA; 12-16%)[3], and partial abnormal pulmonary venous 
return (PAPVR; 18-25%) [5, 6]. These congenital heart defects may affect left ventricular 
(LV) function [7] . However, TS has also been associated with increased LV mass and 
reduced LV dysfunction independent of congenital heart disease [8-10]. The etiology of this 
predominantly sub-clinical LV impairment that exists in absence of hypertension or poor 
metabolic control remains enigmatic [8, 9]. To date there is very little data on left 
ventricular global longitudinal strain (LV GLS) and LV diastolic strain rate (Sre) in adult 
women with Turner syndrome. And studies that did examine left ventricular function in TS 
patients were often done using conventional echocardiography [9, 11]. Where 
conventional echocardiography may not be able to detect early sub-clinical LV dysfunction 
and children may not have developed dysfunction yet. Therefore this study uses 
deformation measurements by 2D speckle-tracking echocardiography (STE) which may 
offer advantages,  such as angle independency, over conventional echocardiographic 
markers for diastolic dysfunction [12-14]. Moreover, the myocardial deformation 
parameters as LvGLS and Sre have not yet been comprehensively described in adult women 
with TS. Furthermore the effect of sub-clinical LV dysfunction on exercise capacity has not 
yet been described in a TS population, whereas this effect is well-studied in non TS cohorts 
[15, 16]. While these effects may be clinically relevant, especially in a population that often 
struggles with unexplained fatigue[17]. Therefore, the aims of this study are threefold; 
firstly to comprehensively describe systolic (LvGLS) and diastolic LV function (Sre) using STE 
and compare it to age and gender matched controls. Secondly, to determine exercise 
capacity in women with TS. Finally, we aim to investigate possible relation between left 
ventricular function and exercise parameters. 
Methods 
Study population and design 
In this multi-center, cross-sectional study 94 consecutive adult women with genetically 
proven TS were included from October 2014 to April 2016. All patients underwent a 
physical examination, transthoracic echocardiogram (TTE), electrocardiogram (ECG) and a 
cardio pulmonary exercise test (CPET) on a bike ergometer on the same day. Electronic 
patient records were used to collect medical history. A total of 32 age-matched healthy 




control group. All healthy controls were free from a history of systemic disease, 
cardiovascular disease, renal dysfunction or cardiac medication use.  Details of this control 
cohort have been described previously [7]. Hypertension was defined as the prescription of 
antihypertensive medication or an elevated blood pressure (systolic >140 mmHg and/or 
diastolic blood pressure >90 mmHg). Hypercholesterolemia and diabetes were defined as 
the requirement for treatment. Body surface area was determined using the DuBois 
formula [18]. This study was approved by the medical ethical committee of the Erasmus 




Two-dimensional greyscale images were obtained by two experienced sonographers using 
the ultrasound system iE33 (Philips Medical Systems, Best, The Netherlands) equipped with 
a S5-1 transducer (1-MHz to 5-MHz, frequency transmitted 1.7 MHz, frequency received 
3.4 MHz). A minimum framerate of 60 Hz is obtained to optimize the speckle tracking 
echocardiograph. Digital images are stored in QLAB workstation (Philips Medical Systems) 
for further analysis.  
 
Image analysis 
Dimensional and functional measurements were done according to the recommendations 
for cardiac chamber quantification in adults [19]. The mitral- and aortic valve regurgitation 
were visually graded as none, mild, moderate or severe. Ejection fraction was visually 
graded as reduced, mildly reduced or good. Left ventricular strain analysis using STE was 
done by A.H. and S.Y, blinded to patient specific information. 2D-speckle tracking analysis 
was done using Tomtec Imaging Systems (2D Cardiac Performance Analysis). Feasibility was 
assessed by both observers, in case of insufficient imaging quality patients were excluded 
from further analysis. The peak systolic LV GLS, defined as the maximum strain value during 
the ejection, was calculated from the apical four-, three- and two-chamber views according 
to the guidelines of the American Society of Echocardiography and the European 
Association of Cardiovascular Imaging [19]. Also, LV global longitudinal early diastolic strain 
rate (Sre) was assessed as the maximum strain rate during early diastole. Sre was calculated 
for each apical chamber view by averaging the segmental Sre values. The myocardial 
contours, both end diastolic and end-systolic, are drawn automatically by the software. 
Contours were checked during the full cardiac cycle and manually adjusted if necessary.   
 
Electrocardiogram and cardiopulmonary exercise test 
Participants underwent a 12-lead standard resting electrocardiogram (ECG) and a 




analysis. The diastolic and systolic blood pressure was measured at rest, and at maximal 
exertion. All parameters are determined according to the ATS/ACCP guidelines [20]. 
Individual standardized reference value are calculated according to the CPET-protocol used 
in our center using the formula for women: ((2*length-2.37*age-73)*1.01+16,6)*0.8.  A 
workload or VO2max lower than 85% of the predicted value is considered as reduced 
exercise capacity. The reference group did not complete a bike ergometry as this was a 
retrospective cohort and this was not included in the protocol at the time of inclusion 
 
Statistical analysis  
Continuous variables are reported as mean ± standard deviation (SD) when normally 
distributed, and as median and IQR in case of a non-normal distribution. Categorical 
variables are expressed in frequencies and percentages. Differences between two groups 
are compared by using the Student unpaired T-test when normally distributed and the 
Mann-Whitney U test in case of a non-normal distribution. Furthermore, differences 
between two measurements in a group were compared by using the paired T-test. 
Correlation analysis is performed by Pearson or Spearman correlation test, as appropriate. 
Univariable linear regression analysis and subsequent stepwise multivariable linear 
regression analysis (p<0.10) was performed to identify patient characteristics that are 
significantly associated with LV function and exercise capacity. In case of collinearity of 
variables, we entered the variable with the strongest correlation with the outcome into the 
multivariate linear regression analysis. A p-value of <0.05 is considered statistically 
significant. The inter-observer variability was analyzed by using the Bland-Altman analysis. 
The limits of agreement between two observers were defined as the mean of the 
differences ±1.96 SD. The coefficient of variation (COV) was calculated as the ratio of the 
standard deviation of the mean difference to the mean of the two measurements. All 
statistical analyses were performed with the Statistical Package for Social Sciences, version 
21.0 (SPSS, Chicago, Illinois). 
 
Results 
Characteristics of the study population 
Ninety-four adult women with TS (mean age 36 ± 13 years, all female) were included. The 
control group consisted of 32 healthy women (mean age 37 ± 6 years). Forty-four women 
had a monosomy X, 14 had a mosaicism, other karyotypes included isochromosome (n=14), 
polyploidy (n=5), ring chromosome (n=3), deletion (n=3), derivative (n=2). 
Of these women, 41 (44%) were known with structural heart disease, such as BAV (n=27), 
PAPVR (n=13), CoA (n=9), persistent left vena cava superior (n=4), arteria lusoria (n=3), 




(n=1), aortic stenosis (n=1), pulmonary atresia (n=1), incomplete double aortic arch (n=1) or 
tetralogy of Fallot (n=1). Baseline characteristics for TS patients and healthy controls are 
shown in Table 1. There was no difference in baseline characteristics between TS women 
with and without structural heart disease. Moreover, eight TS women (9%) had underwent 
aortic intervention at moment of inclusion including: coarctation repair (n=6), coarctation 
repair and a graft replacement of the aortic root (n=1), and coronary artery bypass grafting 
(n=1). Furthermore, seven patients (7%) had underwent valve intervention. There were 23 
(24%) TS women using cardiovascular medication: statin (n=8), angiotensin ll receptor 
blockers (n=6), beta-blockers (n=8) or angiotensin converting enzyme inhibitors (n=7). 
 
Systolic and diastolic myocardial deformation measurements 
Twelve TS patients (13%) and one healthy control (3%) had to be excluded from strain 
analysis in advance because of poor imaging quality. Women with TS had a significantly 
impaired systolic LvGLS (-17.82 ±2.98% vs. -21.80 ±1.85%, p<0.001; figure 1A) and diastolic 
Sre (0.98 ±0.32 s-1 vs. 1.27 ±0.19 s-1, p>0.001; figure 1B) compared to healthy female 
controls. Furthermore, 28 TS women (30%) had a systolic LvGLS below normal (<17%, [19]). 
When compared with the lower limit of normal for their age group (<0.89s-1, [21]), 35 TS 
patients (37%) had a low Sre value. The intra-observer variability analysis showed low mean 
differences and good correlation for systolic LvGLS (0.31% ± 1.36, Pearson’s R: 0.885, p-
value<0.001, supplemental figure 1) and Sre (-0.07s-1 ±0.19, Pearson’s R: 0.817, p-












Baseline    
Age, years 36 ± 13 37 ± 6 0.674 
Height, cm 155 ± 8 169 ± 6 <0.001 








BMI, kg/m2 26 ± 5.5 23± 3.3 0.001 
SBP, mmHg 126 ± 15 118 ± 9 <0.001 
DBP, mmHg 81 ± 12 75 ± 8 0.001 
Hypertension 19 (20) NA  
Hypercholesterolemia 10 (11) NA  
Diabetes 4 (4) NA  
HRT 94 (100) NA  
Exercise   Completeness  n (%) 
Workload, % of predicted 
Workload, watt 
95 ± 23 




Heart rate    
HR, % of predicted 89 ± 9  92 (100) 
Heart rate, beats/ min 163 ± 23  92 (100) 
O2 pulse, ml/min/beat 9.31 ± 2.00  90 (98) 
Blood pressure    
SBP, mmHg 155 ± 22  92 (100) 
DBP, mmHg 80 ± 14  92 (100) 
Ventilation    
VO2, ml/ min 1555 ± 384  91 (99) 
VO2, % of predicted 89 ± 16  91 (99) 
VO2, ml/ min/ kg 25.16 ± 6.10  91 (99) 
VCO2, ml/ min 1819 ± 500  90 (98) 
V’E, l/min 58.5 ± 16.6  91 (99) 
V’E, l/ min/ kg 0.96 ± 0.29  91 (99) 
PETO2, kPa 15.7 ± 0.9  91 (99) 
EqCO2  30.2 ± 4.6  90 (98) 
EqO2 35.4 ± 7.5  90 (98) 
Peak RER 1.2 ± 0.1  91 (99) 
 
Table 1. Continuous 
data are presented as 
‘mean ± SD’ and 
categorical data as ‘n= 
(%)’. BSA: body surface 
area, SBP: systolic blood 
pressure, DBP: diastolic 
blood pressure,  HRT 
homone replacement 
therapy, BAV: bicuspid 
aortic valve, NA: not 
applicable, *: 
significance of the 
difference between 
patients with all Turner 
syndrome patients and 
healthy controls. 
Measurements at 
maximal exertion. HR: 
heartrate, SBP: systolic 
blood pressure, DBP: 
diastolic blood pressure, 
VO2 : O2 consumption, 
VCO2:  CO2 production, 
V’E: minute volume, 
PETO2: End tidal tension 
of oxygen, EqCO2: 
ventilatory equivalent 
for CO2, EqO2: 
ventilatory equivalent 









(n=32)  P-value* 
Age, years 36 ± 13 37 ± 6 0.674 
Height, cm 155 ± 8 169 ± 6 <0.001 
Weight, kg 62.9 ± 15.1 66.1 ± 9.8 0.171 
BSA, m2 1.61 ± 0.20 1.76 ± 0.13 <0.001 
SBP, mmHg 126 ± 15 118 ± 9 <0.001 
DBP, mmHg 81 ± 12 75 ± 8 0.001 









Figure 1. A) Systolic left ventricular global longitudinal strain (%, LVGLS); values for Turner 
syndrome patients (TS) are indicated in red, healthy controls (HC) in blue.  B) Diastolic 
myocardial strain rate (S-1, Sre).  Apical (A) 4, 3 and 2 chamber (ch) views. Completeness is 
indicated (n=) for each view. P-values are shown above each column. 
 
 
Supplemental figure 1. Inter-observer agreement and identity line for LvGLS (A) 
and Sre (B). Bland-Altman plot for LvGLS (B) and Sre (D). Dashed red lines indicate 
±1.96 SD. LvGLS: left ventricular global longitudinal strain, Sre diastolic strain rate. 







Echocardiographic measurements are shown in Table 2. All functional LV parameters, LV 
chamber function, E-wave, and E’-wave were significantly different in TS patients compared 
with healthy women. The absolute LV dimensions were not significantly different; however, 
when corrected for BSA, LV was significantly larger in TS women, both in end-diastole 
(LVEDd: 28mm/m2±3.6 vs. 26mm/m2±2.6, p= 0.002) and in end-systole (LVEDs: 18mm/m2 
±3.2 vs. 16mm/m2± 2.4, p=0.002). TS women may have higher BMI than their non-TS 
peers, which may influence their BSA. Therefore we also examined LV dimension corrected 
for height, where the same statistically significant difference was observed (LVEDd per 
meter: 29mm/m±2.9 vs. 27mm/m±2.1, p= 0.002) and in end-systole (LVEDs: 18mm/m ±3.2 
vs. 16.5mm/m± 2.4, p=0.001). 
 
Electrocardiography  
Women with TS had significantly higher resting heart rate (77 bpm±13) compared to 
healthy controls (60 bpm±8, p<0.001). Also, conduction times differed between groups: the 
PR-duration was shorter (137ms±25 and 148ms±24, p=0.029), and QTc-duration was longer 
(420ms±31 and 395ms± 14, p<0.001) in women with TS compared to healthy women. None 
of the patients had signs of LV hypertrophy on the electrocardiogram and all TS patients, 






Table 2. Baseline characteristics 











Left ventricular function 
    
LVEF, % 53 ± 10 84 (89) 62±5 31 (97) <0.001 
E-wave, m/s 0.84 ± 0.21 90 (96) 0.81 ± 0.18 31 (97) 0.503 
A-wave, m/s 0.66 ± 0.23 89 (95) 0.45 ± 0.12 31 (97) <0.001 
E/A-ratio 1.40 ± 0.55 89 (95) 1.95 ± 0.79 31 (97) 0.001 
DET, ms 199 ± 53 88 (94) 177± 27 31 (97) 0.006 
E’- wave, cm/s 10.1 ± 3.6 84 (89) 10.7 ± 2.0 30 (94) 0.968 
E/e’- ratio 9.7 ± 4.0 84 (89) 7.5 ± 1.7 30 (94) <0.001 
Left sided dimensions 
    
LVEDd, mm 44.6 ± 4.6 93 (99) 45.6 ± 3.5 32 (100) 0.240 
LVEDd per BSA, 
mm/m2 
27.9 ± 3.6 93 (99) 26.1 ± 2.6 32 (100) 0.002 
LVEDs, mm 28.6 ± 4.6 93 (99) 27.9 ± 4.0 32 (100) 0.446 
LVEDs per BSA, 
mm/m2 
17.9 ± 3.2 93 (99) 15.9 ± 2.4 32 (100) 0.002 
Table 2. LVEF: left ventricular ejection fraction, BSA: body surface area, E-wave: mitral flow 
E velocity, A-wave: mitral valve A velocity, E/A- ratio: mitral flow E velocity/ A velocity, DET: 
deceleration time, E’- wave: early diastolic annular myocardial velocity (septal), E/E’-ratio 
mitral flow E velocity/ early diastolic annular myocardial velocity, LVEDd: left ventricular 








Table 2 continued -Baseline characteristics 
.Table 2.MV regurgitation: mitral valve regurgitation, AV regurgitation: aortic valve 
regurgitation, NA: not applicable  
 
Cardio pulmonary exercise test  
Cardiopulmonary exercise testing was performed in 92 (98%) patients and exercise 
parameters are shown in Table 1. Thirty-two TS women (35%) had a reduced workload and 
33 women (36%) had a reduced VO2max (<85%). Moreover, TS women had a significantly 
reduced maximal heart rate (p<0.001), reduced oxygen uptake (p<0.001) and a reduced 
maximal workload (p=0.033) when compared with individual standardized reference 
values. Moreover, exercise capacity did not differ between women with and without 
cardiac defects (94% vs 96% of predicted, p=0.752).  
 
Associations of systolic and diastolic myocardial deformation parameters  
The results of the regression analysis are presented in table 3. In line with previous higher 
age was significantly associated with reduced Sre, and longer QTc times with a higher Sre. 
Also karyotype remained significantly associated with Sre (β-coefficient: 0.005, p-value 
<0.001; R2=0.445). For LvGLS no significant associations were found with baseline 
characteristics (Table 3). Although it was not the main objective of our study we did 
compare patients with and without cardiovascular disease. We did test for a possible 
difference in patients with or without structural heart disease. However, no such influence 
could be found for the main outcome measurements such as strain or exercise capacity. 
Moreover, some minor differences were observed that may point in the direction of minor 





































diastolic dysfunction in the patient group with cardiac disease. A higher a-wave was 
observed in (0.7 vs 0.6 m/s, p= 0.019), a lower e’-wave (9 vs. 11 cm/s, p=0.031). Patients 
with cardiac disease also had a larger ‘LVED/BSA’ both in systole and diastole (28.9 vs 27.2, 
p=0.19 and 18.6 and 17.3 p=0.49). However this was largely explained by them having a 
lower BSA (1.56 vs 1.65; p=0.02). 
Discussion 
This study demonstrates significantly lower myocardial deformation parameters (LvGLS and 
Sre) in women with TS Furthermore. Furthermore, TS women showed reduced 
conventional diastolic parameters, significantly different conduction times and a lower 
exercise capacity. Age, karyoptype and QTc-duration were significantly associated with Sre 
but not with LvGLS in the TS population. We did observe impaired diastolic function on 
conventional echocardiography compared to the healthy controls, mainly:  lower A-wave  
and E/A-ratio, shorter DET, and higher E/e’-ratio. 
 
LV myocardial deformation in women with TS  
Although LV myocardial deformation measurement using STE is superior to tissue Doppler 
imaging (TDI), [22, 23] earlier studies have already described a higher A-wave and 
subsequently a lower E/A- ratio compared to healthy female subjects [8-11]. Our study 
supports these findings and adds a prolonged deceleration time and higher E/e’-ratio 
compared to healthy women. 
Hypertension is an important risk factor for LV diastolic dysfunction and aortic dilatation. In 
line with previous studies, [24-27] we found an elevated diastolic and systolic blood 
pressure in women with TS.  Therefore vigilant surveillance of not only systolic but also 
diastolic blood pressure in TS patients is important as described earlier [25]. We 
hypothesized that this difference in blood pressure may explain the difference in 
myocardial deformation parameters between TS and healthy controls. However, our 
current study shows no significant effect of blood pressure on the myocardial deformation 
parameters. This finding is in line with earlier studies that have shown that the changes in 
LV function seem to occur irrespective of hypertension or metabolic control in women with 
TS [9, 10]. 
An alternative explanation could lie in the increased prevalence of congenital heart disease 
in this population. Some congenital heart defects such as CoA and BAV are known to cause 
a reduced LvGLS, [7, 28] both of which occur frequently in women with TS. Unfortunately 
our study was not designed to and further studies are therefore needed to definitively 
confirm such a relation in TS women.  
A third potential explanation could be offered by the decreased aortic distensibility that is 
described in women with TS [29-32]. Vascular stiffening reduces compliance and increases 




have to compensate for this pressure overload by increasing myocardial wall thickness, 
leading to reduced diastolic compliance or even increased end-diastolic volume. However, 
to our knowledge no longitudinal studies have been conducted that investigate a possible 
relation between diastolic function and aortic elasticity in women with TS. We found an 
indication of increased LV size when corrected for BSA or height in the TS population and a 
decreased exercise capacity. This could resemble the impaired diastolic reserve seen in  HF 
with preserved ejection fraction (HFpEF) which leads to LV end-diastolic pressure (EDP) 
resulting in  exercise intolerance [33]. However, a follow-up study would be needed to 
investigate if this holds any relation to the aortic distensibility.  
Although hypertension, congenital heart disease and vascular compliance may all 
contribute to the observed LV dysfunction in women with TS, a common underlying cause 
could be assumed in TS. Recently, TS women were found to have increased cortisol levels 
[34]. Several aspects of the TS phenotype may well fit a ‘hypercortisolism theory’. Like in 
patients with Cushing syndrome, long term exposure to increased levels of cortisol could 
lead to increased prevalence of left ventricular (LV) hypertrophy, higher frequency of 
concentric remodeling, and subsequent LV systolic and diastolic dysfunction, and left atrial 
systolic dysfunction, as well as increased regional LV wall thickness [35-38]. Possibly the 
electrophysiological changes [39], increased pulse wave velocity [40] and metabolic 
syndrome [37, 41] also fit such an explanation. Also the higher resting heart rate could fit in 
this hypothesis. 
Limitations  
The main limitation is the small sample size of the study, although this is one of the largest 
most comprehensive studies to date. Another shortcoming may be the lack of data on the 
coronary arteries of these patients. This study cannot fully discern the possible influence of 
the presence of structural heart disease on the cardiac function. We show that no 
significant difference on the main outcome parameter were found. However since this was 
not the primary objective of this study we suggest future studies to expand upon our 
current effort.  A possible inclusion bias is unlikely as patients were consecutively included 
into this study. A possible source of bias is the time and effort taken by the study. This may 
cause only less affected patients to participate. As more severely affected patients may 
already be  intensively monitored. Where less affected individuals may be tempted by a 
very comprehensive check-up. In this current study we have no information on the 
behavioral aspects of the deficit in exercise capacity. Future studies should therefore for 





Table 3. Linear regression analysis 
 
Univariable regression Multivariable regression 
 








p value Lower limit Upper limit Lower limit Upper limit 
Age, years -0,009 -0,014 -0,004 <0.001 -0.01 -0,14 -0,005 <0.001 
BMI, kg/m2 -0,005 -0,019 0,008 0.445  
   
Heart rate, 
beats/min 
0,001 -0,004 0,007 0.632 
    
DBP, mmHg 0,004 -0,002 0,010 0.169 
    
SBP, mmHg 0,001 -0,004 0,006 0.610 
    
Karyotype* 0,142 -0,007 0,291 0.061 0.130 0,009 0,250 0.035 
QTc-duration, ms 0.004 0,002 0,007 <0.001 0.005 0,003 0,007 <0.001 
PR-interval 
duration, ms 
-0,001 -0,004 0,002 0.534 
    
 
Left ventricular global longitudinal strain (LV GLS) 
Age, years 0.024 -0.025 0.074 0.335 
    
BMI, kg/m2 0.064 -0.063 0.192 0.316 
    
Heart rate, 
beats/min 
0.025 -0.028 0.079 0.342 
    
DBP, mmHg -0.049 -0.103 0.005 0.074 
    
SBP, mmHg 0.013 -0.032 0.058 0.567 
    
Karyotype* 0.145 -1.623 1.333 0.845 
    
QTc-duration, ms 0.014 -0.036 0.007 0.193 
    
PR-interval 
duration, ms 
0.013 -0.012 0.038 0.315 
    
Table 3. Regression analysis. HR: heartrate, SBP: systolic blood pressure, DBP: diastolic blood 






Systolic LvGLS and Sre were both significantly lower in TS women compared to healthy 
females and exercise capacity was found to be reduced in TS women. Reduced LVGLS and 
Sre were not associated with exercise capacity, but correlation with conventional TTE 
parameters and baseline characteristics were observed. 
 
 Supplemental figure 1
.   
Supplemental figure 1. Inter-observer agreement and identity line for LvGLS (A) and Sre (B). 
Bland-Altman plot for LvGLS (B) and Sre (D). Dashed red lines indicate ±1.96 SD. LvGLS: left 
ventricular global longitudinal strain, Sre diastolic strain rate. COV: coefficient of variation. Both 




Supplemental figure 1. Inter-observer agreement and identity line for LvGLS (A) and 
Sre (B). Bland-Altman plot for LvGLS (B) and Sre (D). Dashed red lines indicate ±1.96 
SD. LvGLS: left ventricular global longitudinal strain, Sre diastolic strain rate. COV: 








1. Stochholm K, Juul S, Juel K, Naeraa RW, Gravholt CH. Prevalence, incidence, diagnostic delay, and mortality in 
Turner syndrome. J Clin Endocrinol Metab. 2006;91(10):3897-902. 
2. Elsheikh M, Dunger DB, Conway GS, Wass JA. Turner's syndrome in adulthood. Endocr Rev. 2002;23(1):120-40. 
3. Donato B, Ferreira MJ. Cardiovascular risk in Turner syndrome. Rev Port Cardiol. 2018;37(7):607-21. 
4. Duijnhouwer AL, Bons LR, Timmers HJLM, van Kimmenade RRL, Snoeren M, Timmermans J, et al. Aortic 
dilatation and outcome in women with Turner syndrome. Heart. 2019;105(9):693-700. 
5. Kim HK, Gottliebson W, Hor K, Backeljauw P, Gutmark-Little I, Salisbury SR, et al. Cardiovascular anomalies in 
Turner syndrome: spectrum, prevalence, and cardiac MRI findings in a pediatric and young adult population. AJR 
Am J Roentgenol. 2011;196(2):454-60. 
6. van den Hoven AT, Chelu RG, Duijnhouwer AL, Demulier L, Devos D, Nieman K, et al. Partial anomalous 
pulmonary venous return in Turner syndrome. Eur J Radiol. 2017;95:141-6. 
7. Menting ME, McGhie JS, Koopman LP, Vletter WB, Helbing WA, van den Bosch AE, et al. Normal myocardial 
strain values using 2D speckle tracking echocardiography in healthy adults aged 20 to 72 years. Echocardiography. 
2016;33(11):1665-75. 
8. Mortensen KH, Gravholt CH, Hjerrild BE, Stochholm K, Andersen NH. Left ventricular hypertrophy in Turner 
syndrome: a prospective echocardiographic study. Echocardiography. 2012;29(9):1022-30. 
9. Andersen NH, Hjerrild BE, Sorensen K, Pedersen EM, Stochholm K, Gormsen LC, et al. Subclinical left ventricular 
dysfunction in normotensive women with Turner's syndrome. Heart. 2006;92(10):1516-7. 
10. Sozen AB, Cefle K, Kudat H, Ozturk S, Oflaz H, Akkaya V, et al. Left ventricular thickness is increased in 
nonhypertensive Turner's syndrome. Echocardiography. 2009;26(8):943-9. 
11. Oz F, Cizgici AY, Ucar A, Karaayvaz EB, Kocaaga M, Bugra Z, et al. Doppler-derived strain imaging detects left 
ventricular systolic dysfunction in children with Turner syndrome. Echocardiography. 2014;31(8):1017-22. 
12. Barbier P, Mirea O, Cefalu C, Maltagliati A, Savioli G, Guglielmo M. Reliability and feasibility of longitudinal AFI 
global and segmental strain compared with 2D left ventricular volumes and ejection fraction: intra- and inter-
operator, test-retest, and inter-cycle reproducibility. Eur Heart J Cardiovasc Imaging. 2015;16(6):642-52. 
13. Ng AC, Delgado V, Bertini M, van der Meer RW, Rijzewijk LJ, Shanks M, et al. Findings from left ventricular 
strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol. 
2009;104(10):1398-401. 
14. Nakai H, Takeuchi M, Nishikage T, Lang RM, Otsuji Y. Subclinical left ventricular dysfunction in asymptomatic 
diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic 
duration. Eur J Echocardiogr. 2009;10(8):926-32. 
15. Barmeyer A, Mullerleile K, Mortensen K, Meinertz T. Diastolic dysfunction in exercise and its role for exercise 
capacity. Heart Fail Rev. 2009;14(2):125-34. 
16. Skaluba SJ, Litwin SE. Mechanisms of exercise intolerance: insights from tissue Doppler imaging. Circulation. 
2004;109(8):972-7. 
17. van den Hoven AT, Bons LR, Dykgraaf RHM, Dessens AB, Pastoor H, de Graaff LCG, et al. A value-based 
healthcare approach: Health-related quality of life and psychosocial functioning in women with Turner syndrome. 
Clin Endocrinol (Oxf). 2020. 
18. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 
1916. Nutrition. 1989;5(5):303-11; discussion 12-3. 
19. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac 
chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography 
and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-70. 
20. American Thoracic S, American College of Chest P. ATS/ACCP Statement on cardiopulmonary exercise testing. 




21. van Grootel RWJ, Menting ME, McGhie J, Roos-Hesselink JW, van den Bosch AE. Echocardiographic chamber 
quantification in a healthy Dutch population. Neth Heart J. 2017;25(12):682-90. 
22. Dandel M, Lehmkuhl H, Knosalla C, Suramelashvili N, Hetzer R. Strain and strain rate imaging by 
echocardiography - basic concepts and clinical applicability. Curr Cardiol Rev. 2009;5(2):133-48. 
23. Jia C, Olafsson R, Huang SW, Kolias TJ, Kim K, Rubin JM, et al. Comparison of 2-D speckle tracking and tissue 
Doppler imaging in an isolated rabbit heart model. IEEE Trans Ultrason Ferroelectr Freq Control. 
2010;57(11):2491-502. 
24. Nathwani NC, Unwin R, Brook CG, Hindmarsh PC. Blood pressure and Turner syndrome. Clin Endocrinol (Oxf). 
2000;52(3):363-70. 
25. Elsheikh M, Casadei B, Conway GS, Wass JA. Hypertension is a major risk factor for aortic root dilatation in 
women with Turner's syndrome. Clin Endocrinol (Oxf). 2001;54(1):69-73. 
26. Gravholt CH, Naeraa RW, Nyholm B, Gerdes LU, Christiansen E, Schmitz O, et al. Glucose metabolism, lipid 
metabolism, and cardiovascular risk factors in adult Turner's syndrome. The impact of sex hormone replacement. 
Diabetes Care. 1998;21(7):1062-70. 
27. Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol. 1998;51(2):147-58. 
28. Zhang X, Zhu M, He T, Yuan J, Zhu H, Morrisroe DE, et al. Cardiac Mechanics in Isolated Bicuspid Aortic Valve 
Disease With Normal Ejection Fraction: A Study of Various Valvular Lesion Types. Medicine (Baltimore). 
2015;94(47):e2085. 
29. Schafer M, Browne LP, Truong U, Jaggers JJ, Mitchell MB, Malone L, et al. Aortic stiffness in adolescent Turner 
and Marfan syndrome patients. Eur J Cardiothorac Surg. 2018;54(5):926-32. 
30. van den Berg J, Bannink EM, Wielopolski PA, Pattynama PM, de Muinck Keizer-Schrama SM, Helbing WA. 
Aortic distensibility and dimensions and the effects of growth hormone treatment in the turner syndrome. Am J 
Cardiol. 2006;97(11):1644-9. 
31. Pees C, Heno JA, Hausler G, Ertl DA, Gulesserian T, Michel-Behnke I. Aortic elasticity deterioration proves 
intrinsic abnormality of the ascending aorta in pediatric Turner syndrome unrelated to the aortic valve 
morphology. Heart Vessels. 2018;33(11):1350-7. 
32. Sharma J, Friedman D, Dave-Sharma S, Harbison M. Aortic distensibility and dilation in Turner's syndrome. 
Cardiol Young. 2009;19(6):568-72. 
33. Chattopadhyay S, Alamgir MF, Nikitin NP, Rigby AS, Clark AL, Cleland JG. Lack of diastolic reserve in patients 
with heart failure and normal ejection fraction. Circ Heart Fail. 2010;3(1):35-43. 
34. Savas M, Wester VL, Dykgraaf RHM, van den Akker ELT, Roos-Hesselink JW, Dessens AB, et al. Long-term 
cortisol exposure and associations with height and comorbidities in Turner syndrome. J Clin Endocrinol Metab. 
2019. 
35. Toja PM, Branzi G, Ciambellotti F, Radaelli P, De Martin M, Lonati LM, et al. Clinical relevance of cardiac 
structure and function abnormalities in patients with Cushing's syndrome before and after cure. Clin Endocrinol 
(Oxf). 2012;76(3):332-8. 
36. Muiesan ML, Lupia M, Salvetti M, Grigoletto C, Sonino N, Boscaro M, et al. Left ventricular structural and 
functional characteristics in Cushing's syndrome. J Am Coll Cardiol. 2003;41(12):2275-9. 
37. Isidori AM, Graziadio C, Paragliola RM, Cozzolino A, Ambrogio AG, Colao A, et al. The hypertension of Cushing's 
syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens. 
2015;33(1):44-60. 
38. Kamenicky P, Redheuil A, Roux C, Salenave S, Kachenoura N, Raissouni Z, et al. Cardiac structure and function 
in Cushing's syndrome: a cardiac magnetic resonance imaging study. J Clin Endocrinol Metab. 2014;99(11):E2144-
53. 
39. Alexandraki KI, Kaltsas GA, Vouliotis AI, Papaioannou TG, Trisk L, Zilos A, et al. Specific electrocardiographic 
features associated with Cushing's disease. Clin Endocrinol (Oxf). 2011;74(5):558-64. 
40. Blain H, Sinaii N, Zeltser D, Lyssikatos C, Belyavskaya E, Keil M, et al. Aortic pulse wave velocity in children with 
Cushing syndrome: A window into a marker of early cardiovascular disease. Endocrinol Diabetes Metab. 
2019;2(2):e00054. 














Objectives. Variations in coronary anatomy, like absent left main stem and left 
dominant coronary system, have been described in patients with Turner 
syndrome (TS) and in patients with bicuspid aortic valves (BAV). It is 
unknown whether coronary variations in TS are related to BAV and to 
specific BAV subtypes. To compare coronary anatomy in patients with TS 
with/without BAV versus isolated BAV and to study BAV morphology 
subtypes in these groups. 
Methods.  Coronary anatomy and BAV morphology were studied in 86 patients with 
TS (20 TS-BAV, 66 TS-tricuspid aortic valve) and 86 patients with isolated 
BAV (37±13 years vs 42±15 years, respectively) by CT. 
Results.   There was no significant difference in coronary dominance between 
patients with TS with and without BAV (25% vs 21%, p=0.933). BAVs with 
fusion of right and left coronary leaflets (RL BAV) without raphe showed a 
high prevalence of left coronary dominance in both TS-BAV and isolated 
BAV (both 38%). Absent left main stem was more often seen in TS-BAV as 
compared with isolated BAV (10% vs 0%). All patients with TS-BAV with 
absent left main stem had RL BAV without raphe. 
 
Conclusions.  The equal distribution of left dominance in RL BAV without raphe in TS-
BAV and isolated BAV suggests that presence of left dominance is a 
feature of BAVs without raphe, independent of TS. Both TS and RL BAV 
without raphe seem independently associated with absent left main 
stems. Awareness of the higher incidence of particularly absent left main 











Turner syndrome (TS) is caused by complete or partial monosomy of the X chromosome in 
all or part of the cells and affects 1 in 2500 women [1]. The mortality rate in patients with 
TS is around three times higher than in the general female population, mainly as a result of 
cardiovascular disorders [2]. This includes coronary artery disease (CAD) [3], the presence 
of a bicuspid aortic valve (BAV, 12%–30%), coarctation of the aorta (CoA, 7%–18%), partial 
anomalous pulmonary venous return (1%–25%) [4-6] and hypoplastic left heart 
syndrome[7]. Also coronary anomalies are reported frequently in patients with TS (20% vs 
5% in the general population), although data are scarce [7]. These coronary anomalies 
mainly seem to involve the left coronary artery (LCA) system, with immediate bifurcation of 
the two major branches of the LCA (i.e., absent main left coronary stem) being the most 
common anomaly reported with an incidence of 14%[7]. A higher prevalence of left 
coronary dominance has also been noted in patients with TS (28% vs 20% in healthy 
controls) [7]. Furthermore, the prevalence of BAV is common in TS, described in 12%–30% 
of patients with TS [5, 8, 9]  vs 1%–2% in the general population [10, 11]. 
BAV is the most common congenital cardiac abnormality and variations in coronary 
anatomy, such as an absent main left coronary stem [12], have been described. The 
incidence of a left dominant coronary artery system in patients with BAV is reported to be 
25%–29%, [13, 14] much higher than the reported incidence of 10%–12% in the general 
population with tricuspid aortic valves (TAV) [15, 16]. Interestingly, a left dominant 
coronary artery system as well as immediate bifurcation of the LCA appears to be 
associated to the left-right fusion BAV without a raphe (ie, strictly bicuspid) [17]. 
Thus, patients with TS are reported to have an increased prevalence of coronary anomalies, 
increased left coronary dominance and increased prevalence of BAV, but data on these 
issues are limited. Furthermore, little is known about the relation between coronary 
anomalies, left coronary dominance and BAV, and the various morphologies of BAV in 
patients with TS. In addition, the relation with the BAV-associated aortic disease (mainly 
aortic coarctation) is unclear. The current study will focus on these issues in patients with 
TS in comparison to patients with isolated BAV. The aims of the current study are: (1) to 
investigate coronary anatomy in patients with TS; (2) to study coronary anatomy in patients 
with TS in relation to the presence of BAV and BAV morphology subtypes; (3) to compare 
coronary anatomy in patients with TS with BAV versus isolated BAV; (4) to investigate the 
relation with aortic pathology, mainly CoA, in patients with TS versus patients with isolated 







This is a multicenter study performed in three different academic medical centers in the 
Netherlands. The study population consisted of 89 patients with TS and 89 non-TS patients 
with isolated BAV, who were regularly visiting the outpatient clinics of the Erasmus Medical 
Center, the Radboud University Nijmegen Medical Center or Leiden University Medical 
Center, The Netherlands. 
The inclusion criteria were: age ≥18 years and no prior aortic valve surgery for all patients. 
In addition, genetic confirmation of chromosome XO was an inclusion criterion for patients 
with TS. Patients with non-determinable aortic valve morphology were excluded from the 
analysis, leaving a total number of 172 patients included in the study. In included patients, 
multiphase CT scanning was performed to assess the aortic valve morphology and coronary 
artery anatomy. The study was conducted according to the principles of the Declaration of 
Helsinki and in accordance with the Medical Research Involving Human Subjects Act 
(WMO). The medical ethical committee of the participating centers approved the study 
(P15.167). All patients provided informed consent in writing. The current study is 
conducted by the research consortium ‘Unravelling etiology and risk factors in patients with 
Bicuspid Aortic valves’, conducted by the Erasmus Medical Center, Rotterdam; the Radboud 
University Nijmegen Medical Center, Nijmegen; and the Leiden University Medical Center, 
Leiden, The Netherlands. 
CT coronary angiography data acquisition and image analysis 
ECG-triggered multiphase CT scanning was performed in the three centers according to a 
standardized imaging protocol with local adjustments (Erasmus Medical Center: Siemens 
Medical Systems, Germany; Radboud University Nijmegen Medical Center: Toshiba Medical 
Systems; Leiden University Medical Center: Toshiba Medical Systems, Otawara, Japan). 
Dose-modulated ECG pulsing was employed. Pitch was adjusted to the heart rate and if 
necessary beta blockers were administered prior to the scan. Iodinated contrast material 
was administered through an antecubital vein followed by a mixture of contrast and saline. 
Imaging started using bolus tracking in the aorta. Images were reconstructed at 1.0 mm 
with a 0.4 mm interval. Aortic valve morphology was evaluated and identified as RL with 
‘fusion’ of right and left coronary leaflets; RN with right and non-coronary fusion; and as LN 
with left and non-coronary fusion. In addition to this, presence or absence of a raphe was 





Figure 1. Schematic overview of different BAV morphologies. Upper panel: BAVs with a raphe; top left: 
BAV with fusion of right and left (RL) coronary leaflets; middle: BAV with fusion of right and non-
coronary (RN) leaflets; right: BAV with fusion of left and non-coronary (LN) leaflets. Lower panel: 
strictly bicuspid valves (without a raphe). Leaflet size and symmetry, as well as the position of the 
commissures, may vary from the schematic overview depicted here. BAV, bicuspid aortic valve; L, left 
coronary leaflet; LA, left atrium; LCA, left coronary artery; N, non-coronary leaflet; PT, pulmonary 
trunk; R, right coronary leaflet; RA, right atrium; RCA, right coronary artery; RVOT, right ventricular 
outflow tract. (Modified after Schaefer et al 20). 
Figure 2. Flow chart indicating the study groups. BAV, bicuspid aortic valve; LN, left and non-
coronary leaflets; RL, right and left coronary leaflets; RN, right and non-coronary leaflets; TAV, 




Coronary anatomy and coronary vessel dominance were assessed in a standardized manner 
by dividing the coronary artery into 17 segments according to the guidelines of the 
American Heart Association[18]. The coronary artery system was classified as right 
dominant when the posterior descending artery (PDA) originated from the right coronary 
artery (RCA) and considered left dominant if the PDA originated from the left circumflex 
artery (LCX). The coronary artery system was classified as balanced, when the PDA 
originated from the RCA in combination with a large posterolateral branch originating from 
the LCX, reaching to or close to the posterior interventricular groove. Subsequently, the 
presence of a left main stem and localization of the coronary ostia were assessed. If there 
was no left main stem, the LCA was designated as having separate ostia of the left anterior 
descending coronary artery (LAD) and LCX. A selection of representative CT scans was 
three-dimensionally reconstructed using the AMIRA V.4.0 software package (Template 
Graphics Software, San Diego, CA, USA). 
Statistical analysis 
Continuous variables are presented as mean±SD or as median and IQR. Categorical 
variables are presented as numbers and percentages. Cross-tabulations were made for 
binary categorical data, on which Χ2 goodness-of-fit tests were performed to test for 
independence. Statistical analysis was performed using SPSS software (V.23.0, SPSS). A p 
value <0.05, by a two-sided test, was considered statistically significant. 
Results 
Patient characteristics 
The study population comprised 172 patients with a mean age of 39±14 years, 65 patients 
(38%) were male, 107 female (62%). Eighty-six patients (50%) had TS, inherently all female. 
Out of 172 patients, 106 (62%) had a BAV, of which 20 had TS (figure 2). Baseline patient 
characteristics are depicted in table 1. 
BAV morphology 
BAV morphology was studied in patients with TS and BAV (TS-BAV) and in patients with 
isolated BAV. 
TS and BAV 
In the group of patients with TS-BAV (n=20), 11 (55%) had a BAV with raphe vs 70% in the 
isolated BAV group. In 9/20 patients (45%), the raphe was located between the left and 
right coronary cusps (RL BAV). In two patients (10%) the raphe was located between the 
right and non-coronary cusps (RN BAV). BAVs without raphe were observed in 9/20 
patients (45%, as compared with 30% in the isolated BAV group), eight patients had an RL 





In the group of patients with isolated BAV, the majority of patients (60/86 (70%)) had a BAV 
with a raphe. In 43/86 patients (50%), an RL BAV with raphe was present, in accordance 
with the prevalence in previous studies in patients with isolated BAV [17, 19, 20] In 17/86 
patients (20%), an RN BAV with a raphe was present. In 26/86 patients (30%), no raphe was 
identified. In this group of strictly BAVs, 13 patients had RL BAV, 10 an RN BAV and 3 an LN 
BAV. 
Table 1. Patient characteristics 
Coronary anatomy 
Of all 172 patients analyzed, 43 (25%) had a left dominant coronary artery system and 122 
(71%) had a right dominant coronary artery system; in one patient there was a balanced 
coronary artery system and in six patients dominance was not clear. Separate ostia of the 
LCA (i.e., no left main stem) were seen in 11 patients (6%). 
Table 2A. BAV morphology subtypes in relation to coronary anatomy; TS-BAV versus TS-TAV 
 
TS-BAV TS-TAV P values 
Left dominance 5/20 (25%) 14/66 (21%) 0.933 
 Type 1A 1/9 (11%) 
  
 Type 1B 3/8 (38%) 
  
 Type 2A 1/2 (50%) 
  
 Type 2B 0 
  
 Type 3B 0 
  
Separate ostia 2/20 (10%) 9/66 (14%) 0.655 













Age (years) 39±14 42±15 37±12 37±13 
Gender, male (%) 65 (38) 65 (76) 0 (0) 0 (0) 
CoA (%) 20 (12) 11 (13) 5 (25) 4 (6) 
Length (cm) 168±15 180±11 154±7 156±9 
Weight (kg) 71±16 79±14 57±10 65±16 
Table 1. BAV, bicuspid aortic valve; TS-BAV, Turner syndrome and bicuspid aortic valve; TS-
TAV, Turner syndrome and tricuspid aortic valve. 
Table 2A. BAV, bicuspid aortic valve; CoA, coarctation of the aorta; TS-BAV, Turner syndrome and 




Coronary anatomy in patients with TS with and without BAV 
There was no significant difference in presence of left dominant coronary artery systems 
between patients with TS-BAV and patients with TS with a TAV (25% vs 21%, p=0.933, table 
2A). In addition, no significant differences were noted in the occurrence of separate ostia 
between patients with TS-BAV and patients with TS-TAV (10% vs 14%, p=0.655). 
Coronary anatomy in TS patients with BAV vs patients with isolated BAV 
There was no significant difference in prevalence of left dominant coronary artery systems 
between patients with isolated BAV and patients with TS and BAV (28% vs 25%, p=0.517, 
table 2B). Separate ostia were more often observed in patients with TS and BAV as 
compared with patients with isolated BAV, although numbers were low (2 vs 0 patients, 
respectively, table 2B) 
Table 2B. BAV morphology subtypes in relation to coronary anatomy; isolated BAV versus TS-BAV 
BAV morphology subtypes in relation to coronary anatomy 
BAV morphology in patients with TS-BAV and patients with isolated BAV is summarized in 
table 2B. In both groups, RL BAVs without raphe showed a relatively high percentage of left 
dominant coronary artery systems (38% in both groups, table 2B), as compared with the 
general population. In the TS-BAV group, both patients with separate ostia had an RL BAV 
without raphe (table 2B). Separate ostia were not observed in the group with isolated BAV 
in this cohort. 
Aortic pathology in patients with TS versus patients with isolated BAV 
Nineteen out of 172 (11%) patients had CoA. Of these 19 patients, 6 (32%) showed a left 
dominant coronary artery system. No significant difference in occurrence of left coronary 
dominance was found between patients with CoA and patients without CoA (32% vs 25%). 
In addition, there was no difference in the presence of left dominance between patients 
with CoA and TS and those without TS (33% vs 30%). A representative example of a patient 
with TS with CoA and RL BAV without a raphe is shown in figure 3.  
 
TS-BAV Isolated BAV P values 
Left dominance 5/20 (25%) 24/86 (28%) 0.517 
 Type 1A 1/9 (11%) 12/43 (28%) 
 
 Type 1B 3/8 (38%) 5/13 (38%) 
 
 Type 2A 1/2 (50%) 3/17 (18%) 
 
 Type 2B 0 3/10 (30%) 
 
 Type 3B 0 1/3 (33%) 
 
Separate ostia 2/20 (10%) 0 <0.05 
 Type 1B 2/2 (100%) 
  





Figure 3.  
 
  
Figure 3. Example of bicuspid aortic valve with fusion of right and left coronary leaflets (RL BAV) 
without raphe, closed (A) and open (B), with separate ostia (arrows) of the left anterior descending 
coronary artery (LAD) and left circumflex artery (LCX) (C). (D, E) Three-dimensional reconstruction of a 
heart with RL BAV without raphe, aortic coarctation (CoA), a left dominant coronary artery system 
and separate ostia of the LAD and LCX. The aortic valve is indicated in yellow. Ao, aorta; LA, left 
atrium; LV, left ventricle; PDA, posterior descending artery; PT, pulmonary trunk; RA, right atrium; 




Role of gender 
Finally, the role of gender was evaluated. Naturally, all patients in the Turner group were 
female. In the group with isolated BAV, 65 patients (76%) were male, 21 patients (24%) 
were female. Twenty of 65 (31%) men in this isolated BAV group had a left dominant 
coronary artery system. Of the 21 women with isolated BAV, 4 (19%) showed left 
dominance as compared with 25% in the TS-BAV group and 21% in the TS-TAV group. In 
summary, there was no significant difference in presence of left dominancy between 
women in the different groups.  
Discussion 
The key findings of this study were: 
 No significant differences in coronary anatomy with regard to coronary dominance or 
absence of left main stem were found between patients with TS with and without BAV. In 
addition, no significant differences in prevalence of left dominant systems between patients 
with BAV with TS versus without TS were observed. 
 Patients with RL BAVs without raphe showed a high prevalence of left coronary dominance 
in the group of TS-BAV as well as in isolated BAV. 
 Separate ostia were more often seen in patients with TS and BAV as compared with 
patients with isolated BAV. No significant differences in the occurrence of separate ostia 
between patients with TS-BAV and patients with TS-TAV were observed. 
 There was no significant difference in occurrence of left coronary dominance between 
patients with CoA and without CoA and between patients with CoA and TS and those 
without TS. 
Coronary anatomy: dominance 
As previously described, there is an association between BAV and the presence of a left 
dominant coronary artery system [17]. Whether this also applies to BAV in TS was to date 
unknown. One previous study described a higher prevalence of left dominant coronary 
artery systems in TS, however this was not specified to aortic valve morphology (BAV vs 
TAV) [7]. The current study shows that patients with TS and BAV do not show significantly 
more left dominant coronary artery systems as compared with patients with TS with TAV 
(25% vs 21%). The higher prevalence of left dominance in TS therefore does not seem to be 
attributed to the presence of BAV, suggesting that the presence of TS may be an 
independent factor associated with LCA dominance, regardless of valve morphology. If 
there was a cumulative effect of TS and BAV, we would have expected the group of TS-BAV 





In general, patients with isolated BAV showed more left dominant coronary artery systems 
(28%) than reported in the general population. This is in accordance with our previous 
study, in which we found a higher prevalence of left dominance in RL BAV without raphe in 
patients with isolated BAV[17], and it is in line with the literature[16, 17].16 17 Identical 
results were obtained in the current study for both patients with TS-BAV and isolated BAV. 
The equal percentages of this distribution in both TS and isolated BAV groups suggest that 
the presence of left dominance is a feature of BAVs without raphe and not affected by the 
presence of TS. In summary, both TS and RL BAV without raphe seem to be independently 
associated with left coronary dominance. 
Coronary anatomy: separate ostia 
Separate ostia or absent left main trunk has been described in 14% of patients with TS 
compared with less than 1% in the general population, which was not specified to aortic 
valve morphology [7, 21]. The current study shows comparable results, showing separate 
left-sided coronary ostia in 13% of patients with TS. No significant differences in absence of 
main stem with regard to valve morphology (BAV or TAV) were found. Remarkably, in the 
current study, separate ostia were not observed in patients with isolated BAV, whereas 
separate ostia were previously observed in patients with isolated BAV in 11%–15% [12, 17]. 
Within the TS-BAV group, both of the separate coronary ostia occurred in RL BAV without 
raphe, which corresponds to previous data in isolated BAV [17]. Therefore, we postulate 
that, as observed in the analysis of coronary dominance, both TS and RL BAV without raphe 
are independently associated with absent left main stems. The fact that RL BAVs without 
raphe often showed a left dominant coronary artery system and separate ostia of the LAD 
and LCX may be explained by molecular mechanisms guiding the ingrowth of coronary 
arteries [22, 23]. It is tempting to speculate that in patients with BAV, where strict 
bordering of the cusps is hampered, variations in coronary anatomy occur more often. This 
might be more outspoken in patients with strictly bicuspid valves, where a raphe is missing 
and no valvar commissures can be determined. 
Coarctation of the aorta 
TS is associated with aortic pathology, especially CoA and (tubular) hypoplasia [24, 25]. In 
contrast to previous results in isolated BAV [17], patients with TS with CoA did not show 
more left dominant coronary artery systems as compared with patients without CoA. In 
addition, there was no difference in the presence of left dominance between patients with 
CoA and TS and those without TS. 
Role of gender 
The role of gender in distribution and outcome of heart disease has received more 
attention in recent years. Gender differences play a role in CAD. Cardiovascular risk factors 




for CAD. In young women, the first symptoms of CAD develop years later than in men, 
related to the benefit of the protective effect of oestrogens [3]. Previous studies have 
reported a higher incidence of CAD (obstructive and non-obstructive) in patients with left 
dominant coronary anatomy [26, 27].In addition, patients with RL BAVs without raphe have 
been reported to be more at risk of developing significant CAD [17]. BAV is almost three 
times more common in men than women[10], which might be related to the increased risk 
of men for CAD, although the mechanism of such a relation is to date unresolved [17]. 
Patients with TS are more at risk of CAD as well, probably due to the lack of oestrogens, but 
possibly also due to the fact that there’s more left dominance in patients with TS. Whether 
or not this is related to strictly bicuspid (no raphe) is yet to be explored. 
Conclusions and clinical relevance 
This study shows that there are no differences in coronary artery dominance between 
patients with TS with and without BAV and between patients with TS-BAV and isolated BAV. 
Patients with RL BAVs without raphe show a high prevalence of left coronary dominance in 
the group of TS-BAV as well as in isolated BAV. The equal distribution in both TS and 
isolated BAV groups suggests that both TS and RL BAV without raphe are independently 
associated with left coronary dominance.Patients with TS-BAV show more separate ostia of 
the LAD and LCX as compared with patients with isolated BAV. In addition, separate ostia 
were more often observed in patients with TS with RL BAV without raphe, suggesting that 
both TS and RL BAV without raphe are independently associated with absent left main 
stems.Patients with TS are more prone to develop CAD at a younger age due to lack of 
oestrogens. The presence of a left dominant coronary artery system and CoA, exposing to 
early hypertension, carry an additional risk of premature CAD. In case of the need for 
diagnostic coronary angiography or surgery, it is important to be aware of the higher 
incidence of particularly separate left coronary ostia, to avoid complications during 
hypothermic perfusion. 
Study limitations 
This study was conducted in a relatively small group of patients, bearing the risk of 
overestimation of results. Although we found an association of BAV subtypes with some 
variations in coronary anatomy in this descriptive study, this does not mean that there is a 
causal relationship. However, as limited data are currently present on coronary anatomy in 
patients with TS in different BAV morphologies, the current study adds insight into this 
issue with respect to the general, non-syndromal, population and could raise awareness of 
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Background Women with Turner syndrome (TS) are at increased risk of aortic 
dissection, which is related to ascending aortic diameter. However, the 
relation between aortic diameter and outcome is not well determined. 
This study evaluates the prevalence of aortic dilatation, the growth rate of 
the aorta and the risk of aortic complications in adults with TS. 
Methods Single centre, retrospective study of all women with TS followed with a 
strict protocol in an outpatient TS clinic. Aortic diameters were analysed 
using advanced imaging. The primary outcome was a combined endpoint 
of aortic-related mortality, aortic dissection and preventive aortic surgery. 
The secondary endpoint was aortic growth and prevalence of aortic 
dilatation, defined as an aortic size index >20 mm/m2 at baseline.   
Results  At least one cardiac MR/CT was available in 268 women with TS, having 
median age of 28.7 (IQR: 21.3–39.7) years. Aortic dilatation was present 
in 22%. Linear regression identified independent factors associated with 
larger aortic diameters: age (coefficient=0.23; p<0.001), hypertension 
(coefficient=2.7; p<0.001), bicuspid aortic valve (coefficient=3.3; 
p<0.001), 45XO karyotype (coefficient=1.7; p=0.002), weight 
(coefficient=0.075; p<0.001) and growth hormone treatment 
(coefficient=1.4; p=0.044). During follow-up (6.8±3.2 years), five women 
(2%) reached the primary endpoint (two dissections, three aortic surgery). 
Women withmore than one scan (n=171; 1015 patient-years follow-up), 
the median aortic growth was 0.20 (IQR: 0.00–0.44) mm/year. In 
multivariate analysis, aortic growth was not associated with baseline 
aortic diameter or other variables.  
Conclusions Aortic dilatation is common and known associations were confirmed in 
large adult TS cohort However, aortic dissection, related mortality and 
preventive aortic surgery are rare. Growth hormone treatment in 





Turner syndrome (TS) is a rare disorder, caused by partial or total absence of an X-
chromosome. Prominent features are short stature, gonadal dysgenesis and congenital 
heart defects. Most commonly seen cardiovascular abnormalities are bicuspid aortic valve 
(BAV), partial anomalous pulmonary venous return, elongation of the transverse aortic 
arch, aortic coarctation and ascending aortic dilatation[1-3]. Depending on the definition, 
the prevalence of aortic dilatation ranges from 4% to 42% [4, 5]. In patients with TS, aortic 
dissection is reported to occur six times more often compared with the general population 
[1]. Reported associated factors of aortic dissection are the presence of BAV, aortic 
coarctation, dilatation of the aorta, hypertension and pregnancy. Dilatation of the aorta 
occurs predominantly at the level of the ascending aorta and is associated with dissection 
[6, 7]. European Society of Cardiology guidelines advise to correct for body surface area 
(BSA) in small body size patients[8]. For the ascending aortic diameter, this index is called 
the aortic size index (ASI). Preventive aortic surgery is advised when the ASI exceeds 
27.5 mm/m2, but this cut-off value is mainly derived from extrapolation of thoracic aortic 
dissection in women with non-TS with mostly normal height and higher age[8]. Other 
guidelines advise preventive surgery even with lower ASI (>25 mm/m2), mainly based on 
registries of aortic dissection [9]. The relation between aortic diameters and clinical 
outcome in patients with TS is not studied in large prospective studies. Increase in aortic 
diameters over time is theoretically expected to be more rapid in patients with a dilated 
aorta based on Laplace’s law and is also expected to be associated with the same factor 
that also are associated with aortic dilatation, but whether this is true for patients with TS is 
also not well investigated[10]. 
In this cohort study of women with TS, we describe the prevalence of ascending aorta 




In March 2003, a dedicated multidisciplinary adult TS outpatient clinic was established at 
Radboud University Medical Centre and a standard protocol for assessment and follow-up 
was initiated [11]. The diagnosis of TS was made based on karyotyping of at least 30 blood 
lymphocytes. All TS karyotypes were included and divided in two main groups 45X0 and 
mosaicism (non-45X0), in which the mosaicism group is divided in six groups (online 
supplementary 1). A strict follow-up protocol was followed [8]. As part of their 
multidisciplinary evaluation, patients were routinely investigated by a cardiologist with ECG, 




endocrinologist and gynaecologist. The yield of this standardised health screening in the 
initial 100 patients of our cohort was published previously [11]. All women with TS visiting 
this specialised outpatient clinic were eligible for inclusion. For this retrospective study, we 
included all women with TS who had at least one CMR/CT at adult age and the images had 
to be available for review. For the study on aortic growth, all patients with at least two 
CMR/CT were included. BSA was calculated using the Dubois formula [12]. Ascending aortic 
dilatation was defined as an ASI≥20 mm/m2. Z-scores for every patient were calculated 
based on the formula published by Campens et al [13]. Hypertension and 
hypercholesterolaemia were defined following guidelines and ‘requiring medical therapy’. 
The Institutional Ethical Board (CMO Arnhem-Nijmegen) approved this study and concluded 
that no informed consent was needed as the treating doctors performed the study and the 
institution adopted an opt-out policy on scientific medical file research. All data were 
handled carefully and confidentially. 
Advanced imaging 
Baseline and follow-up aortic diameters were measured by a dedicated radiologist using 
CMR or when contraindicated CT. In all CMR/CT a standard imaging protocol was used. An 
Avanto 1.5 T whole-body MRI system was used (Siemens). Dedicated phased-array cardiac 
surface coils were placed over the thorax. All images were acquired with breath-hold. The 
ascending aorta was measured on axial TRUFI images in the axial plane. 
For CT acquisition, a 320 slice scanner (Aquilion one, Toshiba) was used. The heart was fully 
covered within a wide volume scan with ECG gating during the whole heart cycle. The 
ascending aorta was measured in the axial plane, during diastolic phase. In both modalities, 
an inner edge to inner edge method was used to measure the ascending aortic diameter at 
the height of the right pulmonary branch [11]. Both the absolute measurements and 
measurements corrected for BSA (ASI) were collected. 
Endpoints 
The primary endpoint was an aortic event, defined as aortic-related mortality (proven or 
high suspicion of dissection or rupture), aortic dissection or (preventive) aortic surgery. 
Information on the vital status of all participants was obtained from the municipal base 
administration of personal data (GBA) of the Netherlands on 1 February 2017. 
The secondary endpoint was the increase in ascending aortic diameters which was assessed 
in the patients with more than one CMR/CT. Patients who reached the primary endpoint 
before having the second CMR/CT were excluded from this analysis. The annual change of 
the aortic diameter was calculated based on the aortic diameter measurements of the first 
and last scan, divided by the time span between these scans. Because of this, negative 






Results are expressed as mean±SD or as median±IQR if the distribution was skewed or the 
Shapiro-Wilk test showed abnormal distribution. A p≤0.05 was defined to be statistically 
significant. The independent samples t-test was used to compare means (eg, aortic 
growth/year) between groups. In case of a skewed distribution, the Mann-Whitney test was 
used. The paired sample t-test was used to compare ascending aortic diameter change in 
time within cases. Univariate and multivariate linear regression analyses were used to 
explore associations with aortic diameter and aortic growth, or logistic regression analysis 
was used to explore associations with aortic dilatation and aortic growth using the same 
variables. Survival analysis could not be performed due to the limited number of events. 
Results 
In total, 270 patients with TS were eligible, of whom 2 had to be excluded due to poor-
quality aorta images. The remaining 268 patients, median age of 28.7 (IQR: 21.3–39.7) 
years and mean height of 155.2±7.2 cm, had at least one CMR/CT with adequate imaging 
and were included in the current study. During follow-up, 171 patients with TS had at least 
one other CMR/CT (figure 1). For the other patients, additional CMR/CT imaging was not 
available due to various reasons (eg, care transfer, refusal by patient, lost to follow-up, 
short period since first scan). No differences were found in baseline characteristics 
between the patients with versus without more than one scan.  
 
Figure 1. Flow diagram of patient inclusion. *Due to artefacts, the CMRs were not suitable for 





Characteristics of all 268 included patients at baseline are shown in table 1. Dilatation of 
the ascending aorta (ASI>20 mm/m2) was present in 59 (22%) patients. Mean z-score was 
0.91±1.50 and 22.8% had an z-score ≥2. The mean age of the patients with TS and a 
dilatated ascending aorta was significantly higher compared with patients with TS without 
dilatation 40.9 (IQR: 29.0–47.3) versus 25.9 (IQR: 20.5–34.8) years, p<0.001. The 
prevalence of hypertension was significantly higher in the women with dilatation (33.9% vs 
12.1%; p<0.001). Figure 2 shows the uncorrected and corrected ascending aortic diameters 
at baseline for all patients according to age. At the age of 35 years, the upper 95% line 
crosses the ASI=25 mm/m2 line. In total, 13 patients had an ASI>25 mm/m2, mean age of 
44.3±7.7 years versus 30.4±10.8 years in ASI<25 mm/m2. Baseline uncorrected ascending 
aortic diameter was independently associated with age, hypertension, BAV, 45X0 karyotype, 
weight and growth hormone treatment (table 2). Although the p-value for aortic 
coarctation in univariate analysis was <0.10, we excluded it from the model. The reason for 
this were: the SE was larger than the coefficient, the number of women with aortic 
coarctation was low and multivariate analysis using backward selection with p<0.1 excluded 










Age, years (IQR) 28.7 (21.3–39.7) 25.9 (20.5–34.8) 40.0 (29.0–47.3) <0.001 
Height, cm (SD) 155.1 (±7.2) 156.5 (±6.7) 150.4 (±6.9) <0.001 
Weight, kg (IQR) 59.0 (51.3–67.8) 60.0 (53.0–70.0) 53.0 (48–59) <0.001 
BSA, m2 (IQR) 1.57 (1.47–1.70) 1.60 (1.51–1.71) 1.47 (1.37–1) <0.001 










BAV 22.0% 15.5% 45.8% <0.001 
CoA 3.4% 2.9% 5.1% NS 
Growth Hormone* 61.0% 66.8% 40.7% 0.001 
Active smoking 9.5% 9.3% 10.2% NS 
Hypertension 16.9% 12.1% 33.9% <0.001 
Dyslipidaemia 4.5% 3.4% 8.5% NS 
Diabetes 3.8% 2.4% 8.5% 0.032 
Table 1. Characteristic of patients with TS with or without aortic dilatation at baseline 
Table 1. ASI: Aortic size index BAV: bicuspid aortic valve, CoA: coarctation of the aorta. 45X0 and 
mosaicism refers to the karyotype; aortic size index (mm/m2) is the ascending aortic diameter divided by 
BSA.*Patients treated during childhood with growth hormone. ↵BMI, body mass index; BSA, body surface 




A history of growth hormone treatment during childhood was reported in 161 (60%) 
patients. Compared with patients who were treated with growth hormone, the non-treated 
group was significantly older (mean age 39.3±10.7 vs 25.0±6.8 years; p<0.001). As a 
consequence of the relative recent introduction of synthetic growth hormone treatment, 
younger age patients were more likely to have been treated with growth hormone. The 
mean aortic diameter and ASI unadjusted for age were smaller for patients who were 
treated compared with the non-treated group (27.2±4.8 vs 29.1±5.2 mm; p=0.004 and 
16.9±3.1 vs 18.9±4.1 mm/m2; p<0.001). However, after correcting for variables shown in 
table 2, previous growth hormone treatment was still associated with a larger ascending 
aortic diameter. 
Follow-up 
Survival status was available for all patients. In total, eight patients died during a mean 
follow-up of 6.8±3.2 years. These eight cases are described in table 3. In two patients, the 
cause of death was assumed to be related to aortic dissection (case 129; case 4). Case 129 
was a 44-year-old patient with TS with an ascending aortic diameter of 65 mm 
(ASI=39.2 mm/m2), who delayed her operation to get married and died suddenly. No  
 Univariate Multivariate* 
95% CI for coefficient Coefficient P values Coefficient P values 
Age (years) 0.209 <0.001 0.230 <0.0001 0.17 to 0.29 
Hypertension 4.024 <0.001 2.677 <0.0001 1.24 to 4.12 
Bicuspid aortic valve 3.254 <0.001 3.307 <0.0001 2.07 to 4.55 
Karyotype 45X0 1.823 0.005 1.702 0.002 0.64 to 2.77 
Weight (kg) 0.056 0.014 0.075 <0.0001 0.04 to 0.11 
Growth hormone treatment† −1.879 0.003 1.404 0.044 0.04 to 2.77 
Diabetes‡ 3.96 0.015    
Aortic coarctation 3.1 0.076    
Height (cm) § −0.07 0.115    
Active smoking 0.36 0.74    
Dyslipidaemia 1.77 0.24    
Body surface area  2.76 0.119    
Table 2. Univariate and multivariate linear regression analysis for the association of absolute 
ascending aortic diameter at baseline 
 
Table 2. *R2=39.1%, indicating that only 39% of the aortic diameter differences could be explained 
by this model; coefficient=regression coefficient also called estimate; analysis of the residuals 
showed a normal distribution.†Multicollinearity between age and history of growth hormone 
therapy (correlation −0.637). ‡In the best fit model, diabetes was excluded as it was not significant 















Figure 2.Ascending aortic diameter at baseline corrected and uncorrected versus age. (A) Aortic size 
index versus age; (B) ascending aorta diameter corrected for height versus age; (C) absolute 
ascending aortic diameter versus age; (D) z-score at baseline versus age. Cases 41, 42 and 231 
underwent aortic preventive surgery. Case 231 had aortic valve dysfunction as primary indication. 
Case 129 is a patient who had presumably a type A dissection. Case 219 had a body mass index of 
40.5 kg/m2 and an ascending aorta of 41 mm. Case 213 is a patient who has an ascending aortic 
diameter of 39 mm and a body surface area of 1.33 kg/m2. The centre line represents the mean of y-
axis variable and the upper and lower line represent the 95% limit of the mean of y-axis variable. 
Figure  3. Forest plot of adjusted odds ratios for aortic dilatation at baseline in women with 
Turner syndrome. R2=38.1%. Aortic dilatation was defined as an aortic diameter >20 mm/m2 




autopsy was performed. Case 4 was also 44 years old and died from acute dissection of the 
descending aorta. This patient had normal ascending (30 mm; ASI=18.4 mm/m2) and 
descending (25 mm) aortic diameters on CMR 3.5 years prior to this event. Preventive 
ascending aortic surgery was performed in three patients. In two patients, the indication 
for surgery was ascending aortic dilatation (45 mm; 48 mm or ASI=28 mm/m2; 
ASI=25.5 mm/m2, respectively) and in one patient the indication was severe aortic valve 
regurgitation with concomitant moderate ascending aortic dilatation (36 mm; 
ASI=22.9 mm/m2). The primary endpoint was therefore reached in five patients. Because of 





In total, 171 (64%) patients had more than one CMR/CT during follow-up (figure 1). There 
was a significant increase in ascending aortic diameter per patient (1.2±2.3 mm; p<0.001) in 
a mean follow-up time of 5.9 (range: 1.1–11.3) years and a total of 1015 patient-years. 
Ascending aortic diameter increase per year was 0.20 (IQR: 0.00–0.44) mm/year. 
The median ascending aortic diameter change in the whole cohort was 0.43 (IQR: 0.00–
0.43) mm/year. The mean time between the first and last CMR/CT was not significant 
different between the women with TS who had a dilated and non-dilated ascending aorta 
















44 39.2 Yes No 45X0 Yes Yes 





58 27.0 no No Non-45X0 No Yes 




67 19.4 No No Non-45X0 No Yes 
6 Cancer 50 19.7 No No Non-45X0 No No 
7 Unknown† 33 19.5 No Yes Non-45X0 No No 
8 Unknown 38 20.1 No Yes 45X0 No No 
Table 3. Causes of death in women with TS 
Table 3. AoD: aortic Dissection, BAV: bicuspid aortic valve, GH: Growth Hormone, CoA: 
coarctation of the aorta, HT: hypertension*Case 129 is also shown in figure 2A. This woman with 
TS was on waiting-list for preventive aortic surgery. †History myocardial infarction on the age of 
30 years; the corrected aortic diameter also called aortic size index (mm/m2) is the ascending 




group was 0.00 (IQR: −0.20 to 0.31) mm/year and 0.24 (IQR: 0.00–0.44) mm/year in the 
non-dilated group (p=0.021). No significant difference was found in ascending aortic 
diameter change between patients with (n=38) or without BAV (n=133) 0.16 (IQR: −0.02 to 
0.37) mm/year versus 0.22 (IQR: 0.00–0.44) mm/year, p=0.75). There was a difference in 
patients with (n=29) or without (n=142) hypertension 0.00 (IQR:−0.22 to 0.30) mm/year 
versus 0.23 (IQR: 0.00–0.44) mm/year, p=0.04). Eight women showed an increase in 
ascending aorta diameter of ≥1 mm/year. Of the nine women who had an ASI>25 mm/m2 at 
baseline, one underwent preventive aortic surgery and one experienced an aortic 
complication during follow-up. 
During the study period, four women became pregnant, and median change in aortic 
diameter was 0.05 (IQR: −0.17 to 0.97) mm/year versus 0.20 (IQR: 0.0– 0.43) mm/year for 
the other women (p=0.84). 
Figure 4 shows the change in ascending aortic diameter for all 171 patients, related to 
baseline ascending aortic diameter (both uncorrected and corrected for BSA). The three 
operated cases had a growth varying between 0.33 and 1.22 mm/year and the woman with 
presumed type A dissection had an ascending aortic growth of 3.25 mm/year (not 
presented in figure 4). Univariate linear regression identified two associations with aortic 
growth, hypertension, and aortic dilatation at baseline, which were not significant in 
multivariate analysis. Based on the upper quartile of ascending aortic change 
(0.43 mm/year), the TS cohort was divided in two groups. Logistic regression did not 
identify significant associations for aortic growth ≥0.43 mm/year. Figure 5 shows the 
unadjusted HRs in a forest plot of all tested variables. 
Discussion 
This study describes one of the largest TS cohorts to date, in which aortic dimensions are 
measured using advanced imaging during a relative long follow-up time. Aortic dilatation 
was present in one-fifth of women with TS at a mean age of 29 years. Classical factors 
associated with larger aortic diameters were age, hypertension, BAV, 45X0 karyotype, 
weight, and growth hormone treatment. During almost 7 years of follow-up, only 2% of the 
women suffered an aortic event and no unexpected ascending aortic complications 
occurred. The aortic growth rate was low (0.20 mm/year), but higher than reported in the 
normal population (0.12 mm/year)[13] [14].   Classical factors associated with larger aortic 
diameters, such as a BAV, were not associated with faster growth of the ascending aortic 






Figure 4. Corrected and uncorrected ascending aortic diameter change versus baseline corrected 
and uncorrected ascending aortic diameter. (A) Ascending aortic change versus aortic size index 
at baseline; (B) ascending aortic change versus ascending aorta diameter corrected for height at 
baseline; (C) ascending aortic change versus absolute aortic diameter at baseline; (D) ascending 
aortic change versus z-score at baseline. Case 129 (diameter change of 3.25 mm/m2) is not 
presented in these figures. 
Figure  5. Forest plot of unadjusted HRs for aortic growth. Aortic growth was defined as aortic 
diameter increase >0.42 mm/year. ACE-I, ACE inhibitors; ARB, angiotensin II receptor blockers; ASI, 




Ascending aortic dilatation 
As shown by others, current study shows that also in women with TS age has a clear impact 
on aortic diameter [15]. This association with age is also observed in the general population 
[13, 16]. This relation is not linear but rather more curved and levelling-off at older age. In 
the current TS guidelines, no correction is made for age, which seems indicated. At a 
median age of 29 years, 22% of the women with TS have a dilated aorta (ASI>20 mm/m2). 
Maybe this high prevalence is partly caused by the ASI method. One of the pitfalls of the 
ASI method is that the ASI becomes lower in obese patients (case 219) and relative larger in 
slim patients (case 213). Due to this ‘overcorrection’ of the aortic diameter, some women 
with TS will be labelled as having a normal aortic diameter. Correcting the aortic diameter 
using height instead of BSA could partly solve this problem. This is especially important 
when realising that ASI is the main indicator for preventive surgery. Recent publications 
have shown that z-scores used for people with a normal height are also fit for women with 
TS [13, 15].The z-score was ≥2 in 22.8% of the women in this cohort. This is comparable 
with the ASI method. Indeed, both the z-score method and the ASI method correct for 
weight and height. It seems more appropriate to use ASI or z-score in women with TS with 
a normal BMI and be cautious in women with a very low or very high BMI. The cross-
sectional analysis confirmed the known factors associated with aortic dilatation [4]. In 
addition to these known associations, our data suggest that growth hormone treatment 
during childhood is associated with larger aortic diameter even after correcting for age and 
height. Due to multicollinearity with age and the chance of having being treated with 
growth hormone, this effect should be interpreted with caution. Dedicated research is 
warranted to investigate the long-term effect of growth hormone treatment on aortic 
diameters, aortic wall composition and vulnerability. Olivieri et al found that a partial cusp 
fusion was associated with larger aortic diameters [17]. In the current study, we did not use 
this partial cusp fusion. 
Aortic growth 
Even though older patients with TS generally have a larger ascending aorta, we do not 
know if these larger dimensions also lead to higher risks of aortic complications. It seems 
logical that dilatation occurring at younger age is associated with more aggressive aortic 
pathology. In the literature, the mean age at which patients with TS present with aortic 
dissection is 32 years[4] [18-20]. The age of both patients with dissection in our series was 
44 years, so also still relatively young. Others showed that especially younger adult women 
with TS who had a dilatated aorta are vulnerable and that after a certain age the risk of 
aortic dissection decreases [7]. 
Limited publication on aortic growth in women with TS are available. A prospective study 
would be the best study design. Our study is retrospective, but because of the standardised 




without selection bias, we believe this to be the second-best option to study aortic growth. 
The observed increase in aortic diameters in the current study is low, but higher than 
reported in the general population[13]. Univariate analysis suggested that hypertension 
and baseline aortic dilatation were associated with aortic growth, but in multivariate 
analysis they were no longer significant. Possibly that treatment of hypertension protected 
these women against accelerated aortic growth. The low increase in aortic diameter and 
the relative short follow-up time could be an explanation for not finding any independent 
associations for aortic diameter change. Mortensen et al developed an aortic diameter 
prediction model using complex mathematical processing based on the follow-up of 78 
women with TS over a period of almost 5 years. These cohesive models identified 
predictors of accelerated aortic growth (aortic coarctation, BAV, age, diastolic blood 
pressure, BSA and antihypertensive treatment)[7]. In our study, we could not confirm these 
findings. Heterogeneity of karyotypes present in patients with TS has been shown. In most 
cases, blood lymphocytes are used for the diagnosis and sometimes additional buccal cells 
are used. Different cell lines can show different karyotypes, making it possible that the 
karyotype of the aortic wall differ from the cell line used for diagnosis[21]. The aortic wall 
properties may therefore be not well presented by the used karyotypes. 
Outcome 
In 7 years of follow-up, the incidence of aortic complications was 2%. This low incidence of 
0.3 %/year immediately illustrates the difficulty of identifying risk factors of aortic 
complications in women with TS. On the other hand, it is important information that the 
absolute risk is very low, although still higher than in women with non-TS [1]. Our data 
certainly do not support a more aggressive approach towards surgery. The indication for 
surgery is still matter of debate. Pape et al showed, in a large cohort of patients, that in 
50% of the patients with a dissection, the aortic diameter was below the advised surgical 
aortic diameter threshold.[22]. This clearly shows that, aortic diameter as sole parameter 
on which preventive aortic surgery is advised in current guidelines is not sufficient enough 
to prevent future aortic dissections.[8, 9, 23] [24].  Future research should focus on other 
parameters to better predict future aortic dissection risk. 
Limitations 
Although we have included all patients, selection bias due to referral cannot be excluded. 
However, if selection bias has taken place, the more severe cases would have been sent to 
our tertiary clinic and therefore the relatively positive and reassuring results would only 
have been more positive. Indeed, information on survival and events was 100% complete. 
The used z-score is based on echocardiographic measurements and could differ from a z-
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Supplement 1 
Mosaicism group division 
1) mosaicism 45,X/46,XX 
2) isochromosome (45,X/46,X,i(Xq), 46,X,i(Xq) or 45,X/46,X,i(Xq)/47,X,i(Xq)) 
3) deletion (45,X/46,X,del(X) or 46,X,del(X)) 
4) polyploidy (45,X/46,XX/47,XXX or 45,X/46,XXX) 
5) ring X material (45,X/46,X,r(X)) 




















Aortic coarctation is a narrowing of the aorta, usually in juxta-ductal position which 
warrants life-long clinical follow-up. In this chapter the etiology, anatomy, natural history, 
diagnosis and treatment of this congenital heart disease will be comprehensively discussed. 






Aortic coarctation, a congenital stenosis usually located in juxta-ductal position [1-3], has 
been recognized since its first description in 1760 by Morgagni during his autopsy of a 
monk [4]. It was more formally recognized as a clinical entity after its description in 1928 
[5], and it has been surgically corrected since 1945 [6]. Nowadays it is generally accepted to 
be part of a general aortopathy, linked with other left-sided heart defects such as bicuspid 
aortic valve (BAV) [7]. The coarctation can vary in severity from quite discrete to a severe 
long hypoplastic segment. The incidence of CoA is approximately 4 per 10,000 live births 
and constitutes 5-8% of all congenital heart disease (CHD) [8]. Nowadays, aortic coarctation 
is preferably repaired surgically at an early age, but catheter intervention has become a 
valid alternative, especially in outgrown children and adults. Lifelong surveillance is 
warranted, also after successful repair, since patients remain at risk for hypertension, re-
coarctation and aneurysm formation [9-11]. When left untreated, most patients die before 
the age of 50 mainly due to coronary artery disease, stroke or intracranial hemorrhage. And 
even in patients with satisfactory repair major complications still occur. In this chapter we 
discuss the etiology, pathophysiology and the clinical aspects of aortic coarctation.  
Pathogenesis, epidemiology and Anatomy 
Anatomy  
Aortic coarctation is defined as a narrowing of the aortic isthmus, often  juxta ductal in 
position. Three main types can be distinguished depending on the anatomical position of 
the infolding of the aortic wall relative to the ductus arteriosus (DA); pre-, post or at the site 
of the ductus (figure 1) In 90% of cases the infolding is directly opposite to the DA. These 
variants present at different ages due to their difference in pathophysiology. The post –
ductal, also called the adult type, variant will have to develop collaterals pre-natally, and 
will therefore often present at adult age. Whereas the pre-ductal or infant-type is a 
cyanotic and duct dependent-lesion because no collaterals develop. Therefore, after birth 
Figure 1: schematic 
depiction of the  three 
possible locations of the 
infolding relative to the 
patent ductus arteriosus 
(PDA). With blood flowing 
from top to bottom and the 




the closure of the DA will result in hypoperfusion of the lower extremities. However, there 
is no evidence that these subtypes differ from each other in etiology. Also, coarctation has 
been described in anecdotal cases to present in the abdominal aorta, which is however 
more likely to be inflammatory, or auto-immune in origin. Aortic coarctation can even be 
traumatic when aortic dissection compromises the true lumen of the aorta. 
Epidemiology 
Aortic coarctation is a relatively frequent congenital heart defect (CHD) and is found in 
approximately 3-4  per 10.000 live births and constitutes 5% of all CHD [8]. It occurs more 
often in males than in females in a ratio between 1.27 to 1.74 to 1 [12, 13].  In most 
patients it is diagnosed shortly after birth, depending on the subtype and clinical 
symptoms. 
Etiology 
There are three possible theories explaining the development of coarctation. There is the 
ductal tissue theory, which suggests that ductal muscular tissue extends into the wall of the 
thoracic aorta, causing the aorta to constrict postnatally simultaneous with the ductus 
arteriosus. Several studies have confirmed the presence of ductal tissue in the aortic wall 
[14, 15].  
Another theory is the developmental theory, which suggests coarctation formation starts 
with a fault in early fetal development. A part of the fetal circulation involutes to form the 
separate dorsal aorta and right subclavian artery. A small segment of the fetal dorsal aorta 
will erroneously involute and will subsequently move cranially with the left subclavian 
artery [16]. This would then form the coarctation. 
The third theory is based on hemodynamical changes. During fetal development the aortic 
isthmus is a naturally occurring narrow segment because it doesn’t have to conduct a large 
flow of blood. This segment will then later be widened to facilitate the increased blood 
flow. If the increase in blood flow remains absent this narrow area will persist and a 
coarctation will be formed. This could also partly explain the association with BAV, as a 
diminished forward flow and increased post ductal flow can predispose to development of 
CoA as well. 
The etiology of CoA remains enigmatic, but it is generally assumed that coarctation is in fact 
part of a general aortapathy, linked with bicuspid aortic valve, aortic dissection and even 
intracranial aneurysms [7]. The underlying cause of these histological abnormalities 
remains largely undiscovered although cystic media necrosis has been reported. More 







The main pathophysiological mechanism by which aortic coarctation causes morbidity and 
mortality is the afterload increase of the left ventricle (LV). This occurs when the arterial 
duct closes post-natally and starts a causal chain in which increased left ventricular 
pressures lead to compensatory hypertrophy and eventually dysfunction. When the 
coarctation is severe enough this can be an acute process, leading to hypoperfusion distal 
to the coarctation, presenting in neonates with signs of shock. But also to a ‘backward 
failure’; where the rapid increase in LV systolic afterload, increased wall stress and 
compensatory left ventricular hypertrophy may cause increased pulmonary venous 
pressures with pulmonary congestion, followed by elevated pulmonary arterial pressures, 
right ventricular pressure overload and subsequently heart failure. The foramen ovale 
might be opened by the sudden increase in pressure causing left to right shunting of blood. 
In less pronounced cases this process will be less rapid and collaterals can develop, 
bypassing the coarctated segment and delaying the onset of clinical signs 
In addition to ductal tissue in the aortic wall other histological wall changes are present in 
CoA patients. Wall stiffness is increased and distensibility is decreased [17]. There is more 
collagen but less smooth muscle tissue in the prestenotic aortic wall when compared to 
post stenotic aortic wall. And cystic medial necrosis, the depletion or disarray of elastic 
tissue, is also seen.  
The effects of coarctation are not yet  fully explained, as patients with a relieved 
coarctation often still suffer from hypertension, requiring pharmacological treatment. No 
clear association could be established between the remaining gradient over the CoA and 
the occurrence of hypertension. Therefore the involvement of the renin-angiotensin-
aldosterone-system is supposed, although also other mechanisms may be involved. 
Complications 
The natural history has been described in coarctation patients before correction became 
imperative. These patients often suffered from left heart failure, intracranial hemorrhage, 
infective endocarditis, aortic dissection and rupture and coronary and cerebral heart 
disease  [2, 10]. Nowadays after intervention the most common complications are 
hypertension, recurrent coarctation, aortic rupture or aneurysm, early coronary artery 
disease and cardiomyopathy. Risk for complications increases with age, and BAV is an 
independent additional risk factor for complications as is age [18]. BAV itself is associated 
with aortic weakness, higher risk ok aortic dissection and rupture, which possibly explains 





The clinical presentation of CoA varies greatly with age. When CoA becomes evident shortly 
after birth it presents as a severe cyanotic heart defect, with poor feeding, tachypnea, 
lethargy, symptoms of congestive heart failure or shock. The onset of symptoms will 
coincide with closure of the ductus arteriosus. When CoA presents later during childhood 
or even in adulthood, the clinical symptoms will be due mainly to high blood pressure in the 
upper extremities and may include: nosebleeds, intracranial hemorrhage, dizziness, 
tinnitus, shortness of breath. Also symptoms from low blood pressure in the lower 
extremities may become evident including abdominal angina, claudication, leg cramps, 
exertional leg fatigue and cold feet [19]. A blood pressure gradient can often be seen as a 
high upper body systolic hypertension, in combination with a relative lower body 
hypotension.  However, when large collaterals exist, this may be more difficult to 
determine. 
There are different diagnostic techniques used to objectify the presence and severity of 
CoA.  
Inspection and patient history might reveal some of the symptoms mentioned above. A 
telltale sign would be differential cyanosis where the upper extremities are normally 
perfused and the lower extremities are hypo perfused.  
On palpitation a weak or absent femoral pulse may be noted, which may have a prognostic 
value, especially in combination with a prominent brachial pulse [20]. Both a radio femoral 
pulse delay and palpable collaterals on palpation are both pathognomonic for CoA. Of note 
is that an origin of the right subclavian artery distal to the coarctation might mask this 
difference, as it would also be decreased and therefore the carotid pulse should be 
palpated as well. In addition ventricular dysfunction may decrease pulses both in the upper 
and lower extremities which may reduce the gradient. 
On auscultation a supra sternal thrill, vascular murmur (often systolic) on the back, or a 
continuous vascular murmur can be heard.  
An electrocardiogram may reveal signs of left ventricular hypertrophy with or without 
secondary ST-segment abnormalities. On chest X-ray rib notching as a result of dilated 
intercostal arteries, a dilated ascending aorta, kinking or double contouring in the 
ascending aorta (figure 3’sign) and a dilated left subclavian artery can be found. Also 





Echocardiography is of great value in estimating site, structure and severity of the CoA. 
Especially in newborns this technique gives excellent opportunities as the entire aortic arch, 
isthmus, arterial duct and descending aorta are imaged from the suprasternal notch and 
from the right and left infraclavicular windows. It can also provide information on the 
function and severity of left ventricular hypertrophy as well as associated cardiac 
abnormalities and vessel diameters. In adolescents and adults echocardiography of the 
isthmus and descending aorta may become difficult as the distance from the transducer 
increases and the airways may form a more prominent barrier.  High systolic velocities are 
generally found, but a diastolic run-off phenomenon in the descending or abdominal aorta 
is presumably the most reliable sign of significant coarctation. Doppler flow tracing can 
show a “serrated” pattern with a rapid acceleration and a high velocity systolic peak, 
followed by a gradual deceleration throughout diastole (figure 2). 
However CMR and CCT are the preferred non-invasive imaging techniques because these 
allow for the entire aorta to be assessed. It allows for the precise location and collateral 
anatomy to be imaged. Also cardiac catheterization and manometry or angiography, are 
important diagnostic modalities. And 3D reconstructions can provides insightful visual aid 
to the surgeon when planning reconstruction (figure 3).  
Treatment  
In case of severe coarctation there is clear evidence that treatment of CoA, will reduce left 
ventricular afterload and will improve the long-term outcome of the patient. There are 
Figure 3. 3D reconstruction (CT) of aortic 
coarctation in a 6-month old child. Very 
prominent A. Anonyma and late branching 
a. subclavia sinistra. 
 




however different treatment options with pro’s and con’s for all techniques and there is no 
clear superior technique.  
Indication for intervention 
The decision to intervene is preferably taken in a multidisciplinary setting where careful 
evaluation on the level of the individual patient is possible. According to the most recent 
guidelines a pressure gradient between the upper and lower body extremities of >20 
mmHg in combination with an upper body hypertension (>140/90mmHg in adults) is a class 
I, level C indication for intervention [19]. Also, an abnormal blood pressure response during 
exercise or significant left ventricular hypertrophy are class I indications for intervention. 
In other cases the indication for intervention is less clearly defined. When there is 
hypertension in combination with a relative coarctation (>50% narrowing) compared to the 
aortic diameter at the level of the diagram as measured on CT, MR or invasive angiography 
an intervention should be considered for intervention (Class IIa, level C). And finally, in case 
of an anatomical narrowing (>50%) in the absence of hypertension or a significant pressure 
gradient an intervention may be considered (Class IIb, level C). This will in practice however 
not often be the sole reason for intervention.  After intervention endocarditis prophylaxis is 
advised for 6 months.  
Choice of intervention 
There are two main therapies for the relief of CoA: surgical and interventional. When 
considering surgery there are several operative techniques to choose from; (extended) 
end-to-end anastomosis, patch aortoplasty, subclavianflap aortoplasty and resection with 
interposition graft. All techniques have different advantages and disadvantages. With patch 
angioplasty for example there is a higher incidence of aneurysm formation, while in 
subclavian flap aortoplasty a higher incidence of recoarctation has been found. The 
incidence of dissection is approximately equal amongst all modalities. [21] The (extended) 
end-to-end anastomosis is the most widely used technique and generally regarded as the 
safest and most effective method. However, this technique is not feasible in every 
situation. 
The other option for gradient relief: catheter intervention, is used more often in full-grown 
children and adults. A balloon is used to disrupt the intimal and medial layers of the 
narrowed segment. Generally a covered stent is deployed to prevent recoarctation and 
aneurysm formation.  
Catheter intervention is a safe and effective alternative to surgery, with good gradient 
relief. Stenting has a lower acute complication rate when compared to surgery or balloon 
angioplasty alone [22], but more often needs elective re-intervention than surgery. There is 




pressure reduction and late complications after stenting. No randomized trials have 
compared stenting to surgery [23], and it is therefore hard to objectively compare the two 
modalities. And the choice is best made on the basis of individual patient characteristics. 
Conservative treatment 
The acute medical treatment of CoA in the neonate is focused on maintaining patency of 
the ductus arteriosus. This is mainly done by administering a prostaglandin E1 inhibitor and 
diuretics can be given to alleviate symptoms of heart failure. In the adult patient treatment 
is mainly focused on  blood pressure control. This is normally achieved using: beta-blockers, 
ACE inhibitors and angiotensin-receptor blockers [24]. The use of ACE-inhibitors has 
however been associated with renal failure, especially when renal perfusion cannot be 
sustained [25]. 
In case of a less severe coarctation or increased intervention risk the choice between 
intervention and conservative treatment is especially important. For example in patients 
with Turner syndrome more complications are seen after intervention than in the normal 
population [26], and the balance may shift towards a more conservative approach. 
Long term outcome 
Patients with CoA historically had a reduced long-term survival, mainly influenced by early 
interventional and the late hypertensive complications. Until the 1980s patients still only 
had an average life expectancy of 38 years [10], as patients often died before the age of 50. 
Nowadays patients, who have been operated using the most recent techniques, have a 
good medium- to long-term survival with actuarial survival of 98% at 40, 98% at 50 and 89% 
at 60 years of age respectively [27]. But still atherosclerotic cardiovascular disease and 
cerebrovascular events contribute significantly to late morbidity and mortality. An 
important risk factor is late repair which associates with hypertension, but even patients 
with early repair have a 30% 10-year incidence of hypertension [28]. Also re-intervention 
and descending aortic aneurysms occur in 34% and 18% respectively and are lowest in 
patients treated using end-to-end repair [27]. Vigilant blood pressure control is therefore 
indicated even in corrected patients. 
Pregnancy 
Cardiac output increases by almost 50% during the second trimester of pregnancy, and 
rises even further during labor. There are cases of aortic dissection during pregnancy in 
woman with CoA [29, 30]. However, in general pregnancy is well tolerated in women with 
repaired CoA. However, there seems to be an excess of miscarriages and hypertensive 
disorders. In the normal population these hypertensive disorders of pregnancy occur in 
approximately 8% of all pregnancies, whereas in CoA patients hypertension and pre-




respectively [31]. Woman with CoA are more likely to deliver by Caesarean section and 
have longer hospital stays. They had more cardiovascular accidents as a composite 
endpoint , there is however no evidence of increased maternal mortality or miscarriage 
[32]. 
Quality of life 
A topic receiving little attention in the medical field is the health perception of patients 
with congenital heart disease (CHD). No specific research on the psychological function of 
CoA patients has been done, but there are studies into other less severe CHD such as 
uncomplicated septal defects which are in part also applicable to CoA patients. These 
studies show that although patients scored significantly better on physical or emotional 
problems, bodily pain, social functioning compared to normative data [33, 34], patients do 
show clearly reduced sexual functioning. This occurs especially around the age of 20, when 
patients actively engage in relationships and feel hampered for example by their scar tissue 
[35]. Sexuality is often ignored by physicians despite a clear demand on information by 
patients. Patients often grow-up in a very protective environment where “risky behavior” 
such as sport participation is discouraged. Whilst even for complex CHD sport can have a 
positive influence on exercise capacity and subjective physical function without an 
increased risk of sudden death or cardiac arrhythmias. Unfortunately many of these topics 
such as contraceptives, sexuality and pregnancy and sport participation are often 
insufficiently addressed by medical specialist and caregivers.  
Associations  
In this paragraph we will discuss a number of syndromes and less well-known congenital 
cardiovascular defects that are seen in combination with CoA.  
There is no known causal genetic defect for CoA, but it often occurs together with several 
other left-sided defects such as BAV. It is seldom associated with right-sided defects. There 
is a myriad of genetic syndromes which are known to have a relatively frequent occurrence 
of CoA and genetic abnormalities occur in 6,2% of patients with a CoA. They have however 
different genetic origins and therefore a single genetic cause for CoA is improbable. Almost 
all syndromes described below have a frequent occurrence of several congenital heart 
defects and therefore it seems plausible that there is a common developmental pathway. A 
patent arterial ductus is found in almost half (43%) of CoA patients and also septal defects 
are very common (39% ventricular, 20% atrial septal defects and atrioventricularseptal 
defects in 4,4%). We will discuss the aortic valve separately but also the mitral, tricuspid 
and pulmonary valves are found to be abnormal in respectively 4,9%, 2.4% and 1% of CoA-
patients. In this paragraph we will discuss a number of the syndromes and less well-known 




Bicuspid aortic valve   
The aortic valve is normally made up of 3 cusps, however in 1-2% of the general population 
abnormal cusp formation during valvulogenesis leads adjacent cusps to fail to segregate 
and form one single cusp. BAV can cause significant morbidity as the valve is prone to 
leakage or stenosis and is often accompanied by aortic dilatation and dissection. Histo-
pathological changes of the aortic media such as loss of smooth muscle and medial layer 
elastic fibers can be seen in the ascending aorta of BAV patients and it has been argued 
that BAV and CoA are part of the same aortopathy. BAV is, as CoA, more often seen in 
males than in females (2:1, male:female). Of the patients who have a CoA between 50% 
and 75% also have BAV [36]. The prevalence of CoA in BAV patients is less well studied but 
is approximately 7% [37].  Aortic dilatation is more severe in patients with both BAV and 
CoA than in patients with an isolated CoA [38]. The dilatation varies from patient to patient, 
and clear associations with age and hypertension could not be shown. A current parameter 
in BAV research is the cusp anatomy; different valve types are discerned [39], based on 
their morphological cusp phenotype. Of which the type with fusion of the left and right 
coronary cusp is associated with CoA. [7].  
Hypoplastic Left-Heart Syndrome 
The hypoplastic left heart syndrome (HLHS) occurs in 0.016% to 0.036% of live births and 
occurs more often in males [40]. It is the clinical presentation in 11% of CoA patients.  It 
entails severe left-sided outflow obstruction due to an abnormal development of the left-
sided cardiac structures; a predominant underdevelopment of the left ventricle, aorta and 
sometimes also mitral atresia or stenosis. The degree of left ventricular outflow obstruction 
can vary from patient to patient [40], and the right heart is often enlarged and 
hypertrophic. Coarctation of the aorta in juxta position is commonly present [41-43]. It is a 
duct-dependent lesion and therefore needs a series of univentricular surgical palliations or 
a heart transplantation. The coarctation of patients with HLHS is histologically similar to 
isolated coarctation as ductal tissue has been shown. [44]  
Taussig-Bing anomaly 
In 1949 Helen Taussig and Richard Bing described the first case of what is now known as 
the Taussig-Bing anomaly (T-Ba); an uncommon form of a double outlet right ventricle 
(DORV) in which both the aorta and pulmonary artery arise from the right ventricle [45]. 
The pulmonary artery overrides a subpulmonary ventricular defect. It is associated with 
additional aortic arch obstruction in 39% to 52% of patients, substantially complicating the 
surgical management [46, 47]. Approximately 6,7% of coarctation patients have this 
anomaly.  Also a complete transposition of the great arteries and transposition complexes 
are found to be associated with an aortic obstruction at subaortic level or in the aortic arch 




Kabuki syndrome  
This syndrome with an estimated prevalence of 1 in 32 000 received its name from the 
supposed resemblance of its typical facial features to make-up worn by the artists in a 
traditional Japanese dance-drama  called ‘Kabuki’. In Kabuki syndrome patients 69 to 91% 
of patients has a congenital heart defect, most of these lesions are left-sided obstructions 
of which 29%  an aortic coarctation[50, 51]. It is caused by a mutation of two genes located 
on the short arm (or p-arm) of the X-chromosome KMT2D or KDM6A (or MLL2) and inherits 
in an autosomal dominant fashion. In a study describing the KMDA6A knocked down 
zebrafish, prominent defects in heart development were found [52].  
Shone’s Syndrome 
Shone’s complex or Shone’s syndrome, first described in eight cases in 1963, includes a 
supravalvular mitral valve membrane, a ‘parachute mitral valve’, a subaortic stenosis and 
coarctation of the aorta (CoA). [53]. In addition BAV was also present in 30-83% of these 
patients. [53-55] CoA is seen in approximately 96% of patients, however only 63% patients 
exhibit all four symptoms. It is managed surgically, where the level of involvement of the 
mitral valve and presence of secondary pulmonary hypertension is the main determinant of 
clinical outcome in these patients [56].  
Myhre syndrome  
Myhre syndrome is a very rare syndrome (prevalence <1/1.000.000), caused by a 
heterozygous mutation in the SMAD4 gene on chromosome 18q21. [57] A study of 32 
patients describes congenital heart defects in 17 patients, including patent ductus 
arteriosus , aortic coarctation (12,5%) mild-to-moderate valvular aortic stenosis (12,5%) 
and one  membranous ventricular septal defect.    
Williams-Beuren syndrome 
Williams-Beuren syndrome is caused by a deletion on chromosome 7q11.23 and occurs in 
approximately 1 in 10 000 live births [58]. One of the deleted genes is the ELN gene which 
codes for the protein elastin [59]. The syndrome was first described by Williams et al. in 
1961 in four patients, and then in the following year also by Beuren et al. in an additional 
five patients. Congenital cardiovascular defects occur in about 80% of all patients where 
some form of arterial stenosis is the predominant form occurring in 40-75% of patients 
[60]. It differs however from the typical juxta ductal CoA in that its preferred location is at 
the sinotubular junction (supravalvular aortic stenosis) and is also often seen as an 
elongated hypoplastic segment [59],  of which the first is the most common, occurring in 





Noonan syndrome (NS) occurs in approximately 1/1000 to 1/2000 live births [61] and it is 
one of the most common syndromic causes of congenital heart disease second only to 
Downs syndrome [62]. It inherited in an autosomal dominant manner, although many 
individuals have a de novo mutation. Mutations recognized to cause the syndrome include 
mutations in the PTPN11, SOS1, RAF1, KRAS, NRAS and BRAF genes. The congenital heart 
disease occurs in between 50 and 80% of patients, with pulmonary valve stenosis and 
hypertrophic cardiomyopathy being the most common (50-60% and 20% of patients 
respectively). However, other structural defects such as: atrial septal defect, patent ductus 
arteriosus, and tetralogy of Fallot have also been described [62]. The left-sided outflow 
obstructions can occur at the valvular or supravalvular level or as classic aortic coarctation 
[63, 64]. CoA itself is seen in approximately 8,8% of patients [63], and is more often seen in 
patients with a PTPN11 mutation [62].  
Alagille syndrome 
Alagille syndrome (AGS) is a multisystem disorder affecting the liver, heart, eyes, face, 
skeleton, and other systems occuring in 1 in 70.000 newborns. Up to 70% of patients have 
a mutation in the Jagged1 gene, which fulfills a function in the Notch signaling pathway. 
The remaining 30% is probably also caused by a mutation in this large gene, but not yet 
found due to testing limitations [65]. The cardio vascular defects are predominantly of the 
pulmonary arteries (67%) [66] In a study describing 268 individuals with AGS aortic 
coarctation was only found in 3 cases (1.1%), still substantially higher than in the normal 
population.  
The 22q11.2 deletion syndrome  
The 22q11.2 deletion syndrome is the most common microdeletion syndrome and is known 
for its wide variety of signs and symptoms.  It has been described under many different 
names of which some well-known include; the Sphrintzen syndrome, DiGeorge syndrome 
and the velo-cardiofacial anomaly.  Its incidence is approximately 1 in 3000 persons and 
75% of patients has a form of CHD.  A common 3 Mb hemizygous deletion of 22q11.2 is 
detected in the majority of patients. Smaller deletions within this 3 Mb region together 
with rare deletions outside of the region account for the other 30% [67]. This syndrome 
occurs in 0.9% of patients with a CoA. Other CHD’s are tetralogy of Fallot, pulmonary 
stenosis, pulmonary stenosis and septal defects. 
Turner syndrome  
Of the aforementioned syndromes Turner syndrome (TS) is probably the most well-known, 
with a prevalence of approximately 1 in 2500 live born girls [68]. It has a broad variety of 
features, amongst which short stature, infertility and a webbed neck. Aortic pathology is 
seen quite frequently in TS. Aortic dilatation and especially aortic dissection are seen more 




patients a CoA is found the presence of CoA in TS patients is often associated with BAV (RR, 
4.6) [69, 70].  More recently Ho et al. found that in 50% of Turner patients aortic 
coarctation appeared to be associated with an elongated transverse aortic arch [1]. 
Supposedly other abnormalities such as an aberrant right subclavian artery (8%), and 
common origin of the innominate and left carotid artery (8%) belong to the same 
cardiovascular phenotype [68]. 
Miscellaneous  
In addition to the syndromes and associations mentioned above there are other 
associations with CoA; congenital rubella syndromes are known to cause cardiac and 
cardiovascular disease especially pulmonary artery stenosis and patent ductus arteriosus in 
50% of patients [71]. But also aortic coarctation has been reported in these children. 
Intracranial Berry aneurysms occur often in patients with coarctation. It is however unclear 
if there is a common pathophysiological ground to this association and whether it is due to 






1   Ho VB, Bakalov VK, Cooley M, Van PL, Hood MN, Burklow TR, et al. Major vascular anomalies in Turner 
syndrome: prevalence and magnetic resonance angiographic features. Circulation. 2004;110(12):1694-700. 
2   Campbell M. Natural history of coarctation of the aorta. Br Heart J. 1970;32(5):633-40. 
3   Verheugt CL, Uiterwaal CS, Grobbee DE, Mulder BJ. Long-term prognosis of congenital heart defects: a 
systematic review. Int J Cardiol. 2008;131(1):25-32. 
4   Morgagni G. De sedibus et causis morborum. Epist XVIII. 1760:6.1760. 
5   ME A. Coarctation of the aorta of the adult type: II. A statistical study and historical retrospect of 200 recorded 
cases with autopsy, of stenosis or obliteration of the descending arch in subjects above the age of two years. 
Abbott ME. 1928;3:574. 
6   Vergales JE, Gangemi JJ, Rhueban KS, Lim DS. Coarctation of the aorta - the current state of surgical and 
transcatheter therapies. Curr Cardiol Rev. 2013;9(3):211-9. 
7   Warnes CA. Bicuspid aortic valve and coarctation: two villains part of a diffuse problem. Heart. 2003;89(9):965-
6. 
8   van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, et al. Birth prevalence of 
congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58(21):2241-7. 
9   Toro-Salazar OH, Steinberger J, Thomas W, Rocchini AP, Carpenter B, Moller JH. Long-term follow-up of 
patients after coarctation of the aorta repair. Am J Cardiol. 2002;89(5):541-7. 
10   Cohen M, Fuster V, Steele PM, Driscoll D, McGoon DC. Coarctation of the aorta. Long-term follow-up and 
prediction of outcome after surgical correction. Circulation. 1989;80(4):840-5. 
11   Brown ML, Burkhart HM, Connolly HM, Dearani JA, Cetta F, Li Z, et al. Coarctation of the aorta: lifelong 
surveillance is mandatory following surgical repair. J Am Coll Cardiol. 2013;62(11):1020-5. 
12   Campbell M, Polani PE. The aetiology of coarctation of the aorta. Lancet. 1961;1(7175):463-8. 
13   Talner CN. Report of the New England Regional Infant Cardiac Program, by Donald C. Fyler, MD, Pediatrics, 
1980;65(suppl):375-461. Pediatrics. 1998;102(1 Pt 2):258-9. 
14   Ho SY, Anderson RH. Coarctation, tubular hypoplasia, and the ductus arteriosus. Histological study of 35 
specimens. Br Heart J. 1979;41(3):268-74. 
15   Russell GA, Berry PJ, Watterson K, Dhasmana JP, Wisheart JD. Patterns of ductal tissue in coarctation of the 
aorta in the first three months of life. J Thorac Cardiovasc Surg. 1991;102(4):596-601. 
16   Keith L. Moore MGTTVNP. The Developing Human: Clinically Oriented Embryology 9/e. Elsevier India; 
December 19, 2011. p. 327-9. 
17   Vogt M, Kuhn A, Baumgartner D, Baumgartner C, Busch R, Kostolny M, et al. Impaired elastic properties of the 
ascending aorta in newborns before and early after successful coarctation repair - Proof of a systemic vascular 
disease of the prestenotic arteries? Circulation. 2005;111(24):3269-73. 
18   Oliver JM, Gallego P, Gonzalez A, Aroca A, Bret M, Mesa JM. Risk factors for aortic complications in adults with 
coarctation of the aorta. J Am Coll Cardiol. 2004;44(8):1641-7. 
19   Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N, et al. ESC Guidelines for the 
management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010;31(23):2915-57. 
20   Novitzky D, Sanchez HE, Human D, Barnard CN. The significance of femoral pulses in coarctation of the aorta. S 
Afr Med J. 1984;65(19):755-7. 
21   Jurcut R, Daraban AM, Lorber A, Deleanu D, Amzulescu MS, Zara C, et al. Coarctation of the aorta in adults: 
what is the best treatment? Case report and literature review. J Med Life. 2011;4(2):189-95. 
22   Forbes TJ, Kim DW, Du W, Turner DR, Holzer R, Amin Z, et al. Comparison of surgical, stent, and balloon 
angioplasty treatment of native coarctation of the aorta: an observational study by the CCISC (Congenital 
Cardiovascular Interventional Study Consortium). J Am Coll Cardiol. 2011;58(25):2664-74. 
23   Padua LM, Garcia LC, Rubira CJ, de Oliveira Carvalho PE. Stent placement versus surgery for coarctation of the 
thoracic aorta. Cochrane Database Syst Rev. 2012;5:CD008204. 
24   Moltzer E, Mattace Raso FU, Karamermer Y, Boersma E, Webb GD, Simoons ML, et al. Comparison of 
Candesartan versus Metoprolol for treatment of systemic hypertension after repaired aortic coarctation. Am J 
Cardiol. 2010;105(2):217-22. 
25   Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular D, the Council for 
High Blood Pressure Research of the American Heart A. Renal considerations in angiotensin converting enzyme 
inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular 





26   van den Hoven AT, Duijnhouwer AL, Eicken A, Aboulhosn J, de Bruin C, Backeljauw PF, et al. Adverse outcome 
of coarctation stenting in patients with Turner syndrome. Catheter Cardiovasc Interv. 2017;89(2):280-7. 
27   Choudhary P, Canniffe C, Jackson DJ, Tanous D, Walsh K, Celermajer DS. Late outcomes in adults with 
coarctation of the aorta. Heart. 2015;101(15):1190-5. 
28   Bhatt AB, Defaria Yeh D. Long-term outcomes in coarctation of the aorta: an evolving story of success and new 
challenges. Heart. 2015;101(15):1173-5. 
29   Beauchesne LM, Connolly HM, Ammash NM, Warnes CA. Coarctation of the aorta: outcome of pregnancy. J 
Am Coll Cardiol. 2001;38(6):1728-33. 
30   Plunkett MD, Bond LM, Geiss DM. Staged repair of acute type I aortic dissection and coarctation in pregnancy. 
Ann Thorac Surg. 2000;69(6):1945-7. 
31   Vriend JW, Drenthen W, Pieper PG, Roos-Hesselink JW, Zwinderman AH, van Veldhuisen DJ, et al. Outcome of 
pregnancy in patients after repair of aortic coarctation. Eur Heart J. 2005;26(20):2173-8. 
32   Krieger EV, Landzberg MJ, Economy KE, Webb GD, Opotowsky AR. Comparison of risk of hypertensive 
complications of pregnancy among women with versus without coarctation of the aorta. Am J Cardiol. 
2011;107(10):1529-34. 
33   Menting ME, Cuypers JA, Opic P, Utens EM, Witsenburg M, van den Bosch AE, et al. The unnatural history of 
the ventricular septal defect: outcome up to 40 years after surgical closure. J Am Coll Cardiol. 2015;65(18):1941-
51. 
34   Cuypers JA, Opic P, Menting ME, Utens EM, Witsenburg M, Helbing WA, et al. The unnatural history of an 
atrial septal defect: longitudinal 35 year follow up after surgical closure at young age. Heart. 2013;99(18):1346-52. 
35   Opic P, Roos-Hesselink JW, Cuypers JA, Witsenburg M, van den Bosch A, van Domburg RT, et al. Sexual 
functioning is impaired in adults with congenital heart disease. Int J Cardiol. 2013;168(4):3872-7. 
36   Roos-Hesselink JW, Scholzel BE, Heijdra RJ, Spitaels SE, Meijboom FJ, Boersma E, et al. Aortic valve and aortic 
arch pathology after coarctation repair. Heart. 2003;89(9):1074-7. 
37   Schaefer BM, Lewin MB, Stout KK, Gill E, Prueitt A, Byers PH, et al. The bicuspid aortic valve: an integrated 
phenotypic classification of leaflet morphology and aortic root shape. Heart. 2008;94(12):1634-8. 
38   Oliver JM, Alonso-Gonzalez R, Gonzalez AE, Gallego P, Sanchez-Recalde A, Cuesta E, et al. Risk of aortic root or 
ascending aorta complications in patients with bicuspid aortic valve with and without coarctation of the aorta. Am 
J Cardiol. 2009;104(7):1001-6. 
39   Sievers HH, Schmidtke C. A classification system for the bicuspid aortic valve from 304 surgical specimens. J 
Thorac Cardiovasc Surg. 2007;133(5):1226-33. 
40   Morris CD, Outcalt J, Menashe VD. Hypoplastic left heart syndrome: natural history in a geographically defined 
population. Pediatrics. 1990;85(6):977-83. 
41   Brenner JI, Berg KA, Schneider DS, Clark EB, Boughman JA. Cardiac malformations in relatives of infants with 
hypoplastic left-heart syndrome. Am J Dis Child. 1989;143(12):1492-4. 
42   Roberts WC, Morrow AG, Braunwald E. Complete interruption of the aortic arch. Circulation. 1962;26:39-59. 
43   Hinton RB, Jr., Martin LJ, Tabangin ME, Mazwi ML, Cripe LH, Benson DW. Hypoplastic left heart syndrome is 
heritable. J Am Coll Cardiol. 2007;50(16):1590-5. 
44   Machii M, Becker AE. Nature of coarctation in hypoplastic left heart syndrome. Ann Thorac Surg. 
1995;59(6):1491-4. 
45   Taussig HB, Bing RJ. Complete transposition of the aorta and a levoposition of the pulmonary artery; clinical, 
physiological, and pathological findings. Am Heart J. 1949;37(4):551-9. 
46   Sadow SH, Synhorst DP, Pappas G. Taussig-Bing anomaly and coarctation of the aorta in infancy: surgical 
options. Pediatr Cardiol. 1985;6(2):83-9. 
47   Konstantinov IE. Taussig-Bing anomaly: from original description to the current era. Tex Heart Inst J. 
2009;36(6):580-5. 
48   Tchervenkov CI, Korkola SJ. Transposition complexes with systemic obstruction. Semin Thorac Cardiovasc Surg 
Pediatr Card Surg Annu. 2001;4:71-82. 
49   Vogel M, Freedom RM, Smallhorn JF, Williams WG, Trusler GA, Rowe RD. Complete transposition of the great 
arteries and coarctation of the aorta. Am J Cardiol. 1984;53(11):1627-32. 
50   Yuan SM. Congenital heart defects in Kabuki syndrome. Cardiol J. 2013;20(2):121-4. 
51   Yoon JK, Ahn KJ, Kwon BS, Kim GB, Bae EJ, Noh CI, et al. The strong association of left-side heart anomalies 
with Kabuki syndrome. Korean J Pediatr. 2015;58(7):256-62. 
52   Van Laarhoven PM, Neitzel LR, Quintana AM, Geiger EA, Zackai EH, Clouthier DE, et al. Kabuki syndrome genes 
KMT2D and KDM6A: functional analyses demonstrate critical roles in craniofacial, heart and brain development. 




53   Shone JD, Sellers RD, Anderson RC, Adams P, Jr., Lillehei CW, Edwards JE. The developmental complex of 
"parachute mitral valve," supravalvular ring of left atrium, subaortic stenosis, and coarctation of aorta. Am J 
Cardiol. 1963;11:714-25. 
54   Ma XJ, Huang GY, Liang XC, Liu XQ, Jia B. Atypical Shone's complex diagnosed by echocardiography. Pediatr 
Cardiol. 2011;32(4):442-8. 
55   Grimaldi A, Vermi AC, Maisano F, Sacco F, Castiglioni A, Zangrillo A, et al. Echocardiographic patterns of 
incomplete Shone's syndrome in adults. J Heart Valve Dis. 2011;20(5):552-6. 
56   Brauner MW, Grenier P, Tijani K, Battesti JP, Valeyre D. Pulmonary Langerhans cell histiocytosis: evolution of 
lesions on CT scans. Radiology. 1997;204(2):497-502. 
57   Michot C, Le Goff C, Mahaut C, Afenjar A, Brooks AS, Campeau PM, et al. Myhre and LAPS syndromes: clinical 
and molecular review of 32 patients. Eur J Hum Genet. 2014;22(11):1272-7. 
58   Stromme P, Bjornstad PG, Ramstad K. Prevalence estimation of Williams syndrome. J Child Neurol. 
2002;17(4):269-71. 
59   Pober BR. Williams-Beuren syndrome. N Engl J Med. 2010;362(3):239-52. 
60   Collins RT, 2nd. Cardiovascular disease in Williams syndrome. Circulation. 2013;127(21):2125-34. 
61   Noonan JA. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. 
Am J Dis Child. 1968;116(4):373-80. 
62   Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet. 2013;381(9863):333-42. 
63   Marino B, Digilio MC, Toscano A, Giannotti A, Dallapiccola B. Congenital heart diseases in children with 
Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr. 
1999;135(6):703-6. 
64   Burch M, Sharland M, Shinebourne E, Smith G, Patton M, McKenna W. Cardiologic abnormalities in Noonan 
syndrome: phenotypic diagnosis and echocardiographic assessment of 118 patients. J Am Coll Cardiol. 
1993;22(4):1189-92. 
65   Kamath BM, Spinner NB, Emerick KM, Chudley AE, Booth C, Piccoli DA, et al. Vascular anomalies in Alagille 
syndrome: a significant cause of morbidity and mortality. Circulation. 2004;109(11):1354-8. 
66   Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA. Features of Alagille syndrome in 92 
patients: frequency and relation to prognosis. Hepatology. 1999;29(3):822-9. 
67   Shaikh TH, Kurahashi H, Saitta SC, O'Hare AM, Hu P, Roe BA, et al. Chromosome 22-specific low copy repeats 
and the 22q11.2 deletion syndrome: genomic organization and deletion endpoint analysis. Hum Mol Genet. 
2000;9(4):489-501. 
68   Mortensen KH, Andersen NH, Gravholt CH. Cardiovascular phenotype in Turner syndrome--integrating 
cardiology, genetics, and endocrinology. Endocr Rev. 2012;33(5):677-714. 
69   Sachdev V, Matura LA, Sidenko S, Ho VB, Arai AE, Rosing DR, et al. Aortic valve disease in Turner syndrome. J 
Am Coll Cardiol. 2008;51(19):1904-9. 
70   Mortensen KH, Hjerrild BE, Andersen NH, Sorensen KE, Horlyck A, Pedersen EM, et al. Abnormalities of the 
major intrathoracic arteries in Turner syndrome as revealed by magnetic resonance imaging. Cardiol Young. 
2010;20(2):191-200. 
71   Oster ME, Riehle-Colarusso T, Correa A. An update on cardiovascular malformations in congenital rubella 














Objectives. Left ventricular global longitudinal strain (LVGLS) analysis is a sensitive 
measurement of myocardial deformation most often done using speckle-
tracking transthoracic echocardiography (TTE).  We propose a novel 
approach to measure LVGLS using feature-tracking software on the 
magnitude dataset of 4D flow cardiovascular magnetic resonance (CMR) 
and compare it to dynamic computed tomography (CT) and speckle 
tracking TTE derived measurements 
Methods.  In this prospective cohort study 59 consecutive adult patients with a 
bicuspid aortic valve (BAV) were included. The study protocol consisted of 
TTE, CT, and CMR on the same day. Image analysis was done using 
dedicated feature-tracking (4D flow CMR and CT) and speckle-tracking 
(TTE) software, on apical 2-, 3-, and 4-chamber long-axis multiplanar 
reconstructions (4D flow CMR and CT) or standard apical 2-, 3-, and 4-
chamber acquisitions (TTE). 
Results.  CMR and CT GLS analysis was feasible in all patients. Good correlations 
were observed for GLS measured by CMR (-21 ± 3%) and CT (-20 ± 3%) 
versus TTE (-20 ± 3%, Pearson’s r: 0.67 and 0.65, p<0.001). CMR also 
correlated well with CT (Pearson’s r 0.62, p<0.001). The inter-observer 
analysis showed moderate to good reproducibility of GLS measurement 
by CMR, CT and TTE (Pearsons’s r: 0.51, 0.77, 0.70 respectively; p<0.05). 
Additionally, ejection fraction (EF), end-diastolic and end-systolic volume 
measurements (EDV and ESV) correlated well  between all modalities 
(Pearson’s r>0.61, p<0.001). 
Conclusions.  Feature-tracking GLS analysis is feasible using the magnitude images 
acquired with 4D flow CMR. GLS measurement by CMR correlates well 
with CT and speckle-tracking 2D TTE. GLS analysis on 4D flow CMR allows 







For decades left ventricular (LV) ejection fraction (EF) has been the gold standard for 
quantification of systolic LV function. [1] It has been a key metric in therapy and 
prognostication, in particular in patients with valvular heart disease. However, more 
sensitive methods have since been in development; [2] of which LV global longitudinal 
strain (GLS) is currently accepted as a more sensitive measurement, that may already be 
reduced before a decrease in LV EF can be observed. Moreover LV GLS allows for 
quantitative assessment of global and segmental ventricular function by measuring 
myocardial deformation, largely independent of angle and ventricular geometry. [3-5] GLS 
is defined as the percentage of shortening between the end-diastolic and end-systolic 
length of the myocardium. This technique of deformation measurement has been validated 
in different populations using speckle-tracking echocardiography. [5-15] More recently it 
was shown that GLS can also be derived from multiphase Computed Tomography (CT) 
datasets and conventional Cardiovascular Magnetic Resonance (CMR) steady state free-
precession (SSFP) cine imaging using feature-tracking algorithms. [16, 17] However, these 
techniques, especially GLS measurement using CT are still new and not yet very well 
validated. In this study we propose a novel method that uses this feature-tracking 
algorithm on magnitude images acquired during 4D flow CMR to quantify LV volumes and 
GLS. 4D flow CMR allows for comprehensive post-hoc evaluation of blood flow patterns by 
3D blood flow visualization and quantification of flow parameters. [18] Previous studies 
have shown that quantification of ventricular volume and function can be accomplished 
with 4D flow MRI with precision and inter-observer agreement comparable to that of SSFP 
cine imaging. [19, 20] Strain analysis would be a valuable additional feature of 4D flow 
CMR, as this would allow for integrative analysis of flow and function in one sequence.  
Methods 
In this prospective cohort study, adult patients with a bicuspid aortic valve (BAV) were 
included [21, 22]. The study protocol consisted of TTE, CT and CMR on the same day. The 
inclusion criteria were age ≥ 18 year and one of the following: [1] aortic stenosis (gradient 
>2.5 m/s), [2] aortic regurgitation (at least moderate) or [3] ascending aortic dilation 
≥40 mm and/or aortic size index >2.1 cm/m2. Patients with contra-indications to CT, CMR 
or contrast agents were excluded. For the current study we only included patients who 
underwent at least two of the three imaging modalities. The study complied with the 
Declaration of Helsinki and was approved by the medical ethical committee of the Erasmus 





One of two experienced sonographers performed a standard two-dimensional 
transthoracic echocardiogram. All studies were acquired using harmonic imaging on an 
EPIQ7 ultrasound system (Philips Medical Systems, Best, the Netherlands) equipped with an 
x5–1 matrix-array transducer (composed of 3040 elements with 1-5 MHz). A non-
foreshortened apical (A) four-chamber (ch), A3ch and A2ch were recorded with manual 
rotation. All echocardiographic images were obtained with a frame rate >60 frames per 
second. 
Computed Tomography  
Acquisition was performed using a dual-source CT (Somatom Force or Somatom Definition 
Flash, Siemens Healthcare, Forchheim, Germany). Retrospective ECG-gated spiral 
acquisition was applied, and kV was modulated to patient size and a vascular exam type. 
Dose modulated ECG-pulsing was employed with nominal tube current during the 0 to 40% 
window of the R-R interval, and tube current reduced to 20% of the nominal output for the 
remainder to reduce the radiation dose.  Reference tube current was set at 150 mAs per 
rotation. The pitch was adapted to increase proportionally with higher heartrates. No beta 
blockers were administered prior to the scan. Reconstructions were made with a medium 
smooth kernel. In total 20 different reconstructions with a slice thickness of 1.5mm and 
1.0-mm overlap were made in each patient at every 5% of the R-R interval. The mean dose 
length product (DLP) was 362mGy-cm (estimated effective dose 5mSv, using a conversion 
factor of k=0.017). A 65 ml bolus of iodinated contrast material (Iodixanol 320, Visipaque, 
GE Healthcare, Cork, Ireland) was administered through an antecubital vein followed by a 
40 ml 70/30% saline/contrast medium bolus, both at 5 ml/s.  
Cardiovascular Magnetic Resonance imaging 
Image acquisition was performed using a 1.5T clinical MRI scanner (Discovery MR450, GE 
Medical Systems, Milwaukee, WI, USA) using a 32-channel phased-array cardiac surface 
coil. The imaging protocol consisted of black blood TSE aorta, 2D phase contrast images for 
pulse wave velocity measurements, SSFP for aortic distensibility measurements, contrast 
enhanced MR angiography and 4D flow CMR of the entire heart and aorta. The 4D flow 
CMR was acquired immediately after the bolus injection of 0.1–0.2 mmol/kg gadolinium-
based contrast agent (Gadovist 1 mmol/ml, Bayer, Mijdrecht, The Netherlands). The 4D 
flow sequence has been described before. [23] In short the sequence was prescribed in 
axial plane, including the entire thorax in the field of view. The k-space was filled with 
variable-density Poisson-disc under sampling with acceleration factors of 1.8 × 1.8 
(phase × slice) and the parallel imaging algorithm used was ESPIRiT. Typical scan parameters 
were: matrix 192 × 160 × 78, acquired resolution 2.1 × 1.8 × 2.8 mm, reconstructed resolution 
2.1 × 1.8 × 1.4 mm, flip angle 15°, views per segment 4, bandwidth 63 kHz, number of 
reconstructed phases 20 per cardiac cycle, and a velocity encoded value set at 250 cm/s. 




Image analysis  
All images (CMR, CT and TTE) were analyzed by one observer (A.T.), who had 6 years of 
experience in cardiovascular imaging, in a random order and blinded to the results of the 
other image modalities. The TTE, CT, and CMR data was then re-measured by a second 
observer (S.Y.), who has one year of experience, blinded to the results of the first observer 
and to the corresponding measurements of the other modalities.  For 2D TTE, speckle 
tracking analysis was performed using dedicated commercially available software (2D 
Cardiac Performance Analysis, Tomtec Imaging Systems). End-systolic and end-diastolic 
frames were identified manually; additionally the annulus and apex were identified 
manually in end-systole (Figure 1). Subsequently, the software semi-automatically detected 
the end-diastolic and end-systolic myocardial contours. These contours were visually 
checked and corrected if necessary. This process was performed in all apical views (A2ch, 
A3ch, and A4ch).  
 





Fig 1. Transthoracic Echocardiography (TTE), Computed Tomography (CT) and Cardiovascular Magnetic 
Resonance (CMR) EDV: end-diastolic volume, ESV: end-systolic volume, EF: Ejection Fraction, GLS: Global 





All CT and CMR images were analyzed semi-automatically using commercially available 
software from Medis Medical Imaging Systems, Leiden the Netherlands. All images were 
loaded into the Medis Suite software (version: 3.1.16.6). A2ch, A3ch, and A4ch 
reconstructions were made from the 3D data sets using Medis 3D View (version: 3.1.18.1). 
For the CMR analysis only the magnitude images, which contain the anatomical data, of the 
4D flow data set were used. All cardiac phases were included in the multi-plane 
reconstructions and endocardial contours were drawn manually at both end-diastole and 
end-systole using Medis QMass software (version: 8.1.30.4) where the papillary muscles 
and trabeculations were included in the LV lumen. Subsequently GLS, ejection fraction (EF), 
end-diastolic and end-systolic volume (EDV and ESV) were calculated using QStrain 
software (version: 3.1.16.6). Volumes were corrected for body surface area (BSA). BSA was 
calculated according to the Dubois formula. [24] In QMass LV contours were drawn 
manually and focused on adequate tracking of the myocardium for precise strain analysis. 
However, changes to the contours necessary for optimal tracking of the myocardium 
caused an underestimation of the ESV. Therefore, in order to provide data on the inter-
modality variability of the volumes, a second set of separate endocardial contours had to 
be drawn for the measurement EDV, ESV and EF. The second trace of endocardial contours, 
drawn for the volumetric analysis, used standard anatomical landmarks (supplemental 
video 1). However, for adequate strain analysis the left ventricular outflow tract (LVOT) had 
to be excluded, and the first trace therefore started more apically in both end-systole and 
end-diastole, (supplemental video 2) to prevent highly positive segmental strain disturbing 
GLS measurement. For the inter-observer variability, twenty patients were chosen at 
random.  
Statistical analysis 
The IBM SPSS® statistics 21.0 software was used to analyze the data. Continuous variables 




range. Categorical variables were presented as 
frequencies and percentages. We tested for 
normality by calculating Z-values of skewness and 
kurtosis, using the Shapiro-Wilk test and by 
visually assessing the data. For comparison of 
normally distributed continuous variables 
between two groups the student’s t-test was 
used. To quantify correlations the Pearson 
correlation test was applied. Inter-observer 
agreement between two investigators was 
assessed using Bland-Altman analysis. [25] The 
bias was defined as the mean absolute difference 
(i.e. the average absolute difference between two 
modalities). The limits of agreement between two 
measurements were determined as the mean of 
the difference ±  
1.96 SD. Additionally, the coefficient of variation 
(COV) was provided to compare the dispersion of 
two variables. The COV was defined as the SD of 
the differences of two measurements divided by 
the mean of their means. The statistical tests 
were two sided and a p-value <0.05 was 
considered significant.  
Results 
Fifty-nine patients were included, of whom 37 
men (63%). Their baseline characteristics are 
presented in table 1. In 56 patients (95%) echo 
measurements could be performed, two patients 
did not undergo echocardiography due to 
organizational reasons and one patient was 
excluded because of insufficient image quality. In 
total 53 patients underwent a CT scan, of which 
one patient was excluded due to technical 
limitations, therefore 52 (88%) patients were 
included for CT analysis. In six patients no CT scan 
was done due to organizational reasons. In 48 





Age, years 34 [19] 
Height, cm 180 [23] 
Weight, kg 75 [19] 
BMI, kg/m2 24 [3] 
BSA, m2 1.9 [0.4] 
SBP, mmHg 123 [17] 
DBP, mmHg 79 [16] 
Aortic valve  
 Vmax, m/s 2.2 (1.6) 
 Peak Gradient, mmHg 19 (32) 
 AoI grade - none 12 (20) 
 AoI grade - moderate 34 (58) 
 AoI grade - severe 13 (22) 
Sievers type*  
 Type 0 – lat 6 (10) 
 Type 0 – ap 7 (12) 
 Type 1 - LR 23 (49) 
 Type  1 - RN 7 (12) 
 Type 1 - LN 1 (2) 
 Type 2 – LR/RN 7 (12) 
 Undetermined 2 (2) 
Table 1. Data are presented as median [IQR] or 
n (%), BSA: body surface area, SBP and DBP: 
systolic and diastolic blood pressure, Vmax: 
peak aortic valve velocity, AoI: aortic valve 
insufficiency. *Valve type according to Sievers  





eleven patients 4D flow CMR  was missing due to organizational reasons (scan time per 
patient was restricted and therefore 4D flow could not always be performed in all patients). 
The results of all measurements are presented per modality in table 2. The results of the 
inter-modality agreement are presented in table 3. All CT and MR scans were included. No 
scans (CT or CMR) were excluded because of insufficient image quality. A sensitivity analysis 
was conducted which showed that the there was no significant difference when only the 
patients who underwent  
all three modalities were considered (n=39) (tables 2 and 3). 
 





Left ventricular global longitudinal strain and ejection fraction 
When comparing CMR and CT versus TTE, strong correlations (table 3: Pearson’s r: 0.67, 
p<0.001 and Pearson’s r: 0.65, p<0.001 respectively) were found for GLS. However, 
especially CMR seemed to slightly overestimate GLS with a mean difference -2% and a bias 
of 3% when compared to TTE (figure 2). The results of the EF measurements per modality 
are presented in table 2; results for the agreement analysis of EF are shown in table 3 and 
figure 3. Of all three modalities EF, measurement by CT yielded the highest mean EF: 
58±6%, where CMR yielded the lowest mean EF of the three modalities (54±7%).  
Volume measurement  
Correlations for LV end-diastolic volumes (supplemental figure 4) were strong for both CMR 
and CT compared to TTE (table 3, Pearson’s r: 0.84 and 0.85, both p<0.001 respectively), 
where the mean difference was smallest between CT and TTE. As shown in table 2, EDV













GLS (%) -20 ± 3 -21 ± 3 -20 ± 3 -21 ± 2 -21 ± 3 -20 ± 3 
EF (%) 58 ± 6 54 ± 7 55 ± 6 58 ± 5 55 ± 7 55 ± 5 
EDV (ml) 192 ± 65 203 ± 62 185 ± 64 183 ± 58 193 ± 62 180 ± 57 
EDV/BSA 
(ml/m2) 
99 ± 26 105 ± 26 95 ± 26 
95 ± 24 100 ± 24 94 ± 24 
ESV (ml) 82 ± 33 94 ± 34 83  ± 33 77 ± 28 87± 32 81  ± 29 
ESV/BSA 
(ml/m2) 
42 ± 13 48 ± 15 42 ± 15 
40 ± 12 45 ± 13 42 ± 12 
Table 2 *In this analysis all patients that completed 2 or more imaging modalities were considered. † In 
this sensitivity analysis data is shown when only patients are considered that completed all three imaging 
modalities. Data are presented as mean ± standard deviation. EDV: end-diastolic volume, ESV: end-systolic 
volume, EF: Ejection Fraction, GLS: Global Longitudinal Strain, BSA: Body Surface Area. Transthoracic 




 Table 3. Inter-modality agreement. 
 
 All Patients All three modalities 
 Pearson’s r† Bias‡ Mean difference Lower LOA Upper LOA Pearson’s r† Bias‡ 
Mean 
difference 
Lower LOA Upper LOA 
 CMR vs. TTE (n=45) CMR vs. TTE (n=39) 
GLS (%) 0.67 3 -2 -7 3 0.69 2 -2 -6 3 
EF (%) 0.61 4 0 -11 10 0.62 4 0 -10 11 
EDV (ml) 0.84 31 16 -53 85 0.86 28 13 -50 75 
ESV (ml) 0.82 17 8 -32 47 0.85 15 6 -28 40 
 CT vs. TTE (n=49) CT vs. TTE (n=39) 
GLS (%) 0.65 2 -1 -5 4 0.65 2 -1 -5 3 
EF (%) 0.67 4 2 -6 11 0.69 4 3 -5 11 
EDV (ml) 0.85 26 8 -61 77 0.88 23 3 -54 59 
ESV (ml) 0.83 13 0 -36 36 0.87 12 -4 -33 25 
 CT vs. CMR (n=42) CT vs. CMR (n=39) 
GLS (%) 0.62 2 1 -4 6 0.56 2 1 -5 6 
EF (%) 0.68 5 3 -8 14 0.56 5 3 -8 14 
EDV (ml) 0.93 19 -11 -56 35 0.93 18 -10 -54 33 
ESV (ml) 0.90 14 -11 -40 19 0.90 13 -10 -38 18 
Table 3. †: all significant with a p<0.001. ‡ Defined as the mean absolute difference, LOA: Limit of agreement. EDV: end-diastolic volume, ESV: end-systolic 
volume, EF: Ejection Fraction, GLS: Global Longitudinal Strain.  Transthoracic Echocardiography (TTE), Computed Tomography (CT) and Cardiovascular 





measurements were larger on CMR (203±62ml) compared with TTE (185±64ml), which 
resulted in the largest bias of 31ml and limits of agreement ranging between -53ml and 
85ml. Correlations for ESV were comparable to those found for EDV (supplemental figure 
5). ESV measured by CMR and CT correlated strongly with TTE (Pearson’s r: 0.82 and 0.83 
respectively, both p<0.001). Here too CT compared best with TTE with a mean difference of 
-0.3ml (bias: 13ml) versus 7.8ml on average for CMR compared with TTE (bias: 17ml).   




Figure 3. Inter-modality agreement for ejection fraction 
 
Fig. 2. Agreement between Transthoracic Echocardiography (TTE), Computed Tomography (CT) and Cardiovascular 
Magnetic Resonance (CMR) for global longitudinal strain (GLS). Bland-Altman plots and identity line (black) for CT 
versus TTE (blue) and CMR versus TTE (green) and CT versus CMR (red). Dashed red lines indicate ±1.96 SD. COV: 
coefficient of variation. 
Fig. 3. Agreement between Transthoracic Echocardiography (TTE), Computed Tomography (CT) and 
Cardiovascular Magnetic Resonance (CMR) for ejection fraction (EF). Bland-Altman plots and identity 
line (black) for CT versus TTE (blue) and CMR versus TTE (green) and CT versus CMR (red).  Dashed red 





Inter-observer variability was assessed for all three modalities; the results of the second 
observer agreement analysis for TTE are presented in supplemental figure 6. Both for GLS 
and EF good inter-observer agreement was found (Pearson’s r: 0.70, p<0.001 and 0.60, 
p=0.006 respectively), and also for EDV and ESV (Pearson’s r: 0.96 and 0.90, p<0.001 
respectively). The relatively large mean difference for EF (-9.4%) for TTE, was mainly driven 
by observer 1 overestimating both EDV (mean difference: 13.7ml) and ESV, with a tendency 
towards a more significant overestimation of the ESV (mean difference: 27.2ml) relative to 
the EDV. Inter-observer variability for CT is presented in supplemental figure 7, where a 
strong correlation between observers was found for GLS with a mean difference of -1.8% 
on average. Finally, inter-observer variability for CMR is presented in supplemental figure 8, 
where a moderate correlation for GLS (Pearson’s r: 0.51, p=0.023) was found. 
Discussion 
In this prospective cohort study we demonstrated for the first time that the assessment of 
GLS is feasible using a feature-tracking algorithm on the magnitude images acquired by 4D 
flow CMR directly after gadolinium contrast. This opens the way for an integrative one-
sequence approach in which both flow and functional information can be acquired 
simultaneously. Moreover, in this study functional LV parameters measured by CMR 
correlated well with 2D TTE, with a mean difference comparable to that found in other 
studies using ‘conventional’ SSFP cine CMR images. [26-29] On average GLS in our cohort of 
BAV patients was similar to that found using SSPF CMR images in a healthy adult 
population. [30]  
Although LV functional analysis by CT has been possible for a number of years there is 
limited data available on the value of CT in GLS assessment. [16, 31-33] CT has been shown 
to correlate closely with CMR and TTE for left ventricular assessment, [27] and more 
recently also for GLS analysis. [28] Additionally, studies have described good correlations 
between CT and TTE. [16, 32] Our study confirms these correlations with TTE and CMR for 
both GLS and EF. Furthermore, CT had the best reproducibility of all three modalities, 
reflected in the lowest coefficient of variation in the second-observer analysis. The 
observed overestimation of EF by CT compared to CMR could be explained by the fact that, 
especially on the long axis A3ch-view, papillary muscles are often difficult to discern 
resulting in a smaller ESV and subsequent high EF. Furthermore, unlike TTE and CMR, CT 
has the disadvantage of significant radiation exposure for the patient, since imaging of the 
complete cardiac cycle is necessary for GLS analysis. CT and CMR correlated well both for 
GLS and EF. Based on the high spatial resolution CT could have been expected to 
outperform CMR, as CMR may require more observer interpretation in determining the 




(COV: 10.7) compared to CMR versus TTE (COV: 12.0) for both GLS and for EF (COV: 7.5 vs 
9.8). Additionally, second observer analysis for CT showed a lower COV for all LV 
measurements.  
A clear limitation of this study is the need for separate contours for the GLS and volumes, 
caused by the frequent inadequate tracking of the basal and mid and anterior septal 
segments by the feature-tracking algorithm on CT and CMR (supplemental figure 9). Tracing 
the endocardial contour in the apical three chamber view from the mitral valve to the 
aortic valve orifice (supplemental video 1) often resulted in positive strain values in these 
segments, lowering the GLS. This could be resolved by placing the endocardial marker more 
apically (supplemental video 2) resulting in an underestimation of the EDV and ESV. A third 
video shows the same process for MR in apical three and 4 chamber views (supplemental 
video 3 and 4 respectively). The difficulty here is that when abandoning the anatomical 
landmark there is no clear alternative, which introduces possible inter-observer variability. 
Although more time consuming we chose to draw a second endocardial tracing focusing on 
the volume quantification when this problem occurred. With regard to the post-processing 
process, we found the TTE workflow to be significantly less time intensive compared to CT 
and CMR, partly because with TTE the sonographer directly acquired the apical 2-, 3-, and 
4-chamber views. Both with CT and CMR the observer had to create these views 
retrospectively. This may allow for more precise reconstruction and analysis, but it is also 
more time intensive as it increases workflow complexity, and creates a possible source of 
bias between observers. It has been shown that both observer experience and the software 
used for analysis can have a significant influence on the agreement for CMR (30, 31) as for 
TTE (32). And although outside the scope of this study we agree that user experience is an 
important factor in LV functional analysis. This is perhaps best reflected in the second 
observer analysis for TTE, where a small but consistent difference in EDV and ESV resulted 
in a systematically lower EF for the second observer. Another limitation is that we did not 
have SSFP CMR cine images available for these patients, which would have allowed to also 
compare 4D flow CMR with the ‘gold standard’ for volume quantification and feature-
tracking strain analyses on SSFP images. We feel that part of the variation between CMR 
and the other modalities could be explained by the inferior spatial resolution of the 
magnitude image datasets. Furthermore, the standard deviation of GLS and EF in this 
patient cohort is small, as all patients had relatively preserved LV function. A future study 
could evaluate how this technique performs in patients with a reduced LV function. 
Conclusion 
Feature-tracking GLS analysis is feasible using the magnitude images acquired by 4D flow 
CMR with adequate imaging quality. GLS measurement by CMR correlates well with CT and 




which flow and functional data can be acquired in one sequence. Future studies should aim 
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Supplemental figure 4. Agreement between transthoracic echocardiography (TTE), Transthoracic 
Echocardiography (TTE), Computed Tomography (CT) and Cardiovascular Magnetic Resonance 
(CMR) for end-diastolic volume (EDV).  Bland-Altman plots and identity line (black) for CT versus 
TTE (blue) and CMR versus TTE (green) and CT versus CMR (red).  Dashed red lines indicate ±1.96 
SD. COV: coefficient of variation. 
Supplemental figure. 5: Agreement between transthoracic echocardiography (TTE), 
Computed Tomography (CT) and Cardiovascular Magnetic Resonance (CMR) for end-systolic 
volume (ESV).  Bland-Altman plots and identity line (black) for CT versus TTE (blue), and CMR 
versus TTE (green) and CT versus CMR (red).  Dashed red lines indicate ±1.96 SD. COV: 











Supplemental figure 7: Inter-observer agreement for Computed Tomography.   
 
Supplemental figure 6: Inter-observer agreement for Transthoracic Echocardiography (TTE) 
(n=20). Bland-Altman plots and identity line (black) for global longitudinal strain (GLS), ejection 
fraction (EF), end-diastolic volume (EDV) and end-systolic volume (ESV). Dashed red lines indicate 
±1.96 SD. COV: coefficient of variation. *All Pearson’s r’s are significant with a p<0.01 
Supplemental figure 7: Inter-observer agreement for Computed Tomography (CT) (n=20). Bland-
Altman plots and identity line (black) for global longitudinal strain (GLS), ejection fraction (EF), 
end-diastolic volume (EDV) and end-systolic volume (ESV). Dashed red lines indicate ±1.96 SD. 













Supplemental figure 8. Inter-observer agreement for Cardiovascular Magnetic Resonance (CMR) 
(n=20). Bland-Altman plots and identity line (black) for global longitudinal strain (GLS), ejection 
fraction (EF), end-diastolic volume (EDV) and end-systolic volume (ESV). Dashed red lines indicate 
±1.96 SD. COV: coefficient of variation. *All Pearson’s r’s are significant with a p-value <0.05 
Supplemental figure 9. contours as drawn for the volume trace (A and 
B) and the contours as drawn for the strain trace more apically (C and 





















Objectives. Integration of volumetric heart chamber quantification by 3D 
echocardiography into clinical practice has been hampered by several 
factors which a new fully automated algorithm (Left Heart Model, (LHM)) 
may help overcome. This study therefore aims to evaluate the feasibility 
and accuracy of the LHM software in quantifying left atrial and left 
ventricular volumes and left ventricular ejection fraction in a cohort of 
patients with a bicuspid aortic valve. 
Methods.  Patients with a bicuspid aortic valve were prospectively included. All 
patients underwent 2D and 3D transthoracic echocardiography and 
computed tomography. Left atrial and ventricular volumes were obtained 
using the automated program, which did not require manual contour 
detection. For comparison manual and semi-automated measurements 
were performed using conventional 2D and 3D datasets. 
Results.   53 patients were included, in four of those patients no 3D dataset could 
be acquired. Additionally, 12 patients were excluded based on poor 
imaging quality. Left ventricular end-diastolic and end-systolic volumes 
and ejection fraction calculated by the LHM correlated well with manual 
2D and 3D measurements (Pearson’s r between 0.43 and 0.97, p < 0.05). 
Left atrial volume (LAV) also correlated significantly although LHM did 
estimate larger LAV compared to both 2DE and 3DE (Pearson’s r between 
0.61 and 0.81, p < 0.01). 
Conclusions.  The fully automated software works well in a real-world setting and helps 
to overcome some of the major hurdles in integrating 3D analysis into 
daily practice, as it is user-independent and highly reproducible in a group 






Left atrial and ventricular volumes and ejection fraction are important diagnostic and 
prognostic parameters, widely used in daily practice. Indication for cardiac surgery in 
patients with valvular abnormalities such as bicuspid aortic valve disease, rely heavily on 
accurate left ventricular (LV) volume and function assessment. For many years, two-
dimensional echocardiography (2DE) has been the most widely used modality for LV 
volumetric assessments; however, it relies on geometric assumptions which cause 
inaccuracy and the reproducibility remains suboptimal. Three-dimensional 
echocardiography (3DE) has largely overcome these drawbacks as it has the ability to 
visualize cardiac structures from any perspective, entailing an accurate quantitative and 
more reproducible evaluation of cardiac chambers. However, the use of 3DE in daily clinical 
practice has been hampered, because there is a learning curve for data acquisition, and 3D 
data analysis can be a time-consuming process, moreover there is need for experienced 
observers.  
A fully automated and user-interference free algorithm may improve the feasibility of 3DE 
in daily clinical practice. Such a method has now been proposed in the new ‘Heart Model’ 
Software (LHM), which promises a rapid and accurate automated quantification of left 
atrial (LAV) and LV volumes and ejection fraction (LVEF). The feasibility and accuracy of the 
new “Heart Model” was recently compared to cardiac magnetic resonance by Tsang et al 
who concluded that this technique is strongly correlated with CMR, with a high 
reproducibility and short analysis time [34, 35]. However, it has not been reported whether 
this also applies to patients with valvular heart disease where high reproducibility and 
feasibility is very important. 
Therefore, this study aims to assess feasibility and reproducibility of the ‘Heart model’ 
software in a prospective cohort study by comparing the results between echo and CT 
using conventional 2D, 2D-xPlane, 3D transthoracic echocardiography TTE (3DE) techniques 




Patients with a BAV who visited the outpatient clinic between October 2014 and March 
2016 were prospectively included. All patients underwent the full study protocol on the 
same day. The study protocol consisted of physical examination, electrocardiography (ECG), 




ethical committee of the Erasmus medical center and informed consent was given by all 
patients who participated in the study. 
Echocardiography 
Image acquisition 
Two experienced sonographers (J.S.M., W.B.V.) performed a standard two-dimensional 
transthoracic echocardiogram (2DE). All studies were acquired in the left lateral decubitus 
position, in harmonic imaging using an EPIQ7 ultrasound system (Philips Medical Systems, 
Best, the Netherlands) equipped with a x5 – 1 matrix-array transducer (composed of 3040 
elements with 1-5 MHz) A non-foreshortened apical four-chamber view (A4C) and two-
chamber view (A2C) were recorded with manual or electronic rotation (iRotate) followed 
by a focused LV, A4C and A2C image. From the focused LV- A4C a true perpendicular image 
view (A2C) was acquired with xPlane mode, in order to retrieve both views from the same 
heart-beat. This was repeated with the focus on the true long axis of the LA [36]. Real-time 
3D-TTE was performed immediately after the 2D-TTE with the same ultrasound unit and 
transducer. A four-or six-beat full volume dataset of the LV and LA was acquired from the 
apical window during a single breath hold. Two extra datasets were acquired from the A4C 
view in the dedicated ‘Heart Model’ acquisition mode. 
Image analysis  
Analysis was performed by A.T.H. and J.S.M. All measurements were blinded to patient 
specific information. Before measurements were performed, the quality of each dataset 
was evaluated by both observers. Patients were excluded from further analysis in cases of 
poor image quality (e.g. poor endocardial visualization).  
2D Echocardiography  
LV end diastolic volume (LVEDV), LV end systolic volume (LVESV) and LVEF were calculate 
using the Simpsons bi-plane method of disk summation, as stated in the guidelines, from 
the standard A4C and A2C and apical xPlane images [37]. LAV was calculated using the area 
length method.  
3D Echocardiography 
Manual: LV volumes and LVEF were measured using commercially available software (QLab-
3DQ, Philips medical systems). The user aligned the mutiplanar view to obtain the true long 
axis of the LV in the A4C and A2C view. Landmarks were placed on the mitral annulus and 
apex. The endocardial border was traced automatically and adjusted manually where 
needed. For the LA volume, the true long-axis was aligned using the multiplanar mode in 
the end-systolic frame and the contour traced as mentioned above. The 3D dataset was 




Automatic: Offline fully automatic analysis of the datasets was performed using the Q Lab 
advanced ‘Heart Model’ analysis software. This software has previously described in detail 
before by Tsang et al [34, 35]. In brief, this software detects the endocardial surfaces by 
using an adaptive algorithm. This identifies a global end-diastolic shape which it uses in 
combination with motion detection to determine an end-systolic cavity [34, 35]. The 
program combines information from a database of 1000 3D TTE studies and its endocardial 
surface detection to model the LA and LV. Afterwards it matches features from the known 
datasets to the current patient for which it needs, much like manual measurements, a 
minimum of approximately 14 or 15 LV segments. The final model (figure 1) is displayed 
with the possibility to manually edit the contours if the user deems this necessary. To 
better estimate the added value over existing 3D techniques we chose not to manually edit 
the contours.  
Cardiac Computed Tomography 
Data acquisition 
Acquisition was performed on a 3rd generation dual-
source CT (Somatom Force, Siemens Healthcare, 
Forchheim, Germany). Retrospective ECG gated 
spiral acquisition was used, with a mean dose length 
product (DLP) of (estimated effective dose 5mSv, 
using k=0.017) 362mGy-cm kVp was modulated to 
patient size. Besides patient size and the selected kV 
the mA was modulated to the heartrate to provide a 
high mA pulse during 1-40% of the RR interval. The 
pitch was adapted to increase proportionally with 
higher heartrates. Reconstructions were made with 
a medium smooth kernel, with a slice thickness of 
1.5mm at an increment of 0.4mm at every 5% of 
the RR interval. 
Image processing 
Images were analyzed semi-automatically using Syngo Via software (vb 10., Siemens, 
Forcheim Germany). Image analysis was performed by AC, with 1 year of cardiac 
CTexperience. All cardiac phases were analyzed the software automatically detects the ED 
and ES phase, this was manually changed if needed. The endo and epicardial contours are 
automatically placed by the software and manually adjusted were need. The papillary 
muscles and if present trabeculations were included into the LV lumen. The basal plane was 
selected perpendicular to the short axis at the level of the mitral valve. Care was used to 
make sure the basal plane was on the same level in the ED and ES phase. 
Figure 1. The model as generated by the 






The IBM SPSS® statistics 21.0 software was used to analyze the data. Continuous variables 
were presented as mean ± standard deviation (SD) or as median with an interquartile 
range. Categorical variables were presented as frequencies and percentages. We tested for 
normality by calculating Z-values of skewness and kurtosis, using the Shapiro-Wilk test and 
by visually assessing the data. For comparison of normally distributed continuous variables 
between two groups the student’s t-test was used. To quantify correlations the Pearson or 
Spearman correlation test was applied. Intra-observer and inter-observer agreement 
between two investigators (A.T.H, J.S.M.) were assessed by repeated analysis of the same 
images in a third of the dataset a month after initial analysis at the same images and 
blinded to the initial results. The limits of agreement between two measurements were 
determined as the mean of the differences (bias) ± 1.96 SD and presented in a Bland-
Altman plot [25]. Additionally, the coefficient of variation (COV) was provided to compare 
the dispersion of two variables. The COV was defined as either the SD of the differences of 
two measurements divided by the mean of their means. The statistical tests were two sided 
and a p-value below 0.05 was considered significant. 
Results 
Fifty-three patients with a BAV were included; baseline characteristics are presented in 
table 1.  Eight patients also had Turner syndrome.  Four patients previously underwent 
aortic coarctation resection and three patients underwent a balloon dilatation of their 
stenotic aortic valve. One patient underwent closure of a type II atrial septal defect. In all 
53 patients, 2DE measurements could be performed and functional echo parameters were 
measured, as presented in Table 1. In four patients, no 3D dataset could be acquired. 
Additionally, 12 patients were excluded based on poor imaging quality. 
Left ventricle 
LHM versus manual 2D measurements 
There was a good correlation between the LHM and the manual bi-and xPlane 
measurements for LVEDV, LVESV, and LVEF. In table 2 the measurements of LV volumes 
and function and LA maximal volume are presented for all different methods. Figure 2a and 
2b show the Bland-Altman plots for EF by 2DE bi-plane and xPlane compared to the LHM. 
The results of the agreement analysis between the LHM and the measurements based on 
the 2DE are shown in table 2. For clarity purposes, we did not include mutual correlations 
between the different echo modalities; however, Bi-plane and xPlane had a high correlation 
for LVEDV (r=0.977), LVESV (r=0.978) and LVEF (r=0.702). Additionally, both methods 




LHM versus manual 3D measurements 
The LHM correlated strongly with the 3D LV measurements as shown in table 2. The LHM 
seems to estimate slightly larger LVEDV and LVESV and a smaller LVEF compared to manual 
3D (table 2). Figure 2c shows the Bland-Altman plot for EF measured by 3DE. 16 patients 
(30%) had to be excluded due to poor imaging quality, which is considered acceptable in 
routine setting for 3DE. 
Table 1. Baseline characteristics of the study population (n=37). 
  Parameter Median (IQR)  
Baseline  Men, n (%) 25 (68)  
 Age, years 35.2 (23)  
 Height, cm 178 (26)  
 Weight, kg 72 (24)  
 BMI, kg/m2 23.9 (3.0)  
 SBP, mmHg 122 (20)  
 DPB, mmHg 80 (19)  
Mitral valve  E-wave, m/s 0.70 (0.2)  
 A-wave, m/s 0.50 (0.2)  
 E/A-ratio 1.2 (0.9)  
 DT, ms 209 (67)  
 E’ septal, cm/s 7.8 (3.1)  
 Ee’-ratio 9.0 (3.6)  
Aortic valve BAV 
(n=32) 
No AoI, n= (%) 5 (16)  
Mild AoI , n= (%) 21 (66)  
Moderate AoI, n= (%) 5 (16)  
Severe AoI, n= (%) 1 (3)  
Peak velocity, m/s 2.65 (1.6)  
VTI, cm 52.8 (45)  
Gradient, m/s 28 (33)  
TS* 
(n=5) 
No AoI, n= (%) 4 (80)  
Mild AoI,  n= (%) 1 (20)  
Moderate, AoI n= (%) 0 (0)  
Severe AoI, n= (%) 0 (0)  
Peak velocity, m/s 1.4 (0.6)  
VTI, cm 28.4 (12)  
Gradient, m/s 8 (6.5)  
Table 1. Data are expressed as median and IQR or as ‘n=, (%)’ for gender and aortic insufficiency. 
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; DT: 






Table 2. Correlations between LHM and four different methods of volumetric chamber quantification. 
  
Method Phase Mean, SD Pearson’s r† Bias Lower LOA Upper LOA 
LHM (n=37) 
 EDV (ml) 146 ±48  
 ESV (ml) 77 ± 29 
 EF (%) 47 ±5 
 LA (ml) 61 ±19 
LHM 2nd dataset (n=12) 
 EDV (ml) 143±61 0.99** -0.8 -9 7 
 ESV (ml) 78±34 0.99** 1 -7 9 
 EF (%) 45±4 0.58* -1.5 -7 4 
 LA (ml) 57±19 0.98** -1 -9 7 
2DE Bi-plane (n=37) 
 
EDV (ml) 145 ±54 0.93** 0.06 -41 41 
 
ESV (ml) 77 ±31 0.88** 0.2 -29.1 29.4 
 
EF (%) 47 ±8 0.63** 0.5 -11.8 12.8 
 
LA (ml) 43 ±16 0.61** 17 -13.6 47.4 
2DE xPlane (n=37)  
EDV (ml) 143 ±52 0.94** 2 -32 36.4  
ESV (ml) 77 ±30 0.88** 0.8 -27.1 28.8 
 
EF (%) 47 ±8 0.43** 0.6 -13 14.2 
 
LA (ml) 42 ±16 0.69** 18 -8.8 45.2 
3D (n=37) 
 
EDV (ml) 143 ±50 0.97** 2 -23 27.6 
 
ESV (ml) 71 ±26 0.91** 6 -16.9 29.8 
 
EF (%) 50 ±7 0.51** -3 -15.5 9.8 
 
LA (ml) 53±19 0.81** 9 -13.1 32.1 
CT (n=37) 
 EDV (ml) 185±63 0.88** -42 -102.3 18.9 
 ESV (ml) 67±24 0.81** 10 -24.1 43.6 
 EF (%) 64±5 0.24 16 -28.3 -4.7 
Table 2. Data are presented as mean and SD. EDV: end-diastolic volume, ESV: end-systolic volume, 
EF: Ejection Fraction, LA: Left atrium, LOA: Limit of agreement, COV: coefficient of variation. †: 
compared with the LHM, **: p<0.01 *: p<0.05. A negative mean implies a smaller value was given 




Figure 2. Bland-Altman plots demonstrating inter-modality agreement of EF and LAV in 2DE biplane 




Figure 2. Left atrial volume measured by bi-plane 2DE (A). Ejection fraction measured by bi-plane 2DE 
(B). Left atrial volumes measured by xPlane 2DE (C). Ejection fraction measured by xPlane 2DE (D). 
Left atrial volumes measured by 3DE (E).  Ejection fraction measured by 3DE (F). Ejection fraction 
measured by CT (G). The solid lines depict the mean difference of the two measurements; the 




Inter- and intra-observer variability 
LHM versus CT 
Although the CT measurements correlated with the LHM for EDV and ESV (r=0.88 and 
r=0.81); mean differences were 42ml (23%) and 10ml (15%) respectively (p<0.001 and 
p=0.002). Compared to CT the LHM seems to estimate smaller LVEDV (table 2) and 
consequently also produces a smaller LVEF (mean difference 16%, p<0.001) as shown in 
figure 2d. The correlations for Bi-plane, xPlane and conventional 3D with CT for LVEF were 
comparable; a low correlation due to the relatively small LVEDV compared to CT. 
The LHM has no intra-, or inter-observer variation as the model produced the exact same 
measurements when the same dataset is used (mean difference: 0±0, p<0.001). In addition, 
when the measurements were repeated on a second acquisition of the same patients 
(n=12) there was some variation but generally there was good agreement reflected by a 
small bias and narrow limits of agreement (table 2). The inter-observer variability for the 
LVEDV and LVESV on conventional 3DE was calculated (r=0.909, p<0.001 and r=0.862, 
p<0.001) in 14 (38%) patients.  
Left atrial volume  
The LAV was estimated consistently significantly larger by the LHM (table 2) compared with 
on both 2DE and 3DE as is shown in figure e, f and 2g. This ‘overestimation’ was the most 
evident comparing to the 2D methods and less pronounced compared with manual 3D 
measurements. The correlation between 2D Bi-plane and 2D xPlane measurements of the 
LA volume was very high (r= 0.946, p<0.001). When comparing the LAV measured on 2D 
with the LA volume measured on 3D, xPlane outperforms Bi-plane (r= 0.632, p<0.001 and 
r= 0.551, p=0.002 respectively). 
Discussion 
The main findings of this study can be summarized as follows:  
 Automated chamber quantification is feasible in patients with bicuspid aortic valve disease 
in a routine clinical setting.  
 The ‘Heart Model’ provides accurate automatic measurements of LVEDV, LVESV and LVEF 
and LAV compared to 2D and 3D echocardiography. 
 There is no inter or intra-observer variability and very little ‘inter-dataset’ variability.  
Left ventricular assessment 
In daily clinical practice LV function is routinely estimated by bi-plane Simpson method of 
disk-summation; however, this requires sufficient experience and has limitations in 




the ventricular or atrial cavity inherent to 2DE [37]. Moreover, the lack of a third dimension 
is generally considered to result in high inter-measurement variability and limits 
endocardial visualization, predominantly of apical lateral segments. Foreshortening of the 
LV often performed  in an attempt to alleviate this shortcoming causes reduced accuracy 
and reproducibility [38]. Volumetric quantification from 3D data sets allows frame-by-frame 
detection of endocardial surface and does not require manual image plane positioning or 
geometric assumption [39] and has furthermore been shown to have a higher 
reproducibility than 2DE [40-42].  
The bias of CT and 3D echocardiography is approximately as low as the bias of MRI when 
estimating LVEF [43]. Additionally, previous studies showed that for LVEF CT has the best 
correlation with MRI. In this light it is remarkable that in our study the correlation with CT is 
weak, as the EDV seems to be systematically estimated to be larger by CT than by the LHM 
or other echo modalities [27, 43]. This systematic underestimation may in part reflect an 
inter observer variability, as more of the trabeculations were included in the LV cavity for 
CT, entailing a larger EDV. Also, the trabeculations in this population may be more 
pronounced than in healthy subjects, adding to the observed difference. 
Left heart chamber quantification by 3DE is hampered by several factors, mainly the ease 
with which these techniques can be used in daily clinical practice. A 3D learning curve is 
often time consuming and a degree of experience is required. Especially in the growing and 
aging population of patients with valvular and congenital heart disease, where patients 
regularly undergo extensive echocardiographic evaluation, user-independent and non-
invasive follow-up imaging is much needed.  
Added value of LHM 
Accurate and reproducible measurements of left chamber volumes are very important in 
clinical practice, as they correlate with prognosis and determine treatment strategies. 
Moreover, in order to test new therapies, changes in these parameters must be accurate to 
demonstrate the efficacy of medical therapy or intervention.  Our results indicate that 
intra-observer, inter-observer, and test-retest reproducibility of this method are very high 
and even exceptionally for intra-observer variability (0%) since this algorithm has no human 
interaction (i.e. phase selection and contouring are automatic). 
We had to exclude 16 patients (30%) in total due to imaging quality limitations which is 
comparable to conventional 3DE in a routine clinical setting. 
The main concern with 3D echocardiography is the accessibility in terms of time and skill 
required to produce accurate and reproducible results. The algorithm described in this 




accuracy in in a population of patients with BAV disease, a population where fast, reliable, 
user-independent and non-invasive follow-up imaging by echocardiography is imperative.  
Left Atrial Volume 
Another remarkable finding is the relatively large LA volume estimated by the LHM 
compared to 2DE measurements. First, we suggested that this could be explained by the 
inclusion of the pulmonary vein orifice into the left atrial cavity by the algorithm. However, 
when carefully re-evaluating the LA contours, most seemed to adequately follow the left 
atrial walls. Another explanation could be that it is actually an underestimation of the 2DE 
measurements. This can partly be explained by the use of the length area formula which 
assumes the LA to be ellipsoid, which is evidently not always the case [37]. The correlation 
of LA volume measurements with 3D TTE was better.  Still, inherent flaws of 2D imaging in 
combination with LA anatomy could contribute to this discrepancy. In the standard 2DE the 
LA measurements are performed on the A4C and A2C views which are focused on the true 
long axis of LV. The true long axis LA may not be in the same plane as the LV and therefore 
may appear foreshortened on the apical four chamber view.  In xPlane a special focus view 
on the true LA long axis was acquired which better correlated with the LHM. 
Limitations 
The golden standard for quantitative volumetric heart chamber assessment is cardiac 
magnetic resonance imaging (MRI). Unfortunately, no cine cardiac images were available in 
this study. Therefore, no comparison with MRI could be made; consequently, we used 
volumetric data from CT as an additional source of validation. Additionally, we feel that EDV 
by 2DE has been slightly underestimated and therefore 3DE is best used as a reference 
modality. We were strict when it came to image quality therefore we had to exclude 12 
patients from analysis. However, a sufficiently large cohort could be analyzed. Eight 
patients had Turner syndrome, patients affected with this genetic disorder are notoriously 
hard to echo, mainly because of a wide ‘barrel-shaped’ thorax and often a high BMI. Three 
of these patients were excluded due to low imaging quality. 
Conclusion 
Automated chamber quantification is feasible and accurate in patients with bicuspid aortic 
valve disease in a routine clinical setting. The ‘Heart Model’ provides accurate automatic 
measurements of LVEDV, LVESV and LVEF and LAV and has a high reproducibility between 
dataset and no inter or intra-observer variability. It does however seem to underestimate 
end-diastolic volume compared to CT. 
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Objective  The objective of this study was to evaluate outcomes of endovascular treatment 
of aortic coarctation in adults. 
Methods Clinical data and imaging studies of 93 consecutive patients treated at nine 
institutions from 1999 to 2015 were reviewed. We included newly diagnosed 
aortic coarctation (NCO), recurrent coarctation, and 
aneurysmal/pseudoaneurysmal degeneration (ANE) after prior open surgical 
repair (OSR) of coarctation. Primary end points were morbidity and mortality. 
Secondary end points were stent patency and freedom from reintervention. 
Results  There were 54 (58%) male and 39 (42%) female patients with a mean age of 44 ± 
17 years. Thirty-two patients had NCO (mean age, 48 ± 16 years) and 61 had 
endovascular reinterventions after prior OSR during childhood (mean, 30 ± 
17 years after initial repair), including 50 patients (54%) with recurrent coarctation 
and 11 (12%) with ANE. Clinical presentation included asymptomatic in 31 
patients (33%), difficult to control hypertension in 42 (45%), and lower extremity 
claudication in 20 (22%). Endovascular treatment was performed using balloon-
expandable covered stents in 47 (51%) patients, stent grafts in 36 (39%) patients, 
balloon-expandable uncovered stents in 9 (10%) patients, and primary angioplasty 
in 1 (1%) patient. Mean lesion length and diameter were 64.5 ± 50.6 mm and 
19.5 ± 6.7 mm, respectively. Mean systolic pressure gradient decreased from 
24.0 ± 17.5 mm Hg to 4.4 ± 7.4 mm Hg after treatment (P < .001). Complications 
occurred in nine (10%) patients, including aortic dissections in three (3%) patients 
and intraoperative ruptures in two patients; type IA endoleak, renal embolus, 
spinal headache, and access site hemorrhage occurred in one patient each. The 
aortic dissections and ruptures were treated successfully by deploying an 
additional covered stent proximal to the site of dissection or rupture. Two 
patients died within 30 days of the index procedure. After a mean follow-up of 
3.2 ± 3.1 years, nearly all patients (98%) were clinically improved and all stents 
were patent. Reintervention was needed in 10 (11%) patients. Freedom from 
reintervention at 5 years was 85%. Two additional patients died during follow-up 
of coarctation-related causes, including rupture of an infected graft and visceral 
ischemia. Patient survival at 5 years was 89%. 
Conclusion  Endovascular repair is effective with an acceptable safety profile in the treatment 
of NCO and postsurgical complications of coarctation after initial OSR. Aortic 
rupture is an infrequent (2%) but devastating complication with high mortality. 
Balloon-expandable covered stents are preferred for NCO, whereas stent grafts 
are used for ANE. The rate of reinterventions is acceptable, with high procedural 






Coarctation of the aorta (CoA) is a common congenital heart defect and affects 5% to 8% of 
live births with congenital heart disease [1-4]. Open surgical repair (OSR) continues to be 
the “gold standard” for its treatment, with excellent operative and long-term 
outcomes[5] since the first successful operation by Crafoord in 1945 [6]. Throughout the 
years, advancements in surgical technique and medical therapy have allowed a dramatic 
improvement in patients' survival, matching the expected survival for the general 
population [3, 7-9]. The introduction of endovascular balloon angioplasty in 1982 
and stenting 10 years later also offered a less invasive alternative in selected cases[10, 
11]. Currently, given the expected longevity of this population of patients, emphasis has 
been placed on management of late complications from prior OSR, including recurrent 
coarctation (RCO), aneurysm/pseudoaneurysm formation (ANE), and valve dysfunction. In 
addition, a small number of patients develop symptoms and are newly diagnosed with CoA 
(NCO) in adulthood [12-15]. 
The clinical data on use of endovascular treatment of CoA in adults remain scarce. The 
largest experience includes 59 patients, although larger reports have shown successful 
results in pediatric patients [12, 16]. These studies have shown a low rate of complications 
and reintervention in the range of 9% to 12%. The aim of our study was to review a multi-
institutional experience and outcomes in adult patients with only endovascular treatment 
of NCO and patients with late complications from OSR in the form of RCO and ANE. 
Methods 
Cohort of patients 
We retrospectively reviewed the clinical data of all consecutive adult patients (older than 
18 years) treated between January 1, 1999, and June 30, 2015, by angioplasty or stenting at 
nine participating institutions (Supplementary Table, online only). The reporting standards 
of the Society for Vascular Surgery were used for definition of stent graft complications 
after thoracic endovascular aortic repair [17]. Indications for endovascular treatment 
included NCO or a late complication from initial OSR, which included RCO and ANE adjacent 
to the initial anastomosis. Technical success was defined by successful angioplasty with or 
without stent placement with no evidence of significant residual stenosis (>30%), pressure 
gradient (>10 mm Hg), type IA endoleak, rupture, or dissection. Consent of individual 
patients for study inclusion was obtained, and the study received approval from each of the 
Institutional Review Boards including the Human Research Protection Program. The data 
collection method was by review of medical records and imaging when available. Data were 




patients' confidentiality, no patient-identifying information was shared between 
participating institutions. 
Data collection included patients' demographics, cardiovascular risk factors, operative 
reports, and radiologic studies. Baseline clinical information at the time of presentation and 
other comorbidities were also recorded. Preoperative computed tomography 
angiography (CTA), magnetic resonance angiography, angiography, and transthoracic 
echocardiography data were also recorded. 
Definitions 
NCO in the adult was defined by imaging evidence of aortic narrowing with resistant 
systemic hypertension, lower extremity claudication, or ischemic nephropathy. Presence 
of end-organ damage (e.g., ventricular dysfunction, stroke, retinopathy) was evaluated. 
Anatomic analysis of the NCO was obtained by cross-sectional noninvasive imaging 
whenever possible, with contrast-enhanced angiography used selectively. Patients with late 
complications after prior OSR during childhood were diagnosed during surveillance studies. 
ANE was defined by fusiform or saccular dilation of at least 1.5 times the diameter of the 
aorta adjacent proximal to the anastomosis. RCO was defined as re-narrowing of the 
previously repaired area causing a pressure gradient measured during angiography and 
signs or symptoms, such as systemic hypertension, lower extremity claudication, and 
ischemic nephropathy. In NCO and RCO patients, technical success after intervention was 
defined with a post intervention pressure gradient of <10 mm Hg and a residual stenosis 
of <30%. 
Adjunctive procedures included carotid to subclavian artery bypasses to increment the 
proximal landing zone, spinal drains to ameliorate the potential for spinal cord ischemia, 
creation of iliac artery conduit for inadequate femoral artery access, and rapid ventricular 
pacing for accurate stent graft deployment. 
Statistical analysis 
Three-way analysis of variance was used for the analysis of primary outcomes, including 
operative morbidity and mortality. Secondary outcomes included stent or stent graft 
patency and freedom from reintervention. Time-dependent outcomes (e.g., survival, 
patency, and reintervention) were analyzed using Kaplan-Meier survival estimates, and 
differences were determined using log-rank test. Data were reported using means and 
standard deviations for continuous variables or as frequencies for categorical variables. 
Differences between categorical variables in two groups were tested using the χ2 test, and 
differences between continuous variables were tested using Student t-test. Analyses were 







There were 93 patients treated with endovascular interventions, including 54 (58%) male 
and 39 (42%) female patients with a mean age of 44 ± 17 years (Table I). Thirty-two (34%) 
patients were NCO with a mean age of 48 ± 16 years. Sixty-one (66%) patients who had a 
prior OSR during childhood presented with postsurgical complications at a mean age of 
42.7 ± 17.4 years (Fig 1). In this group, the mean and median age at the initial OSR were 
14 years and 10 years, respectively. The mean time from OSR to endovascular intervention 





At the time of presentation, 62 patients (67%) were symptomatic. There were 30 (94%) in 
the NCO group and 32 (64%) in the RCO group, respectively. The symptomatic patients in 
the NCO group included 22 (69%) with resistant hypertension and 8 (25%) with bilateral 
lower extremity claudication. Eleven (34%) of these patients also had echocardiographic 
evidence of left ventricular hypertrophy. 
The patients with prior OSR included 50 (54%) in the RCO group and 11 in the ANE group. 
There were 32 (64%) in the RCO group who were symptomatic, and those included 20 
(40%) with resistant hypertension and 12 (24%) with bilateral lower extremity claudication. 
Eleven (22%) of these RCO patients also had echocardiographic evidence of left ventricular 
hypertrophy. Patients in the ANE group were all asymptomatic (Table I). 




Table 1. Patients' demographics , comorbidities,  imaging studies, and anatomic measurements  
 
All CoA 
 (n = 93) 
NCO  
(n = 32) 
RCO  
(n = 50) 
ANE  
(n = 11) 
P 
Demographic information 
     
 Age, years 44 ± 17 48 ± 16 39 ± 16 59 ± 14 NS 
 Male 54 (58) 17 (53) 30 (60) 8 (73) NS 
Comorbidities 
     
 Hypertension 84 (90) 31 (97) 42 (84) 11 (100) NS 
 Hypercholesterolemia 23 (25) 6 (19) 9 (18) 8 (73) 
 
 Left ventricular hypertrophy 22 (24) 11 (34) 11 (22) 0 (0) NS 
 Diabetes mellitus 4 (4) 3 (9) 1 (2) 0 (0) NS 
Symptomatic 62 (67) 30 (94) 32 (64) 0 (0) NS 
 Resistant hypertension 42 (45) 22 (69) 20 (40) 0 (0) NS 
 Claudication 20 (22) 8 (25) 12 (24) 0 (0) NS 
Anatomic measurement 
     
 Diameter of narrowest area of 
CoA, mm 
10.1 ± 4.7 9.1 ± 5.2 10.1 ± 
4.4 
15.0 ± 5.0 NS 
 Length of CoA, mm 19.1 ± 14.6 16.4 ± 9.9 17.5 ± 
10.9 






 (n = 93) 
NCO  
(n = 32) 
RCO  
(n = 50) 
ANE  
(n = 11) 
P 
 Normal aortic diameter proximal 
to CoA, mm 
19.8 ± 5.8 21.2 ± 6.9 18.7 ± 
5.1 
22.1 ± 4.4 NS 
 Normal aortic diameter distal to 
CoA, mm 
21.6 ± 5.9 23.5 ± 6.9 20.5 ± 
5.5 
23.3 ± 2.8 NS 
 Distance from left subclavian 
artery to area of CoA, mm 
18.3 ± 18.2 23.7 ± 11.4 15.4 ± 
15.2 
16.0 ± 34.7 NS 
Imaging study 
     
 CTA only 40 (43) 
    
 CTA and MRA 34 (37) 
    
 MRA only 12 (13) 
    
 Angiography 5 (5) 
    
 Transthoracic echocardiography 2 (2) 
    
 
  
Table 1. ANE, Aneurysm/pseudoaneurysm formation; CoA, coarctation of the aorta; CTA, computed 
tomography angiography; MRA, magnetic resonance angiography; NCO, newly diagnosed aortic coarctation; 
NS, not significant; RCO, recurrent coarctation. Categorical variables are presented as number (%). 




Endovascular treatment of ANE 
All 11 (12%) patients in this group had a previous CoA repair in childhood, and the ANE was 
treated using stent grafts (Fig 1). Across the board, among all institutions, there was 
consensus in the decision to use stent grafts under aneurysmal circumstances. A wide 
variety of different stent grafts were used across institutions, which included brands such 
as Gore Medical (Flagstaff, Ariz), Cook Medical (Bloomington, Ind), and Medtronic Medical 
(Minneapolis, Minn) stent grafts. The normal aortic diameters proximal and distal to the 
area of enlargement were 22.1 ± 4.4 mm and 23.3 ± 2.8 mm. The stent graft diameter and 
length were 23.7 ± 6.9 mm and 81.7 ± 43.0 mm. Total adjunct procedures included two 
spinal drains, one iliac artery conduit, and one rapid ventricular pacing for accurate stent 
graft deployment. Furthermore, there were four patients with a concomitant left carotid to 
left subclavian artery bypass (Fig 2) and two with a right carotid to left carotid to left 
subclavian artery bypass (Table 2). 
 
Fig. 2 Intraoperative angiograms of a patient undergoing pseudoaneurysm repair. 
 
  
Fig 2. (A) before stent deployment (notice the left common carotid artery to left subclavian artery 
bypass [red arrow] and the ascending aorta to descending aorta bypass to relieve the pressure 
gradient [blue arrow]) and (B) after stent graft deployment.(Reprinted by permission of Mayo 





Endovascular treatment of NCO and RCO 
There were 82 patients in this category, 50 (53%) with RCO and 32 (34%) with NCO (Fig 1). 
The decision among institutions on how to treat these patients was diverse; however, there 
seemed to be a degree of consensus regarding the treatment of RCO patients, which was 
significant in the use of balloon-expandable covered stents (p = .043) as opposed to the 
treatment of patients in the NCO and ANE groups. There was no difference in the use of 
stent grafts and balloon-expandable bare-metal stents among NCO and RCO patients. A 
variety of different brands for stents were also used in this group. The balloon-expandable 
covered stents included the Cheatham-Platinum stent (NuMED, Hopkinton, NY) 
and Atrium Advanta stent (Maquet, Wayne, NJ), and the balloon-expandable uncovered 
stents included the Palmaz stent (Cordis, Milpitas, Calif) and the Covidien LD stent 
(Medtronic). 
For the RCO patients, there were 32 (33%) patients treated with balloon-expandable 
covered stents, 12 (13%) patients treated with stent grafts, 5 (5%) treated with balloon-
expandable bare-metal stents, and 1 treated with angioplasty alone. The diameter and 
length of the area of CoA were 10.1 ± 4.4 mm and 17.5 ± 10.9 mm, respectively. The 
normal aortic diameter proximal and distal to the area of CoA was 18.7 ± 5.1 mm and 
20.5 ± 5.5 mm, respectively. The stent diameter and length were 18.4 ± 5.7 mm and 61.9 ± 
54.8 mm, respectively. The angioplasty balloon's diameter used to treat this group was 
19.0 ± 4.4 mm. The pretreatment and post-treatment pressure gradients were 23.4 ± 
14.1 mm Hg and 4.6 ± 8.8 mm Hg (p < .0001). Adjuncts for the endovascular procedure 
included five inductions of hypotension(four rapid ventricular pacing and one inferior vena 
cava occlusion) and one spinal drain placement. Furthermore, there were three patients 
with a right carotid to left carotid to left subclavian artery bypass and one with a left carotid 
to left subclavian artery bypass (Table 2). 
For the NCO patients, there were 15 patients treated with balloon-expandable covered 
stents, 13 patients treated with stent grafts, and 4 treated with balloon-expandable bare-
metal stents. The diameter and length of the CoA were 9.1 ± 5.2 mm and 16.4 ± 9.9 mm. 
The normal aortic diameter proximal and distal to the area of enlargement was 21.2 ± 
6.9 mm and 23.5 ± 6.9 mm, respectively. The stent graft diameter and length were 20.5 ± 
7.3 mm and 65.1 ± 43.4 mm, respectively. The angioplasty balloon's diameter used to treat 
this group was 18.6 ± 3.7 mm. The pretreatment and post-treatment pressure gradients 
were 29.4 ± 19.8 mm Hg and 4.6 ± 4.7 mm Hg (p < .0001). Adjuncts for the procedure 
included 10 inductions of hypotension (7 rapid ventricular pacing, 1 inferior vena cava 
occlusion, 1 infusion of adenosine, and 1 proximal in-flow occlusion using a Coda balloon 
[Cook Medical]) and 1 iliac artery conduit. Furthermore, there was one left carotid to left 




Table 2. Procedure details including adjuncts (n = 93) 
 
All CoA  
(n= 93) 
NCO  
(n = 32) 
RCO  
(n = 50) 
ANE  
(n = 11) 
P 
Stent information      
 Balloon-expandable covered stent 
(NuMED, Maquet) 
47 15 32 0 .043 
 Balloon-expandable bare-metal 
stent (Cordis, Medtronic) 
9 4 5 0 NS 
 Stent graft (Gore Medical, Cook 
Medical, Medtronic Medical) 
36 13 12 11 NS 
 Angioplasty 1 0 1 0 NA 
 Length, mm 64.5 ±50.6 65.1±43.4 61.9±54.8 81.7±43.0 NS 
 Diameter, mm 19.5 ± 6.7 20.5 ± 7.3 18.4 ± 5.7 23.7 ± 6.9 NS 
Largest angioplasty balloon 
diameter, mm 
19.6 ± 5.5 18.6 ± 3.7 19.0 ± 4.4 27.1 ± 8.5 NS 
Residual stenosis, % 6.5 ± 14.8 5.8 ± 12.3 9.2 ± 18.1 – NS 
Pretreatment gradient, mm Hg 24.0 ± 17.5 29.4±19.8 23.4±14.1 – NS 
Post-treatment gradient, mm Hg 4.4 ± 7.4 4.6 ± 4.7 4.6 ± 8.8 – NS 
Adjunct      
Table 2. ANE, Aneurysm/pseudoaneurysm formation; CoA, coarctation of the aorta; NCO, newly diagnosed 
aortic coarctation; NA, not applicable; NS, not significant; RCO, recurrent coarctation. Categorical variables 





All CoA  
(n= 93) 
NCO  
(n = 32) 
RCO  
(n = 50) 
ANE  
(n = 11) 
P 
 Induction of hypotension      
 Rapid ventricular pacing 12 7 4 1  
 Inferior vena cava occlusion 2 1 1   
 Adenosine infusion 1 1    
 Proximal balloon occlusion 1 1    
 Spinal drain 3  1 2  
 Cervical debranching      
 Right carotid to left carotid to    
left subclavian artery bypass 
5  3 2  
 Left carotid to left subclavian 
artery bypass 
6 1 1 4  
 Temporary iliac artery conduit 2 1  1  
 
Procedural success and complications 
Technical success was achieved in 100% of the patients. There were in total nine 
procedure-related complications including four that required immediate attention, which 
included two aortic ruptures, one type IA endoleak, and one access vessel hemorrhage. 
One aortic rupture belonged to the NCO group and one to the RCO group (2% rupture 
rate). Each one of them was treated with stent grafts, and they required the deployment of 
an additional stent graft to seal the rupture. The type IA endoleak patient belonged to the 
RCO group repaired with a stent graft, which also required the deployment of an additional 
stent graft to successfully seal the endoleak. This patient had a left carotid to left subclavian 




stent graft. The right common femoral artery hemorrhage occurred in a patient in the RCO 
group, and this was treated successfully by an open arterial repair. In addition, three aortic 
dissections (3% dissection rate) were recognized at the distal end of the stent, which were 
nonflow-limiting and therefore followed up with serial cross-sectional imaging. In 
the perioperative period, two additional complications were recognized, including a patient 
with left renal artery embolization and a second patient with a spinal headache due 
to cerebrospinal fluid leak who required a blood patch. 
The mean length of hospitalization was 5 ± 26 days, and there were two deaths including 
one of the ruptured patients and one of the dissection patients. These deaths occurred on 
the same day of the operation and included cardiopulmonary arrest and hemorrhage. 
 
Follow-up 
Our cohort of patients was observed for a mean of 3.2 ± 3.1 years. During this time, nearly 
all patients (98%) demonstrated improvement of their presenting signs and symptoms. Two 
patients had residual claudication with long walking distances. All stents on imaging follow-
up in the form of CTA were patent. Ten (11%) patients required 11 reinterventions. Five 
patients with RCO underwent angioplasty alone; three patients with RCO underwent 
angioplasty and stenting (two stent grafts and one balloon-expandable covered stent). One 
patient with a proximal pseudoaneurysm underwent coverage of this pseudoaneurysm 
with a stent graft successfully. One patient with a type IA endoleak underwent cervical 
debranching (left carotid artery to left subclavian artery bypass) and stent graft placement. 
This last patient returned after 22 months with a pseudoaneurysm at the 
distal anastomosis from the debranching graft and underwent a left carotid to left axillary 
artery bypass (Fig 3). On Kaplan-Meier survival analysis, the freedom from reintervention at 
5 years was calculated to be 85% (Fig 4)  
There were in total eight deaths during our follow-up period. Four patients died of 
unknown causes and two were directly related to the CoA repair. One patient ruptured 
after a stent graft infection with Coxiella burnetii. A second patient with prior mesenteric 
bypass developed mesenteric ischemia from a reoperation for a stenotic mesenteric 
bypass. Additional known causes of death included exacerbation of chronic obstructive 
pulmonary disease and cardiac arrest after aortic valve surgery. On Kaplan-Meier survival 








Fig 5. Kaplan-Meier 
estimate of survival 
in 93 patients 
treated for 
coarctation (note 
that only 2 are 







in 93 patients 
treated for 
coarctation. 
Fig 3. A)  Pseudoaneurysm of the left carotid to left subclavian artery bypass before repair. B) Left 
carotid to left axillary artery bypass. (Reprinted by permission of Mayo Foundation for Medical 





CoA of the aorta is a common congenital heart defect and affects 5% to 8% of live births 
with congenital heart disease [1-4]. Advancements in surgical techniques and medical 
therapy in the past 50 years have dramatically improved survival in this population of 
patients [18]. These patients are now at risk for late complications associated with their 
OSR, which include ANE and RCO. There is also a small number of patients who become 
symptomatic in adulthood, NCO [12-15]. Our study addresses the importance of lifelong 
surveillance of all CoA patients. Our mean time from OSR to reintervention was 30 ± 
17 years. 
In review of other series for the treatment of coarctation including both adults and 
children, such as the ones by Forbes et al [16] and Roselli et al, [12] it has been reported 
that intravascular stent placement, although a technically demanding procedure, has an 
acceptable rate of complications and reinterventions. Furthermore, it has been successful 
at reducing the aortic gradient and relieving symptoms in these patients. Morbidity and 
mortality are comparable to our results at 14.3% and 0.4%, respectively (Table 2). Our 
Kaplan-Meier survival analysis demonstrated an 89% survival rate at 5 years. 
Our review is a multicenter series that observed only adults with NCO or patients with prior 
coarctation repair with complications from the previous OSR in childhood. These 
endovascular repairs with our currently available endovascular devices seem safe and 
feasible with good periprocedural outcomes (5% rate of rupture and dissection), good long-
term outcomes, and a freedom from reintervention of 85% at 5 years, which has also been 
demonstrated by Forbes et al [16]. The intermediate outcomes from the Coarctation of the 
Aorta Stent Trial (COAST) published by Meadows et al [19] seem encouraging for the 
treatment of CoA in all patients (adults and children), with excellent technical success (99%) 
and good midterm outcomes at 2 years. Their preferred method of treatment was the use 
of balloon-expandable covered stents, which provided excellent results in this population of 
patients. We were able to observe in our cohort that also the preferred stent was the 
balloon-expandable covered stent in the setting of RCO and stent grafts in ANE. Stent grafts 
seem logical in the treatment of ANE for obvious reasons related to the length of the repair 
necessary to cover the entire diseased aorta, which has also been demonstrated in other 




Table 3.Endovascular coarctation repairs reported in the literature 

































‘11 7 7 Adults 44.8 0 0 0 
Zipfel  
et al 
‘11 8 8 Adults 36 0 0 12.5 
Roselli  
et al 
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The need for reintervention during the follow-up period in the COAST trial was acceptable 
at 8.6%, and the clinical success was also encouraging at 90% in regard to the systolic blood 
pressure difference between upper and lower extremities. In our cohort, the freedom from 
reintervention at 5 years was calculated to be 85%, which is reassuring regarding the 
endovascular treatment of CoA. Furthermore, the risk of death was also extremely low 
from both the procedural and long-term follow-up standpoint. 
Although our study is unique by observing adults with coarctation, it also bears limitations. 
It is a retrospective review of a low-incidence surgical disease with multiple adjuncts used 
at the time of intervention, which limits our ability to draw firm conclusions about the most 
optimal surgical approach. Furthermore, techniques and interventional approaches were 
center specific, which reflects the center's level of comfort using specific devices. 
Therefore, a generalization of the best repair approach would not be accurate without 
larger numbers and a more diverse experience. Adjuncts to the procedure have been 
previously reviewed in other series, [20-27] and they seem reasonable options aiding in the 
process of stent graft deployment and helping avoid potential paraplegia in 
the postoperative period. Last, there are four deaths in our cohort that we could not 
account for as far as the reason of death. Therefore, we should assume that they could 
have been related to CoA. Overall, acceptable clinical outcomes have been demonstrated in 
the management of this population of complex patients, which further encourages the use 





NCO of the aorta and postsurgical complications of CoA are rare in adults. In the current 
era, endovascular treatment is effective with an acceptable safety profile. Balloon-
expandable covered stents are preferred in the setting of NCO. Stent grafts are preferred 
for ANE. Aortic rupture is infrequent (2%) but carries a high mortality rate. The rate of 
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Appendix  
Supplementary table. Patients included in the study from each participating institution (N = 93) 
Institution No. of patients (%) NCO, No. (%) 
1 33 (36) 8 (8) 
2 30 (32) 8 (8) 
3 7 (7) 5 (5) 
4 7 (7) 5 (5) 
5 6 (6) 1 (1) 
6 3 (3) 2 (2) 
7 3 (3) 2 (2) 
8 2 (2) 1 (1) 
9 2 (2) 0 (0) 


















Objectives.  This study examines the outcome and procedural outcomes of 
percutaneous stent angioplasty for aortic coarctation in patients with 
Turner syndrome (TS). TS occurs in 1 in 2500 live-born females and is 
associated with aortic coarctation. 
Methods.  In this multicenter, retrospective cohort study, all patients with TS and a 
coarctation of the aorta, treated with percutaneous stent implantation 
were included. The procedural strategies were dictated by local protocols. 
Adverse events at short and long-term follow-up and qualitative 
parameters concerning the stent implantation were assessed. 
Results.   In the largest study to date of TS patients receiving aortic stents, a total of 
19 patients from 10 centers were included. Twelve patients were treated 
for native and 7 for recurrent coarctation. Age at intervention was 16.9 
(7-60) years (median; min-max). The coarctation diameter increased 
significantly from 8.0mm (2-12) pre-intervention to 15.0mm (10-19) post-
intervention (p<0.001). Three (15.8%) adverse events occured within 30 
days of the procedure, including two dissections despite the use of 
covered stents, one resulting in death.  At long-term follow-up (6.5 years, 
min-max: 1 to 16), two additional deaths occured not known to be stent-
related. 
Conclusions.  Though percutaneous treatment of aortic coarctation in TS patients is 
effective, it is associated with serious morbidity and mortality. These risks 
suggest that alternative treatment options should be carefully weighed 






Aortic coarctation (CoA) is a congenital narrowing of the aorta and is usually located in the 
juxta-ductal position (1-3). The incidence is approximately 4 per 10,000 live births and 
constitutes 5-8% of all congenital heart disease (CHD) (4). It is more common in males and 
usually occurs sporadically (5, 6). If untreated, most patients die before 50 years of age 
from coronary artery disease, stroke or intracranial hemorrhage caused by arterial 
hypertension (2, 3, 7). The first successful surgical correction was performed in 1945 (8). 
Surgical repair of CoA is still performed today; however, percutaneous treatment has 
become a valid alternative with good gradient relief and a low complication rate both for 
native and recurrent CoA (9).  
Turner syndrome (TS) is characterized by a partly missing X-chromosome. It is associated 
with aortic pathology in approximately half of the patients, including bicuspid aortic valve 
(BAV; ~30%), elongation of the transverse aortic arch (49%) and CoA (~17%)(1), and the risk 
of aortic dissection is well recognized (10). More recent studies describe the presence of 
histological abnormalities of the aortic wall in some TS patients, including cystic medial wall 
necrosis, changes in vascular smooth muscle cells and elastin or collagen fibres, occurring 
seemingly independently from any haemodynamic changes (11-14). These changes, 
possibly inherent to TS, might increase aortic wall fragility and contribute to the increased 
risk of dissection (10). Because of these vessel wall abnormalities, percutaneous treatment 
of CoA in TS patients may be associated with a higher risk of complications, especially aortic 
dissection and rupture. Data on outcome and procedural results of CoA stenting in TS 
patients is based on small case series or case reports, and the results are contradictory.  
In this report, we describe the outcome and procedural results of percutaneous 
intervention for CoA in patients with TS and review the current literature on this topic. 
Methods 
Tertiary centers specializing in care for patients with CHD were asked to contribute patients 
to this study. The ethics committees and/or institutional review boards of the participating 
centers gave permission to access and use patient data. In this retrospective study, all TS 
patients with a history of percutaneous intervention for CoA from the participating centers 
were included. Anonymized patient data were entered into a digital format and included 
baseline patient characteristics, medical history, procedure –details, results and 
complications. Pre-procedural parameters included: peak and mean pressure gradients, 
coarctation diameter, aortic diameters proximal and distal to the CoA and, when available, 
aortic diameter at the level of the diaphragm as measured on the angiogram. Post-
procedural results included: peak and mean pressure gradients at the end of the 




defined as a blood pressure >140/90 mmHg or treatment with anti-hypertensive drugs. 
Short-term complications were defined as complications within 30 days from the 
procedure. All adverse cardiac events noted in the patient history during or after the 
intervention were analyzed. We subdivided the adverse events according to two levels of 
severity (15): (1) adverse event (AE): any complication causing no harm; resulting in 
clinically important transient impairment of a body function or transient damage to a body 
structure, requiring more than minor intervention to prevent permanent impairment of a 
body function or damage to a body structure. (2) Serious adverse event (SAE): any 
complication which results in death, is life-threatening, requires hospitalization or causes 
prolongation of existing hospitalization, resulting in permanent impairment of a bodily 
function or permanent damage to a body structure and/or requiring major intervention to 
prevent permanent impairment of a body function or permanent damage to a body 
structure. 
Statistics 
The IBM SPSS® statistics 21.0 software was used to analyze the data. Descriptive 
characteristics are presented as median and minimum and maximum values due to small 
sample size and skewed data for some parameters. We tested for normality using the 
Shapiro-Wilk test. The chi-squared test or Fischer’s exact test were used to compare 
between groups, and the students T-test was used to compare means. Missing values are 
reported in the results tables and were not taken into account in analyses. A two-sided p-
value below 0.05 was considered significant. 
Results 
Ten centers contributed 19 patients with TS and percutaneous treatment of CoA. None of 
these patients have been previously reported in literature. Relevant demographics and 
medical history are presented in Table 1. Median age at the time of percutaneous 
intervention was 16.9 (min-max: 7-60) years, and the median follow-up duration was 
approximately 6 years (min-max: 1-16). Ten patients (53%) were under 18 years of age at 
the time of the procedure. The karyotype of 12 patients was known; 10 had a full 
monosomy X (45,X: 83%), and 2 had an isochromosome. BAV was present in 11 patients 
(58%), and often occurred in association with other types of CHD (see Table 1). Eigth 
patients (42%) who had previous surgical repair of CoA (median age 0.36 years, 1 day-27 





















Associated  heart disease 
1 – 47 138 49.0 165/49 + β-b ▪ 




3 – 21 153 57.0 100/60 + β-b BAV, VSD 
4 – 60 145 37.0 111/78 + ARB, β-b BAV, PAPVR with severe PH, chronic AF, PE 
5 45,X 13 132 42.3 140/80 + none BAV 
6 45,X 10 127 22.0 112/69 + +† BAV 
7 45,X 7 116 22.0 80/49 + +† BAV 
8 45,X 17 161 68.5 120/62 + +† ▪ 
9 45,X 48 150 55.0 145/78 + none PLSVC draining into LA 
10 45,X 12 139 36.0 160/70 + none ▪ 
11 45,X 13 160 45.4 111/67 ▪ None BAV, Dextrocardia 
12 45,X 37 147 60.0 123/62 + +† Sub aortic membrane 
13 45,X 35 140 58.2 150/90 + None BAV, PAPVR: RUPV into SVC 
14 46,Xi(X) 12 136 31.1 111/73 + AI BAV 
15 – 7 113 22.0 89/61 + +† Aberrant subclavian artery 
16 – 12 130 40.0 – + AI 
LA enlargement.  Bilateral SVC with left SVC 
to CS. 
17 46 Xi (Xq) 12 132 33.7 95/56 ▪ none BAV 
18 – 48 140 46.0 88/58 ▪ 
β-b, AI,  
Diuretic, 
BAV, PAPVR, restrictive cardiomyopathy 
19 45,X 29 138 84.7 128/68 + β-b PAPVR 
Median  16.9 139 45.4 112/65 ▪   




Table 2: Intervention characteristics 
    Coarctation 
Diameter 
Gradient   
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   0-16  
Table 1. +: Present, ▪: Absent, –: no data, *percentage with hypertension, †: no details available, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, 
BAV: Bicuspid Aortic Valve, PSLVC: Persistent Left Superior Vena Cava, VSD: Ventricular Septal Defect, PAPVR: Partial Anomalous Pulmonary Venous Return, PH: 
Pulmonary Hypertension, a-fib: atrial fibrillation, LA: Left Atrium, RUPV: Right Upper Pulmonary Vein, CS: Coronary Sinus, PE: pericardial effusion β-b: Beta-blocker 
ARB: angiotensin receptor blocker, AI: ACE-inhibitor 
 
Table 2: – no data, ▪ Not Applicable, CoA: coarctation of the Aorta, Native: no previous intervention, recurrent: previous intervention, residual: stented 




Outcome – procedural and short-term 
No procedural complications were observed, however five of the 19 patients had a serious 
or somewhat serious adverse event during follow-up (26%). Three occurred within 30 days 
of the procedure. All three (table 2: 1, 9 and 18) had been treated with a covered stent. 
Two patients (table 2: 1 and 9) had a dissection of the descending aorta, these patients also 
had high gradients and systolic blood pressures. “One dissection with entry point just distal 
of the stent, included the descending  and abdominal aorta until the superior mesenteric 
artery and was treated conservatively with spontaneous resolution after a few days (table 
2: 9). 
The other dissection (table 2: 1) was fatal, and the patient died shortly after stenting of a 
residual coarctation from end-to-end anastomosis performed eighteen years earlier. The 
procedure was uneventful without detection of a dissection or rupture by angiography 
immediately post-stent placement. The patient was admitted to the cardiology ward when 
she reported pain in the back several hours after the procedure. Her hemoglobin 
concentration was low but stable (106.3 g/L or 6.6 mmol/), but the back pain worsened, 
followed by hypotension. A computed tomography scan showed an active massive 
hemorrhage in the mediastinum, medio-caudal of the stent (Figure 1). Before surgery could 
be performed, the patient suffered a cardiac arrest and could not be resuscitated. 
Another patient (table 2: 18), diagnosed with restrictive cardiomyopathy, in addition to the 
coarctation, presented with signs of heart failure 15 days after the stent procedure. She 
was treated with diuretic and inotropic agents. On the 24th day after the stent placement, 
she developed cardiogenic shock with refractory hypotension. She went into cardiac arrest 
with unsuccessful resuscitation. As no autopsy was performed, the exact cause of death 
could not be determined, and, therefore, a direct causal relationship to the stenting 
procedure is not certain. While no procedural deaths were observed, the 30-day mortality 
was 11%. 
Outcome – Long-term 
In 11 of the 19 patients (58%) follow-up imaging had been performed. In none of these 
patients signs of subclinical stent related pathology was detected (table 2). However, in 
patient 2 LV dilatation has been observed.Two deaths (12%) occurred >30 days after stent 
implantation (table 2: 4 and 13). One patient died at 61 years of age one year after stent 
implantation, due to progressive heart failure, without a clear cause. The second patient 
died at 39 years of age 4 years after stent implantation. At autopsy, a large thrombus was 
discovered near the mitral valve, suggesting that this death likely was not related to the 
stent procedure. Two other patients (table 2: 7 and 17) developed a significant re-





Fig. 1. Aortic rupture (in patient 1). A computed tomography scan showing an active 
massive hemorrhage in the mediastinum, medio-caudal of the stent site. Adobe Photoshop 





The complications from stenting in the coarctation population is low (~1% AE) (17).In 
studies conducted in non-TS populations  major complications for stenting of CoA ranged 
from 0 to 7% (15, 18, 19).  In our cohort of TS patients however, we found a high risk of 
adverse events; two of the three patients had a proven aortic dissection, fatal in one of 
them. In the third patient vascular injury as a cause of death was implied, but could not be 
proven.. This study illustrates that non-stent related fatal cardiovascular events may occur 
during long term follow-up. However, spontaneous dissection as may occur in TS patients, 
was not seen in this cohort. These long-term results have to be interpreted with caution as 
TS patients have a high cardiovascular risk profile. In this population hypertension and 
diabetes are more prevalent, which may result in a higher risk of dissection and heart 
failure.  
Etiology 
A possible mechanism responsible for the apparently high risk of arterial complications in 
the TS population is not easy to provide, but some processes in TS, like cystic medial 
necrosis, are similar to those seen in thoracic aortic aneurysm and might provide a basis for 
understanding the observed aortic wall fragility.”. Changes have been described  in the 
collagen fiber composition and intima-media with cystic medial degeneration of the aorta 
(20, 21). TGF-β signaling may also play a role, as its disruption is observed in other genetic 
disorders that result in aneurysm formation and increased risk for dissection and rupture 
(22). Aortic frailty may also occur when molecules such as biglycan and vascular endothelial 
growth factor (VEGF) are decreased (23, 24), as shown in non-TS aortic aneurysmal tissue. 
These factors were not assessed in this retrospective study, but, in future efforts, 
histological analyses of aortic tissue might prove valuable. In this series of TS patients a high 
risk of complications was observed, which could be due to an inherent aortopathy in TS 
similar to that in Marfan syndrome (MFS). In MFS, because of this associated elastopathy, 
thoracic endovascular aortic repair (TEVAR) is contraindicated (25).  
Procedural results 
The two post-procedural aortic dissections occurred in patients who were treated with 
covered stents, and these events illustrate that the use of covered stents does not prevent 
the occurrence of dissection. In addition, the two patients who developed dissections had 
the highest gradients and also had high blood pressures. Other studies have reported 
hypertension as a risk factor for complications in Turner patients. (26) 
One of the patients in the series (patient 4), did not receive a traditional balloon 
expandable stent, e.g. covered or uncovered CP or Advanta V12 stents, instead received a 




covered coarctation segment. In TS patients it may be safer to use self-expanding nitinol-
based stent grafts which are designed to treat aortic aneurysms, as they cover a larger area 
of tissue around the coarctation. The left subclavian artery, however, limits the degree to 
which the stent can be extended proximally in the arch.  
Furthermore, the positive effect of covered stents is still under discussion. In at least one of 
the cases with a dissection, the entry point was known, and it was at the distal edge of the 
stent. If a mechanism of aortic injury is related to the ends of the stents, a covered stent 
may not be effective at preventing the dissection or leakage. Conceptually positioning of a 
longer endovascular stent graft and a subsequent expansion of a stent within the lumen of 
the graft may provide a better alternative.  Still, these results in this study are in contrast 
with what is suggested in literature in for example the COAST II trial, where a possible 
advantage for the use of covered stents compared to bare metal stents is suggested when 
examining aortic wall injury (15). However no protective effect was shown and especially 
when looking at aneurysm formation long term results are needed (15). 
Literature Review 
Our literature search yielded one case series and four case reports regarding stenting in TS 
patients. Zanjani et al. describe a series of 10 TS patients with CoA treated with stent 
implantation, of which 7 patients have been treated with a bare metal stent (BMS) versus 3 
with a covered stent (27). There were no dissections or deaths within a follow-up of  2.5 
years, however, 2 (20%) late aneurysms at the coarctation site occurred. Two case reports 
describe uncomplicated stent implantations in patients with TS (28, 29), while two other 
case reports describe dissections of the aorta (14, 30) (Table 3). The two late deaths in our 
study could have had a cause not directly related to the stent implantation. Excluding these 
two cases, the results of the pooled studies show dissection and/or death occurring in 5 out 
of a total of 35 cases (14%). However, Including case-reports may overestimate incidence 
of for example dissection. Although the complication rate is high, the stent angioplasty 
itself is effective. We found a significant increase in coarctation diameter and a clear 
reduction in the gradient over the stented segment in all patients. Our results are in that 
aspect comparable with published results for the non-TS population (31). TS patients with 
severe CoA should be counselled not only about the advantages of this treatment, but also 
about the risk of dissection and death with this treatment. Whether surgical treatment for 
CoA in TS is a safer alternative remains unclear. Two studies suggest that surgical repair by 
end-to-end anastomosis also shows an increased risk, especially of perioperative 
hemorrhage (32, 33). These studies, however, are dated and probably not valid for 
comparison. Although conservative medical management is an option, long-standing 
ascending aortic and upper extremity hypertension in these patients with known 
aortopathy is not necessarily a lower-risk option. Further study is needed to understand the 




Table 3. Literature overview 










Zanjani et al. [1] 2010 10 0 2 0 12 (9-24) 30.5 70 
Kataoka et al. [2] 2006 2 0 0 0 14.5 42 – 
Thanopoulos et al. [3] 2000 2 0 0 0 9.5 30.5 – 
Fejzic and van Oort [4] 2005 1 1 (type B diss.) 0 1 19 0.25 – 
Lin et al. [5] 1986 1 1 (type A diss.) 0 0 8 42 100 
Present study  2015 19 3 (2 type B diss.) 1 2 17 72 77 
Total  
 
35 5 (14%) 3 (9%) 3 (9%)    
 
 
1   Zanjani KS, Thanopoulos BD, Peirone A, Alday L, Giannakoulas G. Usefulness of stenting in aortic coarctation in patients with the Turner syndrome. Am J Cardiol. 
2010;106(9):1327-31. 
2   Kataoka K, Ozawa A, Inage A, Benson LN. Transcatheter repair of native coarctation in children with Turner syndrome: three case reports and literature review. Congenit 
Heart Dis. 2006;1(6):315-20. 
3   Thanopoulos BD, Hadjinikolaou L, Konstadopoulou GN, Tsaousis GS, Triposkiadis F, Spirou P. Stent treatment for coarctation of the aorta: intermediate term follow up and 
technical considerations. Heart. 2000;84(1):65-70. 
4   Fejzic Z, van Oort A. Fatal dissection of the descending aorta after implantation of a stent in a 19-year-old female with Turner's syndrome. Cardiol Young. 2005;15(5):529-31. 
5   Lin AE, Lippe BM, Geffner ME, Gomes A, Lois JF, Barton CW, et al. Aortic dilation, dissection, and rupture in patients with Turner syndrome. J Pediatr. 1986;109(5):820-6. 
 






This study is limited by its sample size: TS is a relatively uncommon disorder, and in these 
women stenting procedures are not frequently performed. It is also limited by its 
retrospective nature without consistent clinical follow-up and therefore late aneurysms, 
dissection, or other complications may have been missed. The long-term results and causes 
of death are to be interpreted with care, especially in the cases where no autopsy could be 
done. Patient selection bias cannot be excluded, as only patients from tertiary care centers 
with expertise in CoA stenting were included in this study; hospitals with less stenting 
experience may experience an even higher complication rate.  
Conclusions 
In this series of TS patients, stent treatment for coarctation of the aorta was effective but 
was associated with dissection or death in several cases. The advantages and disadvantages 
of conservative medical management, end-to-end anastomosis surgery, and percutaneous 
stent treatment should be separately considered and discussed with the individual patient. 
Additional studies are needed to determine the best treatment strategy for TS patients 
with CoA and to determine the etiology of the histologic abnormality. 
To our knowledge, we present the largest study of CoA stenting in TS patients to date. Our 
study reinforces the concern of potential aortic dissection with stenting in TS patients 
which appears not to be prevented by the use of covered stents. 
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Objectives.  The combination of aortic coarctation (CoA) and bicuspid aortic valve 
(BAV) is assumed to be associated with a higher risk of ascending aortic 
dilatation and type A dissection, and current European Society of 
Cardiology (ESC) guidelines advise therefore to operate at a lower 
threshold in the presence of CoA. The aim of our study is to evaluate 
whether the coexistence of CoA in BAV patients is indeed associated with 
a higher risk of ascending aortic events (AAE). 
Methods.  In a retrospective study, all adult BAV patients visiting the outpatient 
clinic of our tertiary care center between February 2003 and February 
2019 were included. The primary end point was an ascending aortic event 
(AAE) defined as ascending aortic dissection/rupture or preventive 
surgery. The secondary end points were aortic dilatation and aortic 
growth. 
Results.   In total, 499 BAV patients (43.7% female, age 40.3 ± 15.7 years) were 
included, of which 121 (24%) had a history of CoA (cBAV). An aortic event 
occurred in 38 (7.6%) patients at a mean age of 49.0 ± 13.6 years. In the 
isolated BAV group (iBAV), significantly more AAE occurred, but this was 
mainly driven by aortic valve dysfunction as indication for aortic surgery. 
There was no significant difference in the occurrence of dissection or 
severely dilated ascending aorta (>50mm) between the iBAV and cBAV 
patients (p = 0.56). The aortic diameter was significantly smaller in the 
cBAV group (30.3 ± 6.9 mm versus 35.7 ± 7.6 mm; p < 0.001). The median 
aortic diameter increase was 0.23 (interquartile range (IQR): 0.0-0.67) 
mm/year and was not significantly different between both groups (p = 
0.74). 
Conclusions.  Coexistence of CoA in BAV patients was not associated with a higher risk 
of aortic dissection, preventive aortic surgery, aortic dilatation, or more 
rapid aorta growth. This study suggests that CoA is not a risk factor in BAV 







Bicuspid aortic valve (BAV) is the most common congenital heart defect with a prevalence 
of 0.5–1.3% [1]. In about half of all BAV patients, ascending aortic dilation develops, 
predisposing for life-threatening complications such as aortic dissection [2]. BAV can occur 
isolated (iBAV), but also in combination with additional heart defects or in the context of a 
syndrome.Depending on age groups studied, the prevalence of aortic coarctation (CoA) in 
BAV patients varies between 22% and 36% and is increased in younger age groups [2,3,4,5]. 
Whether there is a difference in prevalence of aortopathy between BAV patients with 
(cBAV) or without a CoA remains unknown.After CoA correction, many patients suffer from 
hypertension, which is a known risk factor for aortic dissection and higher mortality, 
especially in BAV patients [4,6]. In a pediatric cohort of BAV patients, CoA was associated 
with smaller ascending aortic diameters, while in adults, contradicting studies about CoA in 
BAV patients have been published, with some showing a higher risk of ascending aortic 
events (AAE) when CoA was present in these patients, while others found no relation 
[4,7,8].The aortopathy in BAV patients is generally assumed and feared, and although the 
incidence of type A aortic dissections is low, it is clearly higher compared with the general 
population with BAV patients having an estimated 6 times higher risk [9]. Although only a 
few studies have investigated the impact of CoA in BAV patients on the incidence of 
aortopathy, current ESC guidelines on aorta pathology advise to consider preventive aortic 
surgery at a lower aortic diameter in BAV patients when a history of CoA is present [10]. 
The aim of this study is to investigate whether the coexistence of CoA in BAV patients is 
associated with ascending aortic events (AAE), aortic dilatation and aortic diameter 
increase. 
Method 
Medical ethical committee region Arnhem–Nijmegen approved this study under file 
number CMO: 2017-3599. In this retrospective study, we included all BAV patients who 
visited the adult outpatient clinic between February 2003 and February 2019. Exclusion 
criteria were presence of an associated complex congenital heart disease (e.g., tetralogy of 
Fallot) or a hereditary thoracic aorta disease (e.g., Marfan syndrome) (Flow diagram Figure 
1) and incomplete data. Hemodynamic unimportant small defects or corrected defects 
were not excluded (e.g., ventricular septal defect, atrial septal defect, persisting left cava 
vein, persisting ductus arteriosus, subaortic membrane, abnormal pulmonary venous 
return). BAV presence was diagnosed on echocardiography or on cardiac magnetic 
resonance imaging (CMR) or by the surgeon during aortic valve surgery. Patients with a 
hemodynamic important CoA (gradient >20 mmHg across the isthmus stenosis invasively 




diameter at the diagram) were assigned to the BAV with CoA group (cBAV). All patients with 
a hemodynamic important CoA underwent an intervention (surgery or percutaneous). 
Patients without CoA were assigned to the isolated BAV group (iBAV). 
Figure 1: Inclusion flow chart  
Following our standard protocol, during each visit all patients underwent an electric 
cardiography (ECG) and echocardiography. Cardiologists with expertise in congenital heart 
disease and echocardiography evaluated the echocardiographic images. Quantification of 
valve dysfunction severity was done according to current guidelines [11,12]. Moderate to 
severe stenosis or regurgitation was defined as significant aortic valve dysfunction. 
BAV morphology was classified following the Sievers classification [13]. Frequency of 
follow-up was determined depending on the severity of valve dysfunction and other 
relevant comorbidities. In most cases, this was either annually or biannually. Hypertension 
was defined as a blood pressure above 140/90 mmHg on several measurements, all these 
patients were treated with antihypertensive medication [14]. 
The primary end point of this study was an ascending aortic event (AAE), defined as the 
occurrence of acute dissection of the ascending aorta or the occurrence of (preventive) 
ascending aortic surgery. The secondary end points were aortic diameter on CMR or CT at 
age >16 years of age and aortic growth during follow-up using CMR or CT during adulthood. 
Advanced aortic imaging 
Aortic diameters were measured on advanced imaging by experienced radiologists. Cardiac 
Magnetic Resonance Imaging (CMR) was preferably used and in case CMR was not possible 




measured in the axial plane, during diastolic phase. In both modalities, the inner edge to 
inner edge method was used to measure the ascending aortic diameter at the height of the 
right pulmonary branch [15]. Ascending aortic diameter was defined as dilated when the 
ascending aorta >40 mm or aortic size index >20 mm/m2 [10]. Frequency of advanced 
imaging was based on indication, but performed at least once during the first visit to the 
adult outpatient clinic and typically repeated every 5 years. 
The aortic diameter change (in mm) between two CMR/CT ascending aortic measurements 
was divided by the time between the two measurements, which had to be at least one year 
apart. For every successive scan, the aortic diameter change was calculated. This implies 
that multiple “means” could be present in one patient, in that case the means were added 
up and divided by the number of means for that specific patient, resulting in one mean 
aortic diameter change per patient. 
Statistical analysis: 
Statistical analysis was performed using Statistical package for social sciences, version 25 
for Windows (SPSS, Chicago, IL, USA). Results are expressed as mean ± standard deviation 
or as median 25% and 75% interquartile range (IQR) if the distribution was skewed. A p-
value <0.05 was defined to be statistically significant. The independent samples T-test was 
used to compare means between groups. In case of a skewed distribution, the Mann–
Whitney U test was used. To evaluate a significant difference between proportions, a chi-
square test was used. Univariate and multivariate logistic regression was used to correct for 




A total of 499 BAV patients were identified, of which 121 (24.2%) were diagnosed to have 
CoA (cBAV). Baseline characteristics of all included BAV patients are shown in Table 1. 
Aortic events 
The median age of coarctation repair was 10 month (IQR: 2 months; 7.9 years), of which 
107 had a surgical repair. Balloon angioplasty of descending aorta was performed in 14 
patients, at a median age of 13.5 (IQR: 3.8; 31.5) years, and a stent was implanted in 12 of 
them. 
The prevalence of aortic valve regurgitation was significant higher in the iBAV group (p = 
0.006). There was no age difference between patients with (41.6 ± 16.2 years) or without 




(42.6 ± 16.1 years in no significant versus 44.0 ± 16.9 years in significant aortic valve 
regurgitation). 
 presents the percentage of each age group with an event for the iBAV and CoA-group. Only 
age was related to the occurrence of an aortic event and was still significant after 
correction for CoA. In the multivariate analysis CoA was not associated with aortic events. 
Due to the low event rate a limited number of variables could be tested.  
Events Analysis 
Table 2 shows the ascending aortic events (AAE) for the total group and iBAV and cBAV 
groups separately. The mean age at AAE was not significantly different between both 
groups. Aortic dissection occurred in two iBAV patients and in one cBAV patient, who was 
also a Turner patient; none of these three patients survived. No aortic ruptures occurred. 
There was a significant difference in AAE between iBAV group and cBAV group (p = 0.016). 
This was mainly driven by aortic valve dysfunction as primary indication for aortic valve 













Female (%)  43.7 44.2 42.1 0.695 
Age at end of study (years) 40.3±15.7 42.5±16.1 33.6±12.2 <0.001 








Height (cm)  172.8±12 172.7±12.6 173.5±11.4 0.482 
Turner (%)  14.9 16.9 5.0 0.001 
Hypertension (%)  19.8 28.9 28.9 0.005 
Smoking (%)  10.7 10.4 11.6 0.713 
Diabetes (%)  2.0 1.9 2.5 0.683 
Hypercholesterolemia (%) 7.6 9.4 3.3 0.031 
Other congenital defect* (%) 22.9 17.2 38.8 <0.001 
Aortic sinus of Valsalva (mm)** 33.4±8.9 33.8±6.2 32.3±5.8 0.026 
Ascending aorta (mm)** 34.4±7.2 35.3±7.2 31.6±6.5 <0.001 
Aortic regurgitation 
moderate/severe (%) 
17.9 20.7 9.2 0.006 
Aortic valve stenosis 
moderate/severe (%) 
5.7 5.7 5.5 0.924 
Table 1. * persisting left cava vein (n=4), persisting ductus arteriosus (n=16), ventricular septal 
defect (n=23), atrial septal defect (n=10), subaortic membrane (n=6), abnormal pulmonary 
venous return (n=4).**echocardiographic measurement at first visit adult outpatient clinic 




valve dysfunction as primary indication were excluded, there was no significant difference 
in prevalence of AAE between iBAV and cBAV groups (p = 0.743). There was no significant 
difference (p = 0.711) in the prevalence of high-risk BAV patients (ascending aortic 
diameter >55 mm and ascending aortic dissection).  
Table 2: characteristics of patients with an aortic event 
Figure 2: aortic events in 499 BAV patients as percentage of total in each age group and iBAV or 
BAV+CoA-group. 
 
Figure 2 illustrates the age distribution at which the AAE occurred for both groups. For each 
age group, the patients with an AAE were divided by the total patients in this age group. In 
the age groups <20 years, 30–40 years, and 50–60 years, no AAE were observed. In the 
 All iBAV CoA-group p-value 
Number of events  
(% of event in group)* 
38 (7.6%) 35 (9.3%) 3 (2.5%) 0.016 
Age at event  49.0 ± 13.6 49.3 ± 13.6 46.4 ± 19.2 0.821 
Type of event     
Dissection 
(% of total in group)* 
3 (0.06%) 2 1 NA 
Surgery indication: 35 33 (8.7%) 2 (1.7%) 0.007 
Valvular dysfunction 
(% of total in group)* 
21 (4.2%) 21 (5.6%) 0 0.004 
Aortic dilatation 
(% of total in group)* 
13 (2.6%) 11 (2.9%) 2 (1.7%) 0.743 
Unknown 1 1 0  




other age groups, the percentages were comparable. Table 3 show the univariate and 
multivariate analysis of AAE. Due to the low event rate, a limited number of variables could 
be tested (CoA, hypertension, age, aortic regurgitation). 
Table 3. Predictors of acute aortic events. 
 
Univariate Analysis 
Odds Ratio (95% CI) 
p-Value 
Multivariate Analysis, 
Odds Ratio (95% CI) 
p-Value 
Age 1.063 (1.041–1.086) <0.001 1.054 (1.029–1.080) <0.001 
Aortic 
coarctation 
0,249 (0.075–0.825) 0.023 0.410 (0.117–1.441) 0.164 




1.364 (0.922–2.017) 0.120   
 
Ascending aortic diameter on CMR/CT.  
At least one CMR/CT was available in adulthood in 416 BAV (83%) patients. The mean aortic 
diameter at first CMR/CT was 34.4 ± 7.8 mm, at a median age of 27.2 (20.2–43.1) years. 
There was a significant difference in age between the 312 patients in the iBAV group 
(median age of 30.5 (21.0–47.5)) and the 104 patients in the cBAV group (median age 21.9 
(18.4–30.8)) (p < 0.001) and a significant difference in aortic diameter between iBAV (mean 
diameter of 35.7 ± 7.6 mm) and cBAV group (mean diameter 30.3 ± 6.9 mm) (p < 0.001). 
The aortic diameter in the cBAV group was still significantly smaller (coefficient = −3.42; p < 
0.001) after correcting for age (coefficient = 0.23; p < 0.001). The mean aortic size index 
(absolute diameter divided by body surface area) was 18.6 ± 4.0 mm/m2 and was 
significant lower in the cBAV group compared with the iBAV group (16.2 ± 3.7 versus 19.4 ± 
3.9 mm/m2; p < 0.001). After correcting for age, cBAV patients had still a smaller aortic size 
index (coefficient of −2.6; p < 0.001).Ascending aortic dilatation defined as a diameter >40 
mm was significant more prevalent in the iBAV group compared with the cBAV group 
(31.1% versus 9.8%; p < 0.001).Ascending aorta dilatation when defined as aortic size index 
>20 mm/m2 was also significant more prevalent in the iBAV group (45.0% versus 13.7%; p < 
0.001). In Turner women, the aortic size index was significantly larger compared with the 
rest of the group (19.9 mm/m2 versus 18.6 mm/m2; p = 0.043). cBAV was present in 8.6% 
of all Turner women and in 1.2% of all BAV patients.All patients with an ascending aortic 
diameter >55 mm were operated. There was no significant difference between the iBAV 
and cBAV groups (2.6% versus 1.0%; p = 0.46) in the prevalence of nonoperated patients 
with an ascending aortic diameter >50 mm.Aortic diameter increase during follow-up 
Aortic Diameter Increase during Follow-up 
In 162 patients (49 cBAV, 30%), more than one CMR/CT was available. The mean follow-up 




mm/year. Figure 3 shows the boxplot of the median ascending aortic diameter change of 
the iBAV group (median age at first CMR/CT 28.6 (20.3–45.0) years) and the cBAV group 
(median age at first CMR/CT 21.2 (18.0–29.9) years. There was no significant difference (p = 
0.74) in median aortic diameter change between the iBAV group (0.24 (−0.02–0.76) 
mm/year; n = 114) and the cBAV group (0.20 (0.00–0.57) mm/year; n = 49). None of the 
patients had an aortic diameter increase of >3 mm/year. 
In the 162 patients with two or more CMR/CT scans (follow-up group), 22.7% had 
hypertension, this was not significantly different in the iBAV and cBAV groups (20.2% versus 
28.6%; p = 0.241). Of the 14 patients with an ascending aortic diameter of >50 mm at first 
CMR/CT (1 cBAV patient), four patients were operated before the second CMR/CT was 
performed. The remaining 10 patients had a median ascending aortic change of −0.13 mm 
(−0.85–0.14). 







The presented data in this large study of relative young BAV patients suggest that patients 
with and without aortic coarctation are both similarly associated with aortic events and 
show a comparable increase in ascending aortic diameter. The current idea is that large 
ascending aortic diameters are associated with a higher risk for future AAE. In this study, 
ascending aortic diameter was significantly higher in the iBAV group, probably due to 
higher age. Nevertheless, the prevalence of preventive ascending aortic surgery was 
comparable to the cBAV group, when the primary indication was ascending aortic dilation. 
The current ESC aortic guideline and ESC valve guideline both state that ascending aortic 
surgery should be advised (class IIa, level C) at a lower ascending aortic diameter (50 mm 
instead of 55 mm) in BAV patients with a (history of) CoA [10,16]. In this study, no evidence 
to substantiate this recommendation is found. In fact, the results points towards a more 
favorable course in cBAV patients, and therefore the recommendation of the ESC should be 
revisited. 
Eleid et al. presented a small cohort of aortic dissection in BAV patients, in which they 
concluded that cBAV was associated with dissection, since they found that 23% of the BAV 
patients had a CoA [5]. This conclusion is debatable because the normal prevalence of CoA 
in BAV is about 23% and, therefore, represents a normal distribution of iBAV and cBAV [5]. 
Oliver et al. described a group of BAV patients (n = 341), in which they found that the 
coexistence of CoA was associated with more ascending aortic events. They defined an 
event as a dissection or rupture of the sinus of Valsalva or an aortic dilatation > 55 mm [4] 
They experienced the same problem as the current study of a low event rate and a 
younger-aged cBAV group with a mean age of 18 (16–23) years [4]. The difference with the 
current study can partly be explained by a slightly different AAE definition (in this study, 
also preventive aortic surgery patients were included), which could have caused a higher 
event rate in the current study. 
Michelena et al. reported 416 BAV patients, in whom they found no increased AAE in cBAV 
patients during a mean follow-up time of 16 ± 7 years [6]. Tzemos et al. showed that a 
history of CoA was associated with a lower event rate [17]. 
The fact that this study and other studies did not find significant differences in AAE 
between iBAV and cBAV suggest that the recommendation of earlier preventive surgery in 
cBAV patiënts needs to be reconsidered [6,17]. 
Aortic diameter is the most important parameter on which the indication for preventive 
aortic surgery is based, although some other factors are important too, such as 




coexistence of CoA was associated with smaller aortic diameters [6,19,20]. This implies that 
cBAV patients are less likely to develop an aortic aneurysm needing preventive aortic 
surgery. On the other hand, a higher prevalence of hypertension was observed in the cBAV 
group, and hypertension has been associated with AAE, especially dissection [21]. The 
development of hypertension could be induced by the relative aortic hypoplasia after CoA 
correction. The definition of aortic hypoplasia is guided by the application of the Z-score for 
the aortic arch, but at which z-score hypertension develops is not clear. 
Rapid aortic growth (>3–5 mm/year) is a risk factor for future AAE and is an indication to 
consider preventive surgery [10]. 
The ascending aortic diameter increase was slow (0.20–0.23 mm/year) and not different 
between the iBAV and cBAV groups in the current study, and this is in line with previous 
reports (Oliver 2009). This suggests that CoA is not associated with increased growth rates 
in BAV patients and thus probably not associated with a higher risk of AAE, also after longer 
follow-up. 
In this study, only patients with a BAV were analyzed, and whether these data also apply to 
patients with an aortic coarctation and a normal aortic valve was not investigated 
Limitations 
Several potential limitations must be noted. All limitations associated with retrospective 
research apply to this study. Due to the low number of events, no hard conclusions can be 
drawn from this paper, only suggestions, but for now it is the best we have. Our study 
population consisted of patients receiving care in a specialized center and may therefore be 
less generalizable. The age difference between the two groups was partly caused by 
referral bias, since BAV was, especially in the older patients, more often diagnosed during 
aortic surgery. This problem was largely corrected by conducting a multivariate analyses in 
which we corrected for age. A potential limitation is also caused by the fact that CMR/CT 
was not performed in every patient at a fixed time interval. Finally, we did not evaluate 
specific aortic dilatation patterns. 
Conclusion 
This study suggests that the ascending aortic event rate is not different between BAV 
patients with or without a history of aortic coarctation. Implying that a difference in 
indication for ascending aortic surgery is not justified in BAV patients based on a history of 
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SMAD 3 mutations cause an aggressive form of aortic aneurysms, vascular tortuosity and 
osteoarthritis which has a profound effect on the lives of patients. The clinical phenotype is 
encapsulated in the aneurysm-osteoarthritis syndrome (AOS) which is now often 
recognized as a separate type (III) of Loeys-Dietz syndrome (LDS). Our researchgroup has 
previously described the aortic dilatation and clinical outcomes in this patient group. This 




Pathogenic SMAD3 mutations are a known cause of early aortic dilatation and dissection. In 
combination with osteoarthritis at young age this is encapsulated in the Aneurysms-
Osteoarthritis Syndrome (AOS) [1]. AOS has many similarities with Loeys-Dietz Syndrome 
(LDS), and is recognized by some as part of LDS [2]. It is currently unknown how the rate of 
aortic dilatation in SMAD3 patients compares to other syndromic causes of aortic 
dilatation. 
We have followed SMAD3 mutation carriers in our center per in-house protocol since 
December 2011. This protocol includes yearly ECG-gated contrast enhanced thoraco-
abdominal computed tomography angiography (CTA). In ten patients earlier scans were 
available (2003 to 2011), which were included only when aortic diameters could be reliably 
measured according to protocol standards. Aortic dimensions were repeatedly measured 
perpendicular to the vessel at 8 standardized levels using double-oblique multi planar 
reconstruction by an experienced cardiovascular radiologist, blinded to clinical data and to 
previous measurements. To account for correlations between multiple measurements 
within each patient, average time trends were estimated using linear mixed models. Cubic 
splines were used to model non-linear growth curves. Patient-specific intercepts and slopes 
allowed for individual deviations from the average growth. As described in our in house 
protocol patients with an aortic diameter of 42mm or above are considered in the 
interdisciplinary heart team for intervention. The study protocol was approved by the 
medical ethics committee of our center.  
Baseline characteristics are shown in figure 1 (Panel A). When looking at the average 
increase per year (figure 1: Panel B), significant growth was seen at three levels: the sino-
tubular junction (STJ), the ascending aorta and the level of the diaphragm. The average 
growth was largest at the STJ with 0.4mm/year (95%CI: 0.12-0.62, p=0.005), followed by 
the ascending aorta and diaphragm with 0.2mm/year (95%CI: 0.04-0.38, p=0.018 and 
95%CI: 0.10-0.27, p<0.001 respectively). The aorta did not show significant growth at the 
level of the annulus, sinus of Valsalva, aortic arch, the descending and the abdominal aorta. 
Age had an impact especially at the level of the aortic arch and abdominal aorta. During 
follow-up no mortality occurred; however, 14 (50%) patients needed elective valve sparing 
root replacement (VSRR). The median age at time of operation was 40.6 years (IQR: 22.76). 
Additionally, fourteen vascular interventions, most often embolization of a side branch 
aneurysm, were needed in nine patients. Five of these patients also underwent a VSRR. In 
total 18 patients (64%) underwent at least one cardiovascular intervention during the 
duration of this study. Interventions were done at the discretion of the vascular surgeon, as 




The mean rate of increase in aorta diameter in the normal population is 0.07mm and 
0.09mm per year of life in women and men respectively[3]. The natural course of this 
process is influenced by many factors such as: age, sex and blood pressure. In the last 
decade much attention has been paid to genetic aortopathies. In Marfan syndrome for 
example the aorta dilates fastest at the level of the sinus of valsalva with a rate of 
approximately 0.49mm±0.5mm per year [4]. In comparison to LDS, where the aorta can 
grow at rates of up to 10mm/year, dilatation in our cohort may seem relatively mild [5]. 
However, in earlier studies mortality was high, and although no deaths occurred during our 
follow-up, it should be noted that this could be explained by the intensive management 
and preventive surgery at relatively mild dilatation of the aorta.  
The current results differ from a previous report from our group especially in growth rate 
and location of fastest growth, which can be explained by longer follow-up duration, 
inclusion of milder cases discovered by family screening, and by using different analysis 
methods. Still, we can appreciate that SMAD3 mutation carriers show aortic dilatation at a 
rate similar to other genetic aortopathies, dilatation occurs predominantly at the STJ and 
ascending aorta, but also in all other parts of the aorta and large arteries. With this study 
we provide evidence that SMAD3 mutations cause an aggressive form of aortic dilatation, 
warranting vigilant follow-up. The fastest growth rate (0.4mm/year) was observed at the 
level of the sino-tubular junction. In 64% (18/28) of the patients in this study a potentially 
fatal arterial pathology was discovered. However, for the management of SMAD3 patients 
this implies that the current protocol adequately addresses the clinical problem in these 
Figure 1. Baseline characteristics and aortic growth. A, baseline characteristics, *most patients 
shared the same heterozygous mutation R287W, 859C>T, SMAD3 ex 9. Data are shown as 
mean±SD, median (25%–75%), or n (%). B, aortic growth: average of all aortic measurements per 




patients as no patients died from aortic rupture or suffered from aortic dissection during 
follow-up. Additionally this study provides an important measure of reference to other 
known causes of genetic aortopathies. More research is needed to determine predictors 
for fast growth and possible medical therapies in SMAD3 patients hopefully resulting in a 
better understanding and improved outcome.Source of funding: 
This study was funded by a grant of the Dutch Heart Foundation (The Hague, The 
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Objectives.  Aneurysms-Osteoarthritis Syndrome (AOS) is characterised by arterial 
aneurysms and dissection in combination with early-onset osteoarthritis, 
which can impact quality of life. 
Methods.  We describe the subjective quality of life and investigate anxiety and 
depression in 28 AOS patients aged 15 to 73 years. Three questionnaires 
were used: (SF-36), Hospital Anxiety and Depression Scale (HADS) and 
Rotterdam disease specific questionnaire. Results of the SF-36 and HADS 
were compared to a reference Dutch cohort and the SF-36 questionnaire 
also to patients with Marfan syndrome. 
Results.   Compared to the general population, AOS patients scored significantly 
lower on the following SF-36 domains: physical functioning, vitality, social 
functioning, bodily pain and general health. Physical functioning was also 
lower than in Marfan patients. Patients with AOS scored higher on the 
HADS depression scale, while anxiety did not show a significant difference 
compared to the general population. No difference in SF-36 and HADS 
domain scores were found between patient with and without orthopaedic 
symptoms or patients with or without previous aortic surgery. 
Additionally, we found that patients’ worries for their future and heredity 
of their disease are important factors for anxiety, which should be 
addressed in clinical practice. 
Conclusions.  In conclusion, our population of AOS patients showed reduced quality of 
life in comparison with the general population on physical functioning, 
role limitations due to physical functioning, bodily pain, general health, 






An aneurysm or dilatation of the thoracic aorta can cause aortic dissection, which is a 
potentially life threatening event as over half of all patients with an acute thoracic aortic 
dissection die within 30 days (1). In 20% of the patients an aortic aneurysm results from a 
heritable thoracic aortic disease (HTAD) (2, 3). In 2011, a new HTAD was described, the so-
called “Aneurysms-Osteoarthritis Syndrome (AOS)”, caused by a pathogenic variant in the 
SMAD3 gene(4), which is part of the TGF-β pathway. Aneurysms-Osteoarthritis Syndrome 
has many similarities with Loeys-Dietz syndrome (LDS), and is therefore also referred to as 
LDS type 3. In AOS, aneurysms can occur within the aorta and other arteries (among which 
the splenic, iliac, hepatic and intracranial arteries). Furthermore, the arteries show 
tortuosity and aortic dissections or ruptures already occur in a mildly dilated aorta. In 18% 
of the patients aortic dissection is even the first manifestation of the disease(5). In addition 
to the vascular findings, joint abnormalities are an important feature of this syndrome, 
which are often the reason for first presentation. These joint abnormalities include 
osteoarthritis and osteochondritis dissecans at a relatively young age(6). Other 
characteristics associated with pathogenic variants in the SMAD3 gene are widely spaced 
eyes, bifid uvula, umbilical or inguinal hernias varices, velvety skin and striae(4). These 
physical symptoms and the risk of life threatening dissection of the arteries might cause 
reduced quality of life, anxiety and depression. Anxiety in AOS patients can also be caused 
by experiencing the consequences of the disease through relatives, since this autosomal 
dominant genetic disorder is often diagnosed in multiple family members. Therefore 
knowledge about psychological well-being and causes of impaired quality of life and anxiety 
or depression in AOS patients is important in order to develop specific management 
strategies. Although psychosocial well-being has been investigated for other vasculopathies 
such as Marfan syndrome(7) and Ehlers-Danlos(8), no attention has been paid yet to the 
quality of life and occurrence of depression or anxiety in patients with this life-threatening 
syndrome. Therefore, the aim of this study was to comprehensively describe the subjective 
quality of life and investigate anxiety and depression in AOS patients. 
Materials and methods 
Study population 
All carriers of a pathogenic variant in the SMAD3 gene undergoing follow-up in our tertiary 
center per in-house protocol since January 2009 were invited for this study. Family 
members which were 50% risk carriers with obvious AOS related symptoms (aortic 
dilatation or osteoarthritis at an early age) were also included. Demographic and clinical 
data were obtained from the electronic patient files. Diabetes mellitus was defined as 
current use of medication. As part of our protocol, all patients underwent 




measurements of the sinus of Valsalva, ascending aorta, aortic arch and descending aorta 
were measured using the inner edge-to-inner edge method on the most recent CTA. 
Aneurysms and dissections were categorized by the following locations and definition: head 
and neck, thoracic, coronary, abdominal, leg and/or arm or pulmonary artery. Information 
on the following valvular, ventricular and arrhythmic abnormalities was collected: bicuspid 
aortic valve, aortic stenosis (Vmax >2.5 m/s), aortic regurgitation (at least moderate)(9), 
valvular disease other than from the aortic valve, congenital heart disorders, ventricular 
hypertrophy (septal wall>13 mm), left ventricular dilatation (diastolic diameter >60 mm) 
and atrial fibrillation (former, paroxysmal or current). The study complied with the 
Declaration of Helsinki and was approved by the medical ethical committee of the Erasmus 
Medical Centre (MEC17-057). Written informed consent was provided by all patients.  
Questionnaires 
All participants received three questionnaires: the Short Form-36 Health Survey (SF-36)(10), 
the Hospital Anxiety and Depression Scale (HADS)(11) and the Rotterdam disease specific 
questionnaire. The questionnaires were sent at first on the 14th of November 2017 and 
were collected until the 1st of February 2018. If participants did not respond at first, they 
received a maximum of two reminders. The SF-36 was used to determine patient-reported 
quality of life. It covers the following eight domains: physical functioning, role limitations 
due to physical health, bodily pain, general health, mental health, role limitations due to 
mental health, vitality (energy or fatigue related) and social functioning. The scale ranges 
from 0 through 100 points. A lower score per subcategory, reflects a lower quality of life on 
that life domain. In addition, two sum scores, the mental component summary (MCS) and 
physical component summary (PCS), were calculated(12). These summary scores are 
standardized according to the general Dutch population(13), which means that all scores 
above and below 50 are above and below the average in the Dutch population. The HADS 
questionnaire determines the levels of anxiety and depression on two subscales with a total 
score ranking from 1 to 21. A score of 0 to 7 for either subscale is in the normal range, a 
score of 8 to 10 is possible abnormal and 11 or higher indicates the probable presence of 
anxiety or depression. The “Rotterdam disease specific questionnaire” was developed by 
our multidisciplinary team in the Erasmus Medical Center (supplemental file A) to 
investigate the impact of having AOS related aortic aneurysm on daily life, work 
participation, sexual functioning, pregnancy wish and sports participation. Patients received 
18 statements and were asked to grade how they felt on a continuous scale from 0 to 10, 0 





Comparison with the general population and other aortic disease patients (Marfan 
syndrome) 
For the HADS and SF-36 questionnaires we compared our data to the reference values of 
the age-matched general Dutch population(13, 14). For the SF-36, a cohort of age and sex 
matched Marfan patients was also available, which allowed us to compare AOS with 
another syndromic HTAD(15). For the results of the Rotterdam disease specific 
questionnaire, there are no reference values available yet because this questionnaire was 
newly developed  for this study’s aim.   
 
Statistical analysis 
Continuous variables with a normal distribution were reported as mean with ± standard 
deviation and the median and interquartile range was reported in case of non-normal 
distribution. Categorical variables were summarized as frequencies and percentages. Data 
distribution was checked using histograms. Because of the non-normally distribution of the 
values in the domains of the SF-36 and HADS questionnaires, the median and interquartile 
ranges are presented in the table and the p-value of the one-sample Wilcoxon signed rank 
test was presented in the text and figures. With the one-sample Wilcoxon signed rank test 
the median of a continuous variable in our cohort was compared with a hypothesized 
median of a reference group. Since our reference article showed their values only with 
mean ± S.D., we assumed that the variables were distributed normally. Because mean and 
median are comparable in normally distributed variables, we used the mean of the 
reference as hypothesized median in our non-parametric test. To visually compare our data 
 Domain/scales Score Summary 
measures† 
Score 
SF-36 Physical functioning 45.0 (30.0-78.8) PCS 34.3 (25.0-48.2) 





 Bodily pain 57.5 (35.0-75.0)   
 General health 40.0 (25.0-55.0)   
 Mental health 76.0 (57.0-88.0) MCS 50.4 (39.4-59.9) 





 Vitality 50.0 (20.0-63.8)   
 Social functioning 62.5 (50.0-87.5)   
HADS Depression scale 5.0 (2.0-9.8)   
 Anxiety scale 5.0 (2.0-7.8)   
 Table 1. Note: Data is shown as median (25–75%). Abbreviations: AOS, aneurysms‐osteoarthritis 
syndrome; HADS, hospital anxiety and depression scale; MCS, mental component summary; PCS, 
physical component summary. a Standardized scores with use of the general Dutch population 
(Aaronson et al., 1998). 
 




with reference data presented as mean ± SD, also our data were presented as mean ± SD in 
the figures although we could not proof normal distribution. However, only small 
differences were found between the calculated mean and median of the HADS and SF-36 
domain scores. To further investigate if patients with orthopaedic symptoms or previous 
aortic surgery had higher levels on the SF-36 and HADS domains, we performed the Mann-
Whitney U test. A p-value of less than 0.05 was considered statistically significant. All 
statistical analyses were performed using the Statistical Package for Social Sciences 
(Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp). 
Results 
Study population 
Of the 31 patients with AOS in our centre, 28 patients (90%) agreed to participate and 
returned the questionnaires. The other three patients were approached two times, but 
could not be reached (n=2) or decided not to participate due to time-constraints (n=1). 
There were no major differences between the 28 responders and 3 non-responders. The 
baseline characteristics of the 28 study patients are presented in Table 1. Our cohort 
contained 23 participants with a confirmed SMAD3 mutation representing 10 different 
genetic mutations with the most common heterozygous mutation (R287W, 859C> T, 
SMAD3 ex 9) present in 9 patients. The mean age was 44.0±17.3 years with an age range 
from 15 to 73 years. Of the 28 patients, 17 (61%) were women. Cardiac or vascular 
abnormalities were present in 22 (79%) patients and orthopaedic symptoms were present 
in 24 (86%) patients. In 18 (64%) of the 28 patients both cardiovascular manifestations and 
orthopaedic symptoms were reported. 
Quality of life, anxiety and depression  
The median values with interquartile range of the domains from the SF-36 and HADS 
questionnaires are presented in Table 2. Our cohort scored significantly lower compared to 
the age-matched reference group of 1742 Dutch citizens(13) on the following domains: 
physical functioning (p<0.001), role limitations physical health (p=0.001), bodily pain 
(p=0.001), general health (p<0.001), vitality (p<0.001), and social functioning (p=0.002). 
AOS patients showed a standardized PCS score of 34.3 (25.0-48.2) and a MCS score of 50.4 
(39.4-59.9). When comparing the SF-36 with age-matched Marfan patients, only physical 
health was lower in patients with AOS (p=0.005). The mean values with standard deviation 
of the domains from the SF-36 questionnaire for AOS patients, Marfan patients and the 
reference group are visualized in Figure 1. The HADS questionnaire showed no differences 
in anxiety (median 5.0 versus 5.1, p=0.569) between AOS patients and the general 
population. However, patients with AOS scored higher on the depression subscale (median 
5.0 versus 3.4, p=0.036) compared to a sample of 199 Dutch adults (14). In our population 




while 1 patient (4%) scored in the range for clinical anxiety. The mean values with standard 
deviation of the domains from the HADS questionnaire are shown in Figure 2 for the AOS 
patients and the reference group. No significant differences in SF-36 and HADS domain 
scores were found between patient with and without orthopaedic symptoms or patients 
with or without previous aortic surgery.  
Fig 1. Comparison of eight SF‐36 domains between AOS patients, Marfan patients and healthy control. Data is 
shown as mean (incl. 95% CI). The SF‐36 scale ranges from 0 through 100 points. The lower the point count per 
subcategory, the more prevalent it is that the individual has a negative effect of that sub scale's premise. For social 
functioning and general health one patient was missing, because he forgets to fill in one page of the questionnaire. 
* Significant lower compared to the mean of the general population (One‐sample Wilcoxon signed rank test). † 
Significant lower compared to both the mean of the general population and the mean of patients with Marfan 
syndrome (One‐sample Wilcoxon signed rank test). AOS, aneurysms‐osteoarthritis syndrome; BP, bodily pain; GH, 
general health; HADS, hospital anxiety and depression scale; MH, mental health; PF, physical functioning; RM, role 
limitations due to mental health; RP, role limitations due to physical health; SF, social functioning; VT, vitality 
Fig. 2 Comparison of two HADS domains between AOS patients and healthy control. Data is shown as mean 
(incl. 95% CI). The anxiety and depression sub scales have a point system of 0 through 21 points total. The 
higher the point count for any sub scale, the more likely that the individual suffers from anxiety or 




Table 2. Baseline characteristics 
  
Baseline characteristics AOS patients (N=28) 
Sex (female) 17 (61%) 
Age (years) 44.0 ± 17.3 
Confirmed SMAD3 mutation carriers (a) 23 (82%) 
BMI (kg/m2) 24.9 ± 3.4 
Smoking (currently) 2 (7%) 
Systolic blood pressure (mmHg) 128.2 ± 16.9 
Diastolic blood pressure (mmHg)  80.4 ± 9.5 
Medication use 14 (50%) 
           - Beta-blocker 8 (29%) 
           - Diuretics 0 (0%) 
           - ACE inhibitors 4 (14%) 
           - Angiotensin receptor blocker 2 (7%) 
           - Calcium channel blocker 0 (0%) 
           - Cholesterol lowering drugs (statins or other) 3 (11%) 
           - Platelet inhibitor 6 (21%) 
           - Oral anticoagulant 2 (7%) 
Comorbidity  4 (14%) 
           - Diabetes Mellitus 0 (0%) 
           - Coronary artery disease 1 (4%) 
Aortic aneurysm or dissection 19 (68%) 
           - History of aortic surgery 9 (32%) 
           - Thoracic aortic aneurysms (>40 mm) (b) 5 (18%) 
           - Head and neck arterial anomaly 6 (21%) 
           - Coronary arterial anomaly 0 (0%) 
           - Abdominal arterial anomaly 5 (18%) 
           - Leg or arm arterial anomaly 0 (0%) 
           - Pulmonary artery dilatation (>40mm) 2 (7%) 
Aortic diameter (b)  
           - Sinus of Valsalva 36.0 ± 3.5 (range 30-44) 
           - Ascending aorta 30.6 ± 3.6 (range 25-40) 
           - Aortic arch 26.5 ± 3.7 (range 21-34) 
           - Descending aorta 24.9 ± 3.4 (range 19-33) 
Cardiac anomalies 9 (32%) 
           - Bicuspid valve 0 (0%) 
           - Aortic stenosis (Vmax > 250 m/s) 0 (0%) 
           - Aortic regurgitation (at least moderate) 0 (0%) 
           - Valve disease other than aortic (at least moderate) 1 (4%) (c) 
           - Congenital heart disease (i.e. VSD) 1 (4%) 
           - Ventricular hypertrophy (>13 mm) 2 (7%) 




Table 2  continued  
Disease specific anxieties/concerns 
In the Rotterdam disease specific questionnaire, the majority of the patients reported fear 
and/or anxiety according to their future or the future of their siblings or offspring’s (Figure 
3). Concerns about dying at an early age (median 3.5, IQR 1.0-7.0), future health (median 
5.0, IQR 2.3-7.0), future surgery (median 6.5, IQR 1.0-9.0) and heredity of their disease 
(median 7.0, IQR 4.3-10.0) were mentioned. The risk of developing aortic dilatation or 
dissection or already having aortic pathology did not have a significant impact on 








          - Atrial fibrillation (former/paroxysmal or 
currently) 
4 (14%) 
Age first vascular or cardiac abnormalities (in years) 38.0 (26.5-56.0) 
Orthopaedic abnormalities (d) 24 (86%) 
Age first orthopaedic abnormalities (in years) 20.0 (13.8-46.0) 
Figure 3. Results of the Rotterdam disease specific questionnaire. This figure shows the influence 
of (possible) aortic dilatation or dissection on different aspects of life. Data shown as median with 
interquartile range 25–75% 
Table 2. Data is shown as median (25–75%), mean ± SD or as N (%). Missing values for BMI (n = 
2).a Five patients have a 50% chance of having AOS, since they are not yet genetically tested. 
They are included because they showed significant aortic, cardiac or orthopaedic symptoms 
associated with AOS.b Aortic diameters of the sinus of Valsalva and ascending aorta and 
prevalence of thoracic aortic aneurysm (>40 mm) are presented for patients who have not 
undergone aortic surgery.c This patients showed moderate mitral valve regurgitation.d 
Orthopaedic abnormalities such as arthritis, arthrosis, osteochondritis dissecans, orthopaedic 





The results of our study show that patients with AOS report a lower quality of life, mainly 
on the physical health subscales, and higher scores on the depression subscale compared 
to the general Dutch population. Disease specific anxiety was most often related to the 
future of their own health or the health of their close relatives. Although anxiety, 
depression and quality of life have been described in other patients groups with aortic 
pathology (16-18), specifically after thoracic aortic surgery(19), it has not yet been 
described in AOS patients or Loeys-Dietz syndrome. In general, AOS is not a very well-
known syndrome among cardiologist and other specialists, while pathogenic variants in the 
SMAD3 gene are responsible for 2% of familial thoracic aortic disease (20). This patient 
group is of great interest, because of their recently discovered extensive presentation 
including severe joint abnormalities and most importantly aggressive cardiovascular 
phenotype requiring vigilant follow-up (5). Therefore it is important for all clinicians 
involved in the care for these patients to be aware of the psychological aspects in order to 
provide adequate care. We showed lower SF-36 scores, on almost all domains compared to 
the general population (13). The median PCS score of our patients with pathogenic variants 
in the SMAD3 gene was 34.3, which means a much lower physical health than the general 
population, while the median MCS score (50.4) showed that mental health was comparable 
with the general population. However, on two subscales of mental health, namely vitality 
and social functioning, AOS patient did score lower than the general population. We know 
that middle aged Dutch patients with congenital heart disease show similar or even more 
favorable levels compared to normative data using the SF-36 survey (21). This difference 
between patients with congenital heart disease and AOS patients can be explained by the 
moment at which the symptoms are present. Orthopedic and cardiovascular symptoms 
associated with AOS start at a median age of 22 and 38 years respectively, which cause an 
acute change in patients’ health with clear impact on quality of life. Whereas the patient 
with congenital heart disease are known with their defect from birth, AOS patients need to 
adapt and accept that they have this disease at later age. Compared to patients with 
Marfan syndrome (15), AOS patients scored only lower on the SF-36 questionnaire for the 
domain of physical functioning. This can be a result of the more extensive presentation of 
musculoskeletal complaints in patients with AOS including osteoarthritis, osteochondritis 
dissecans, scoliosis and pectus excavatum (6, 22). This assumption is supported by data 
from patients with Ehlers-Danlos syndrome, a connective tissue disorder which presents 
with extreme musculoskeletal symptoms including hypermobility (23). Ehlers-Danlos 
patients report even lower physical function score (39.6) and general health score (26.8) 
compared to AOS patients (8, 24). We did not find a difference between patients with and 
without orthopedic symptoms. However, this should be tested in larger cohorts, since our 
cohort might be too small to prove the association between orthopedic symptoms and 




heritable thoracic aortic disease, have lower quality of life than the general population, but 
there seem to be some differences between syndromes. By assessing quality of life, anxiety 
and depression, we found unfavorable outcomes and impairments, warranting attention 
and in some cases treatment. In our population of patients with pathogenic variants in the 
SMAD3 gene, 4% scored above the cut-off for clinical anxiety, while 7% scored in the range 
for clinical depression. These percentages are comparable to or even slightly lower than the 
prevalence’s in the general German population, which are 5.2% for anxiety and 9.6% for 
depression based on the HADS questionnaire (25). However, the median of the continuous 
outcome of the depression scale was higher in OAS patients than in the general population. 
With the development of our own Rotterdam disease specific questionnaire, we were able 
to identify patients concerns due to their disease. Most importantly, patients report 
worries concerning the future of their own health or the health of their close relatives. 
These results emphasize the need for physicians to discuss patient’s future and risk for 
family members and check in each patient whether someone is concerned about this. This 
is not only important for AOS, but for all inherited syndromes. Generic questionnaires such 
as SF-36 or EuroQol (EQ-5D) are commonly used for quality of life assessment. Although 
the use of validated questionnaires is extremely important, these questionnaires do not 
distinguish between quality of life based on the disease itself or as a result of other 
problems like small or short-term injuries and life events. With the use of more disease-
specific questionnaires, such as the Rotterdam disease specific questionnaire, in larger 
cohorts we will be able to identify the cause of physiological burden in a disease more 
precisely in the future. Nevertheless, before using these questionnaires in clinical practice, 
they should be validated.  
In this study, we used questionnaires to measure self-reported quality of life, anxiety and 
depression, which may have caused documentation of more complaints than patients 
would have mentioned spontaneously. Also, it may cause some information bias, although 
we assume that the high response rate of 90% reduced the chance of bias. Because of our 
single center design, we included a small cohort, which prevented us from extensive 
identification of factors associated with quality of life, anxiety or depression.  
Conclusion 
In conclusion, our population of AOS patients showed reduced quality of life in comparison 
with the general population on physical functioning, role limitations due to physical 
functioning, bodily pain, general health, vitality, and social functioning. Physical functioning 
was also lower than in Marfan patients. Although the prevalence of depression was similar 
to the general population, patients with AOS scored significantly higher on the depression 




found that patients’ worries for their future and heredity of their disease are important 
factors for anxiety, which should be addressed in clinical practice. 
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Chapter 1 provides a general introduction and overview of the studies included in this 
thesis.  
Part I  Turner syndrome   
Chapter 2 is based on a book chapter and introduces the phenotype associated with Turner 
syndrome (TS); its genetic etiology is discussed and the known associated pathologies are 
described. It provides the foundation on which the rest of ‘Part I’ of this thesis builds. In 
Chapter 3 we describe a retrospective cohort of 96 patients with TS patients with detailed 
imaging of the pulmonary vasculature. Earlier studies indicated that TS patients may have 
an increased incidence of partially abnormal pulmonary venous return (PAPVR). Which was 
confirmed as 1 out 4 TS patients had such a PAPVR. This study changed clinical practice, as 
advanced imaging in these patients is now routinely checked for presence of PAPVR. In 
Chapter 4 we describe the health-related quality of life of 177 women with TS and 
investigate the factors that influence it. This study is a part of the value-base healthcare 
program in the Erasmus MC.  Value-based healthcare entails aiming at improving outcomes 
that matter most to patients in their everyday lives. In order to do this, these outcomes 
should first be measured. In this study we showed that TS women suffer from impaired 
QoL, more perceived stress and increased fatigue compared to healthy controls. A 
relationship between non-cardiac comorbidities and HR-QoL was found. Furthermore, TS 
women appeared to practise individual sports, like running, almost exclusively. In addition 
to this, we also examined how content TS women were with their body on the ‘body 
satisfaction’ scale. TS women were most dissatisfied with their waist, build, figure, belly, 
and weight. These results, especially those of perceived stress and increased fatigue, can be 
considered targets for improvement of HR-QoL in women with TS. In Chapter 5 we describe 
systolic left ventricular global longitudinal strain (LvGLS) and left ventricular peak early 
diastolic strain rate (Sre) in 94 adult women with TS and relate it to clinical outcome. 
Women with TS had a significantly lower systolic LvGLS (-17.82 ±2.98% vs. -21.80 ±1.85%, 
p<0.001) and Sre 0.98 ±0.32 s-1 vs. 1.27 ±0.19 s-1, p>0.001) compared to healthy females’ 
controls. Furthermore, TS women had reduced diastolic function as measured by 
conventional echocardiographic parameters. Moreover, LvGLS and Sre were comparable 
between TS patients with and without structural heart disease. Women with TS also had a 
significantly reduced maximal workload, reduced oxygen uptake and a reduced maximal 
heart rate during exercise. In Chapter 6 the coronary anatomy of patients with TS is 
compared to that of patients with a BAV. This study shows that patients with BAV with 
fusion of right and left coronary leaflets (RL BAV) without raphe have a high prevalence of 
left coronary dominance in the group of TS-BAV as well as in isolated BAV (both 38%) and 




compared with patients with isolated BAV (0%). Aortic dilatation is a significant concern in 
TS women. Often the aortic diameter increases faster compared to the general population 
and elective surgery is needed. Therefore, we studied a large retrospective cohort of 268 
TS women with advanced imaging of the aorta. Chapter 7 discusses the outcome and aortic 
dilatation in these women with TS. This is a much-debated topic within the TS literature as 
dilatation is common and many associations, such as growth hormone treatment during 
childhood, are described. In this study we confirmed some of these associations. 





Part II  the Bicuspid Aortic Valve and Aortic Coarctation  
Chapter 8 is based on a book chapter and serves as an introduction to ‘Part II’ of this thesis. 
In this chapter the aortic coarctation is discussed, which is a form of aortic pathology that is 
interwoven with Both Turner syndrome (discussed in Part I) and the bicuspid aortic valve 
(which is also discussed in Part II). In Chapter 9 we evaluated a novel method of strain 
analysis using 4D flow CMR.  We showed that GLS analysis is possible using the magnitude 
datasets produced by 4D flow CMR with adequate imaging quality in BAV patients. GLS 
measurement by CMR correlated well with CT and speckle-tracking 2D TTE. Chapter 10 
focuses on volume quantification of the left ventricle using a novel algorithm on 3D 
echocardiography datasets. In theory, use of a fully automated method of volume 
quantification allows for a user-independent and thereby highly reproducible 
measurement. Left ventricular end-diastolic and end-systolic volumes and ejection fraction 
was calculated by the software and correlated well with manual 2D and 3D 
echocardiographic measurements. Left atrial volume also correlated significantly, although 
LHM did estimate larger left atrial volume compared to both 2D and 3D echocardiography. 
Software like this may help to overcome some of the major hurdles in integrating 3D 
analysis into daily practice, as it is user-independent and highly reproducible in a group of 
patients with BAV. Bicuspid aortic valve is often seen together with aortic coarctation. 
Chapter 11 describes the outcomes of 93 patients who underwent aortic coarctation 
stenting. Complications occurred in nine patients (10%), including aortic dissections in 
three patients (3%) and intraoperative ruptures in two patients. The aortic dissections and 
ruptures were treated successfully by deploying an additional covered stent. Two patients 
died within 30 days of the index procedure. After a mean follow-up of 3.2 ± 3.1 years, 
nearly all patients (98%) were clinically improved and all stents were patent. Reintervention 
was needed in 10 (11%) patients. Freedom from reintervention at 5 years was 85%. Two 
additional patients died during follow-up of coarctation-related causes, including rupture of 
an infected graft and visceral ischemia. Patient survival at 5 years was 89%. This study 
demonstrates that endovascular repair of aortic coarctation is effective and has an 
acceptable safety profile in the treatment of newly diagnosed CoA and after initial surgical 
repair. Additionally, it was demonstrated that aortic rupture is an infrequent (2%) but 
devastating complication with high mortality. The rate of reinterventions is acceptable, with 
high procedural and long-term clinical success. Chapter 12  builds on the previous chapter 
in the sense that the outcome of coarctation stenting might be safe for the average CoA 
patient, but in women with TS a vasculopathy of the aorta exists, with a frailer aortic wall as 
a result. In women, CoA is one of the most prevalent congenital heart diseases (7-18%). 
Resolution of the aortic narrowing is generally considered to be a safe alternative for the 
surgical approach in selected cases. However, the inherently weaker aortic wall of TS 
patients may expose them to greater risk than their non-TS peers. Therefore, our 




coarctation stenting in a cohort of TS patients. However, TS is a relatively rare disease and 
CoA treated using stenting in these patients therefore is even more rare. Consequently, we 
had to do our utmost to find the 19 patients with TS, from different 10 centres, who had 
been treated using percutaneous stent angioplasty for aortic coarctation. Three (15.8%) 
adverse events occurred within 30 days of the procedure, including two dissections 
(despite the use of covered stents), one of which resulted in death. At long-term follow-up 
(6.5 years, min-max: 1-16), two additional deaths occurred that are not known to be stent-
related. Thereby, we showed that although percutaneous treatment of aortic coarctation in 
TS patients is effective, it is associated with serious morbidity and mortality. These risks 
therefore suggest that alternative treatment options should be carefully weighed against 
percutaneous stenting strategies. Chapter 13 seeks to put an end to the controversy 
around whether having a CoA is associated with larger aortic diameters and higher 
complication rates. In order to do so, this study describes the outcome of 483 BAV patients 
and evaluates whether the coexistence of CoA is associated with aortic events, aortic 
dilatation and aortic diameter growth. We concluded that the coexistence of CoA was not 
associated with a higher aortic event rate, a higher prevalence of aortic dilatation, or faster 
ascending aorta growth. CoA should thus not be seen as a risk factor that justifies earlier 
preventive aortic surgery in BAV patients. 
Part III SMAD3  
In 2011, our study group described the aneurysm–osteoarthritis syndrome (AOS) caused by 
a mutation in the SMAD-3 gene for the first time. Chapter 14 describes the long-term 
follow-up of outcome and aortic diameters in patients with AOS. We demonstrate that, 
although these patients remain high-risk, when they are screened according to the 
intensive clinical follow-up protocol there was no mortality. Analogous with patients with 
TS, quality of life is affected in AOS patients. Therefore, Chapter 15 studies, for the first 
time, how the subjective quality of life is affected in (28) AOS patients and investigates how 
the levels of anxiety and depression are affected by the burden of this disease. Compared 
to the general population, AOS patients scored significantly lower on the following SF-36 
domains: physical functioning, vitality, social functioning, bodily pain, and general health. 
Patients with AOS scored higher on the HADS depression scale, while anxiety did not show 
a significant difference compared to the general population. This study emphasizes that 
patients' worries for their future and heredity of their disease are important factors for 






This thesis focusses on three specific forms of aortopathies: women with Turner syndrome, 
patients with a bicuspid aortic valve, and patients with a SMAD3 gene mutation. At the 
most favourable end of the spectrum we find the BAV aortopathy, which is relatively 
common and can follow a benign course in most cases, where mere watchful waiting can 
be appropriate. Other aortopathie may be rare rare but can be very aggressive and require 
vigilant follow-up, such as the Aneurysm-osteoarthritis syndrome (AOS) caused by 
mutations in the SMAD-3 gene we discussed in ‘Part III’. However, the dilemma shared 
between the patients who suffer from these diseases is that an optimal treatment 
approach for them is still unclear, and many etiological questions remain. This thesis 
attempts to find answers to these questions by retrospectively reviewing data from our 
own centre and contributing to the research efforts of other centres. Moreover, we also 
included BAV and TS patients in the new multi-centre prospective cohort study designed 
for this purpose: the BAV-study. This thesis describes the answers that were found as a 
result of those studies and reflects on the challenges that still remain for future 
consideration.  
Turner Syndrome  
Women with TS experience an overall threefold increase of mortality [1-3], and a 13-15 
year reduction in life expectancy [2, 4]. Especially women with a 45,X0 monosomy, who are 
more prone to have congenital heart disease, are adversely affected [1, 5]. Therefore, 
cardiovascular disease is an important factor as cardiovascular pathology such as: aortic 
disease, valvular pathology, hypertension and ischaemic heart disease contribute to nearly 
half of this excess mortality [1, 6]. Careful documentation of the TS cardiovascular 
phenotype is essential discovering its cause.  
Congenital heart disease 
The etiology of Turner syndrome (TS) is still unknown and, as discussed previously in this 
thesis, several theories exist. A genetic cause, probably located on the X chromosome is 
suspected [5, 7]. TS women typically face a lifelong heavy burden of congenital and 
acquired cardiovascular disease, with increased mortality and morbidity [1, 4]. The most 
frequent cause of early mortality is congenital heart disease, occurring in approximately 
23–50% of patients [4, 8-10]. Especially prevalent congenital heart diseases are a bicuspid 
aortic valve (BAV: 15-30%) and the coarctation of the aorta (CoA 12-17%). In this thesis, a 
relatively unknown vascular anomaly is described in more detail, the partial abnormal 
pulmonary venous return (PAPVR). We found that it occurred even more frequently in TS 
women than previously thought (Chapter 3). The prevalence of PAPVR is estimated to be 
0.1% (18) In the general population, where we found an estimated prevalence of 25% in 




marker for the TS diagnosis, as CoA [11]and BAV are [12]. Consequently, women with TS 
will have to be systematically screened to detect such anomalies, preferably using 
advanced imaging techniques, such as cardiac CT or MRI. The high spatial resolution of 
ECG-triggered cardiac CT may have the highest sensitivity to detect the sometimes small 
PAPVRs. However, CMR allows for shunt size quantification, which is ultimately needed for 
clinical decision making. In addition to the clinical relevance to the individual patient, the 
discovery of new aspects of the TS phenotype may provide valuable information about the 
etiology of CVD in TS women.  
Another addition to the TS cardiovascular phenotype this thesis has made are the 
congenital morphological coronary artery anomalies described in chapter 6. Variations in 
coronary anatomy, like absent left main stem and left dominant coronary system, had 
already been described in women with TS and in BAV patients [13, 14]. However, such 
variations in coronary anatomy in TS women had not yet been related to the presence of 
BAV or even specific to BAV morphotypes. Therefore, we compared coronary anatomy 
between patients with TS and patients with an isolated BAV. We observed no difference in 
coronary dominance between patients with TS with and without BAV. Furthermore, 
bicuspid valves with fusion of right and left coronary leaflets, but without raphe, showed a 
high prevalence of left coronary dominance in both women with TS and isolated BAV. 
Absent left main stem was seen only in TS patients with RL- type BAV without raphe, which 
may be an important insight for the cardiothoracic surgeon to avoid complications during 
hypothermic perfusion. However, whether these coronary malformations increase 
mortality risk is unknown and is an important subject for further studies.  
The third, and perhaps the most interesting addition to the TS phenotype, is the systolic 
and diastolic left ventricular dysfunction we described in Chapter 5 of this thesis. There 
seems to be a decrease in ventricular function in women with TS compared to healthy 
controls. We did not find an obvious reason for such a decrease in ventricular function. It 
would be logical to expect a connection to the high prevalence of congenital heart disease 
in this population. However, we could not establish such an association. The impaired LV 
function seemed to exist independently of traditional causes such as hypertension or CoA. 
An alternative explanation may lie in the disturbed hemodynamics in TS women via 
ventricular-arterial coupling [15]. TS women are known to have decreased aortic 
distensibility [16-19], and both systolic and diastolic hypertension are prevalent in these 
women. Increased vascular resistance could decrease the efficiency of the ventricular-
arterial coupling. Reduced vascular compliance and increased arterial pressure may 
increase vascular resistance. The LV of TS women may subsequently compensate by 
increasing end-systolic volume and lengthening contraction, which in turn may cause 
hypertrophy [20]. Future studies will have to investigate a possible relation between 




potentially provide a pathophysiological basis on which we can understand and predict the 
disease process that takes place in TS, it does not provide information as to its etiology. A 
common underlying cause could be supposed.  
Role for Cortisol?  
Such a primary causative mechanism could lie in glucocorticoid metabolism; a recent study 
showed that long-term cortisol concentrations in scalp hair were elevated in patients with 
TS when compared to matched control subjects. [21]. Several aspects of the TS phenotype 
may well fit an important role for Cortisol. 
Cortisol acts through both the glucocorticoid receptor and the mineralocorticoid receptor, 
the latter of which is expressed in the myocardium, endothelial cells, and the vascular 
smooth muscle [20]. The high cortisol level in TS patients was associated with short stature, 
total cholesterol levels, and a worse cardio metabolic profile in terms of fasting glucose and 
triglyceride levels [21]. It could be supposed that long-term exposure to increased cortisol 
levels is also related to the diastolic dysfunction in women with TS. Such dysfunction is for 
example frequently seen in populations of patients that are exposed to high levels of 
cortisol, such as patients with Cushing’s syndrome (CS). It is well-known that the high 
cortisol in CS has multiple effects on the heart; increased prevalence of left ventricular (LV) 
hypertrophy, higher frequency of concentric remodeling, LV systolic and diastolic 
dysfunction, and left atrial systolic dysfunction, as well as increased regional LV wall 
thickness [22-25]. Additionally, subtle ECG-changes, such as prolonged QT-corrected 
dispersion, have also been described in CS patients [26]. In CS, the hypothesis is that not 
the severity of the excess, but rather the duration of hypercortisolism relates to the level of 
cardiac dysfunction [23]. Moreover, these negative cardiac effects are reversed upon 
initiation of treatment [27]. Pulse wave velocity was also increased in a cohort of pediatric 
patients with CS and was positively associated with midnight Cortisol [28]. Cortisol has also 
been associated with aortic pathology; mainly as a factor in aortic aneurysm formation [29] 
and aortic dissection [30]. Additionally, it is also found to be predictive of outcome in heart 
failure patients [31]. Moreover, individuals who are chronically exposed to elevated cortisol 
levels are prone to develop metabolic syndrome, including central obesity, insulin 
resistance, hyperglycemia, and dyslipidemia [24, 32].  
These cardiac, aortic and metabolic effects strongly resemble those described in women 
with TS, especially those with a 45,X monosomy compared to other genotypes [33]. In our 
current study we also find a negative effect of the 45,X monosomy on diastolic function 
compared with other genotypes. This raises the question whether an underlying genetic 
cause of TS observed hypercortisolism could be supposed. And, indeed, such a gene, 5-
HT2RC, located on the X-chrome is involved in the cortisol regulation. Studies by Brummett 




increased incidence of death or MI, independent of several traditional risk factors and two 
conventional markers of CVD severity [34, 35].  
Despite these interesting similarities found in literature, such an association is still highly 
speculative and further studies are needed to confirm a possible causative relation 
between hormonal influences and the TS cardiovascular phenotype. 
Aortic dilatation and dissection 
Aortic dilatation poses a challenging dilemma in the clinical care of TS women. It is currently 
not well understood what its etiology is and what factors aggravate it. Moreover, it is not 
evident in which way we should measure it, absolute diameters or relative to body size or 
to the relevant population reference. This hampers establishing an optimal treatment 
strategy. Currently, it is considered to be appropriate to intervene earlier in the disease 
process than in dilated non-TS aortas.  
In chapter 7 we described a TS cohort, in which aortic dimensions are measured using 
advanced imaging during a relatively long follow-up time. Aortic dilatation was found in 
22% of women. Factors that are typically associated with large aortic diameters were 
hypertension, BAV, 45X0 karyotype, weight, and growth hormone treatment. These women 
were followed-up for 7-years during which 2% had an aortic event. The aortic growth rate 
was low (0.20 mm/year) but still exceeds that in the general population (0.12 mm/year) [36, 
37]. No associations for faster aortic growth could be determined upon long-term follow-
up. 
Another important aspect that comes into clearer view with the results of this study is the 
correction of the aortic diameter using the aortic size index in TS patients. The ASI corrects 
the Aorta for BMI, as it is based on the idea that relative aortic size is more important than 
absolute aortic size in predicting complications [38]and that a disproportionally large aorta, 
though ‘small’ in absolute terms, in a small female may still expose her to an increased risk 
for complications. This may, however, cause an ‘overcorrection’ of aortic diameter in some 
TS women, who are prone to be overweight and thus underestimate the risk these women 
are exposed to. The use of Z-score may be a valid alternative for ASI as this may take into 
account a TS-specific population mean. The Z-score, or standardized score, is the number of 
standard deviations that an individual's aortic diameter is above or below the mean value 
of a reference population. Z-score is a reliable method to evaluate the severity of the aortic 
diameter in women with TS [37, 39], especially in TW women >15 of age [40]. 
Especially the possible unfavourable effects on the aortic wall of growth hormone 
treatment are controversial. In animal and human cell models, treatment with GH has been 





Recently, Mortensen et al. have described comparable or smaller aortic growth rates as 
compared to age and gender matched healthy controls [41]. They confirm the adverse 
influence of BAV and CoA on aortic diameter in this population. These results reflect the 
difficulty of this research topic and there remains a need for validation by prospective 
studies in larger cohorts 
Quality of life 
In addition to comprehensive description of the TS phenotype a second aim of this thesis 
was to add value to the care of the individual TS patient. Often the quality of life (QoL) is 
not affected not only affected by disease severity or general health [42], but also by other 
socioeconomic factors such as the ability to take on life insurance or to find full-time 
employment [43]. Consequently, improvements in understanding of, for example, disease 
etiology may not always translate well to an actual increase in the perceived quality of life. 
More recently, ‘value-based competition in health care’ (VBHC) has become a guiding 
principle in the quest for high quality health care for acceptable costs [44]. It aims at 
achieving high value for patients, where value is defined as the health outcomes per dollar 
spent [45]. This introduces efficiency into the equation of healthcare, given that value is 
defined here as outcomes relative to costs. However, measuring these outcomes, which 
are inherently condition-specific and multidimensional, is difficult. This is particularly 
difficult given that for the majority of medical conditions, no single outcome captures the 
results of care. Therefore, as part of the corporate value-based health care program we 
developed, we report on a set of clinician and patient reported outcome measures in 
Chapter 4. Moreover, we described the health-related quality of life of women with Turner 
syndrome, because in order to improve health-related QoL (HR-QoL), we should first 
comprehensively measure outcome. By doing so, we showed that TS women suffer from 
impaired QoL, more perceived stress and increased fatigue compared to healthy controls. 
Such outcomes are important because perceived stress and increased fatigue can be 
considered targets for improvement of HR-QoL in TS women. Furthermore, a relationship 
between non-cardiac comorbidities and HR-QoL was found, which demonstrates that 
adequate multidisciplinary care for these women is vital to their perceived quality of life. 
However, more studies will be needed to establish cost-effective new targets for 
intervention that improve health care for women with Turner syndrome. 
A paradigm shift towards VBHC means aiming at improving outcomes that really matter 
most to patients’ lives. Before the introduction of this concept healthcare providers often 
tended to measure only what they could directly control in a particular intervention or 
what was easily measured, rather than the outcomes that effectively improved the 
standard of care as perceived by the patients [45]. However, we will also need to 
acknowledge some shortcomings of VBHC. Although VBHC improves many aspects of 




translated to the context of health care. Groenewoud et al. [44] have recently discussed 
what they deem to be the four significant challenges of VBHC posed to ethics. Firstly, they 
argue that VBHC tends to neglect patients’ personal values [1] by its narrow framing of the 
concept of ‘value’. It simply assumes a certain hierarchy in values that may not be 
representative for every individual patient. Secondly, VHBC arguably ignores the intrinsic 
value of the ‘caring act’ [2] as it reduces it to its cash equivalent. Furthermore, VHBC is said 
to disproportionately replace trust in professionals with accountability, which has led to 
soaring bureaucracy and tightening organizational control over daily medical practice. 
Some authors argue we should not throw away the child with the bathwater, but rather a 
form a notion of ‘intelligent accountability’ that may alleviate the heavy administrative 
burden and secure the patient-doctor relationship [46]. Finally, VHBC may undermine 
solidarity, as it encourages patients to leave [3] if they feel that they may receive better 
healthcare elsewhere [44]. This consequently may create differences between rich and 
poor due to variances in access to information and access to alternative (private) 
healthcare options. To overcome these shortcomings, we will need to focus on increasing 
personal value by ensuring the outcome relates well to the values of each individual by 
providing both comprehensive and comprehensible information. This should entail 
increasing allocative value by equally distributing health-care assets amongst different 
subgroups by increasing health-care budget in a fair manner. This could for example be 
done by shifting allocated budget populations from evident overuse of low value to more 
high value interventions. Finally, we will need to develop systems on a population level that 
stimulate shift from low to high value interventions.  
In short, the QoL of women with TS is compromised by several factors which we studied in 
Chapter 4. Knowledge of the factors that determine QoL in these women is essential in 
developing patient-centred health care. Whereas knowledge of these factors will not 
replace the need for an individual approach to patient-care, it will be a useful addition to 





Bicuspid aortic valve and Aortic Coarctation 
Novel imaging techniques in bicuspid aortic valve patients 
This thesis focused on different aspects of the bicuspid valve. One of them being the 
development of new imaging techniques that may facilitate the workflow of the caregiver. 
In Chapter 9 and 10 we described two novel methods, the measurement of GLS in 4D flow 
MR images and left-heart model based on speckle-tracking echocardiography, both of 
which have the potential to significantly reduce the effort and time spent per patient. Such 
techniques may also reduce inter- and intra-observer biases. Workflow automation is a 
double-edged sword, with benefits for both patient and physician. On the one hand,  a 
more efficient, less user-dependent workflow may add value for the patient as it may 
potentially reduce medical errors and improve patient outcome [47]. On the other hand, 
these new techniques, using fully automated software based on artificial intelligence and 
big data have the potential to improve workflow efficiency for the physician tremendously 
[48]. By doing so, the time spent by physicians analyzing images could then be spent 
elsewhere and so such findings can be seen as of high value. 
Aortic coarctation 
The final three chapters of Part II (Chapter 11, 12 and 13) focus specifically on a problem 
that is related to the BAV: the aortic coarctation. BAV can be found in 70–75% of patients 
with the coarctated aorta (CoA) [49-51]. Conversely, approximately 7% of BAV patients 
have CoA [50]. Both lesions are part of the same diffuse arteriopathy [52]. Chapter 8 
provides a comprehensive picture of this serious defect that warrants lifelong vigilant 
follow-ups. Several questions in the treatment of patients with CoA still remain. One of 
which concerns the optimal treatment of the defect; therefore, in Chapter 11 we described 
a cohort of adult patient with a CoA and chapter 12 specifically focuses on women with 
Turner Syndrome with concomitant coarctation of the aorta. Traditionally, since 1944, CoA 
has been treated surgically [53], which provides long-term follow-up and although it has 
significant risks it is considered a safe treatment option, as is described in chapter 8. 
Endovascular treatment of adult aortic coarctation has been developed in the early 90’s 
[54]and is thus a relatively new alternative compared to surgery, and therefore the long 
term outcome is less well known [55]. We described 93 patients who were treated using 
stenting and primary angioplasty. We described 2 perioperative deaths and a 5-year 
survival of 89%. This adds important information to the existing evidence that 
percutaneous treatment is a safe and effective treatment as an alternative to CoA surgery 
for adults in the general population. However, women with TS differ from the general 
population in a key aspect for this discussion: fragility of the aortic wall. As described 
earlier, TS patients have a generalized aortopathy, which leads to increased prevalence of 
aortic dilatation and dissection. Our hypothesis was that this fragility may also potentially 




using open surgery, where complications may be more readily dealt with. Therefore, we 
have performed our own multi-center study that aimed to retrospectively include only 
women with TS who had also been percutaneously treated for CoA. In total, 19 such 
patients were found in 10 centers. Twelve patients were treated for native and 7 for 
recurrent coarctation. Three (15.8%) adverse events occurred within 30 days of the 
procedure, including two dissections, one resulting in death. After 6.5 years, two additional 
deaths occurred, not known to be stent-related. This event-rate is markedly higher than in 
the general population, especially when considering the literature review of smaller similar 
cohorts. These risks suggest that alternative treatment options should be carefully weighed 
against percutaneous stenting strategies. Such decisions should be carefully made, 
preferably in a multi-disciplinary team with ample expertise in treatment of TS women.  
The interrelation between BAV and CoA is further explicated in Chapter 13 which 
investigates the influence of a history of CoA on aortic events and dilatation in BAV 
patients. The current ESC guidelines advise ascending aortic surgery at a lower ascending 
aortic diameter in BAV patients with a history of CoA (50mm instead of 55mm, class IIa, 
level C) [51, 56]. An earlier study did find a higher aortic event rate in BAV with a history of 
CoA patients [57]; however in our cohort of 483 BAV patients we could not find evidence to 
substantiate this claim. Our study differed in the definition of primary endpoint event and 
study groups. Similar results to our study have been found [58, 59]with no significant 
difference or even lower event rates in non-CoA BAV patients. We also did not find a 
difference in aortic growth rates, which may suggest that preventative surgery is 
necessarily indicated earlier in these patients. However, hypertension is more prevalent in 
CoA patients, which is a risk factor for dissection, and therefore careful individual decision-




Part III of this thesis focusses on the most aggressive aortic pathology, that caused by 
pathogenic SMAD3 mutations. Together with osteoarthritis at young age this is 
encapsulated in the aneurysms-osteoarthritis syndrome or AOS [60, 61].  AOS has many 
similarities with Loeys-Dietz syndrome and is recognized by some as part of Loeys-Dietz 
syndrome [62]. Short-term follow-up showed fast and unpredictable aortic growth with 
high morbidity [61]. However long-term follow-up had not yet been described and it was 
yet unknown how the rate of aortic dilatation in SMAD3 patients compares to other 
syndromic causes of aortic dilatation. Therefore, we described all patients who had been 
under frequent follow-up in our center. This resulted in a small cohort of 28 patients, which 




could be appreciated is that although the growth is fast, it is currently adequately 
monitored using our in-house protocol which includes yearly full-body advanced imaging, 
as no mortality occurred during this follow-up period. In our cohort aortic growth rates 
were lower than expected, although clearly higher than in the general population: 0.07 and 
0.09 mm per year of life in women and men respectively [63]. The highest growth rate was 
observed at the sinotubular junction, 0.4mm/year, which resembles other aortopathies 
such as Marfan syndrome [64]. Obviously, from a patient-perspective not the growth of the 
aorta but the zero deaths are the most important finding. Moreover, half of patients 
needed very invasive surgery of the aorta and another 14 vascular interventions were 
done. Future research will have to show whether less frequent follow-up may be 
appropriate for a sub-set of the patients. 
Quality of Life 
Another question in this patient group is how the impending high risk of aortic dissection or 
rupture affects the psychological well-being in SMAD3 patients. It is known already that 
their orthopedic complaints have a significant influence on day-to-day life and may 
influence their feeling of well-being even more. Therefore, we described the psychological 
well-being of the 28 patients under follow-up in our center. We found significantly 
decreased health-related quality of Life, as scored by the SF-36, compared to the general 
population. This difference was mainly driven by the lower physical component summary 
compared to the mental component summary. There is, however, a marked discrepancy 
with congenital heart disease patients, who have as described earlier, similar or even more 
favorable levels compared to healthy controls [42]. We suggest that this difference 
between patients with congenital heart disease and AOS patients is most likely due to the 
timing of the onset of the complaints. Congenital heart disease by definition starts at birth, 
meaning that patients learn to cope with their limitations early on, and perhaps look at life 
as a glass that is half full. AOS patients, however, typically develop symptoms between the 
age of 22 to 38 years old, which cause a sharp decrease in their perceived health. In 
addition to this decreased perception of health due to being diagnosed with a heart 
disease, these patients often experience the accompanying osteoarthritis as most 
debilitating. This creates the need for them to adapt to these new ‘patient ship’ with all the 
challenges this presents.  
Future directions 
During this thesis we encountered several limiting factors, not due to shortcomings in study 
design but due to the nature of the defects we were studying. The first limitation is study 
size; Turner syndrome is a relatively rare and very heterogeneous disease. Often the 
complications we want to study in these women, such as aortic dissections, are rare. 
Therefore, close cooperation between academical medical centers involved in the care for 




and organize and standardize the TS research nationally. We are under way with such an 
effort in the cooperation between the university hospitals of Nijmegen and Rotterdam and 
the Dutch-Flanders collaboration. The second obstacle is standardization, with variability 
between methods being a problematic source of bias. It hampers clinical interpretation of 
the, often small, differences between outcomes. Also, the method of defining aortic 
dilatation and with use of ASI or Z-score needs more attention and standardization. The 
third and final task for future researchers is patience; if we want to study processes such as 
aortic dilatation, we need time. The pathophysiological changes in the aorta do not happen 
overnight and if we want to understand what is happening, we will need to observe these 
patients very closely over the decades to come. 
Conclusions 
The aims of this thesis were to elucidate the etiologies and pathogenic mechanisms leading 
to BAV or aneurysm formation and unravel risk factors for disease progression. To explore 
the myriad of cardiovascular abnormalities associated with TS and study their impact on 
the quality of life of the individual patient. We found PAPVR to be prevalent among TS 
women, providing important information on the TS phenotype. We showed that the health-
related quality of life in the women was impaired compared to relevant controls, driven by 
increased fatigue and stress. This may offer opportunities for therapeutic interventions in 
the future. We showed that systolic and diastolic left ventricular function is reduced in TS 
women compared to age and gender matched controls in TS women. We studied coronary 
anomalies in TS and BAV patients and found presence of left dominance to be a feature of 
BAVs without raphe, independent of TS. Both TS and RL BAV without raphe seemed 
independently associated with absent left main stems. Awareness of such anomalies may 
be important to avoid complications during surgical procedures in these patients. We 
showed that aortic dilatation is common in TS patients; however, aortic dissection, related 
mortality, and preventive aortic surgery are rare. Finally, we found that SMAD3 patients 
had a reduced quality of life compared to the general population, with their worries for the 
future and heredity of their disease constituting particularly important factors for anxiety. 
This is an important insight and should be addressed in clinical practice. Regarding their 
aortic pathology we showed that although many need invasive preventative aortic surgery, 
no mortality occurred. The observed aortic growth was highest at the sino-tubular junction 
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Nederlandse samenvatting  
Deel I    Het syndroom van Turner  
Hoofdstuk 2 is gebaseerd op een boekhoofdstuk en introduceert het fenotype dat wordt 
geassocieerd met het syndroom van Turner (TS). In dit hoofdstuk wordt de genetische 
etiologie van het syndroom besproken, het is de basis waarop ‘Deel I’ van dit proefschrift 
voortbouwt. In hoofdstuk 3 beschrijven we een retrospectief cohort van 96 patiënten met 
TS met gedetailleerde beeldvorming van de longvasculatuur. Eerdere studies suggereerden 
dat TS-patiënten een verhoogde incidentie van gedeeltelijk abnormale pulmonale veneuze 
terugkeer (PAPVR) kunnen hebben. Dit vermoeden wordt bevestigd in hoofdstuk 3 waar we 
aantonen dat circa 1 op 4 van al onze TS-patiënten een dergelijke PAPVR had. Met deze 
studie veranderde ook de klinische praktijk, aangezien geavanceerde beeldvorming bij deze 
patiënten nu routinematig wordt gecontroleerd op aanwezigheid van PAPVR. In hoofdstuk 
4 beschrijven we het begrip ‘health-related quality of life’ (HR-QoL): de gezondheid 
gerelateerde kwaliteit van leven. We beschrijven deze HR-QoL van 177 vrouwen met TS en 
onderzoeken de factoren die deze kwaliteit van leven beïnvloeden. Deze studie maakt deel 
uit van het ‘value-based health-care programma’ in het Erasmus MC. Value-based 
healthcare betekent gericht zijn op het verbeteren van resultaten die er het meest toe 
doen voor patiënten. Om dit te doen, moeten we eerst deze resultaten meten. In deze 
studie hebben we aangetoond dat vrouwen met TS een verminderde kwaliteit van leven 
ervaren, meer stress hebben en vermoeider zijn in vergelijking met gezonde controles. Wat 
daarnaast opviel is dat vrouwen met TS vaker individuele sporten te beoefenen, het vaakst 
hardlopen. We hebben ook onderzocht hoe tevreden TS-vrouwen waren met hun lichaam 
op een speciale schaal van 'lichaamstevredenheid'. TS-vrouwen waren het meest 
ontevreden over hun taille, lichaamsbouw, figuur, buik en gewicht. Deze resultaten, vooral 
ervaren stress en verhoogde vermoeidheid, kunnen nu als specifieke doelen voor 
verbetering van kwaliteit van leven worden gebruikt. In hoofdstuk 5 beschrijven we de 
systolische linkerventrikel globale llongitudinale strain (LvGLS) en linkerventrikel 
diastolische strain (Sre), een maat voor de functie, bij 94 volwassen vrouwen met TS en 
relateren deze aan hun klinische uitkomsten. Vrouwen met TS hadden een significant 
lagere systolische LvGLS (-17,82 ± 2,98% versus -21,80 ± 1,85%, p <0,001) en Sre 0,98 ± 
0,32 s-1 versus 1,27 ± 0,19 s-1, p> 0,001) in vergelijking met gezonde vrouwen. Bovendien 
hadden TS-vrouwen een verminderde diastolische functie, hoewel LvGLS en Sre 
vergelijkbaar waren tussen TS-patiënten met en zonder structurele hartziekte. Vrouwen 
met TS hadden ook een aanzienlijk lagere maximale inspanningscapaciteit, verminderde 
zuurstofopname en een verminderde maximale hartslag tijdens inspanning. In hoofdstuk 6 
wordt de anatomie van kransslagvaten van patiënten met TS vergeleken met die van 
patiënten met een bicuspide aorta klep (BAV). Deze studie toont aan dat patiënten met 




hebben van linker coronaire dominantie in de groep van TS-BAV evenals in geïsoleerde BAV 
(beide 38%). Daarnaast wordt afwezigheid van de linker hoofdstam vaker gezien bij 
patiënten met TS èn BAV (13%) in vergelijking met patiënten met geïsoleerde BAV (0%). 
Aortadilatatie is een belangrijke zorg bij TS-vrouwen. Vaak neemt de aortadiameter sneller 
toe in vergelijking met de algemene bevolking en is electieve chirurgie nodig. Daarom 
hebben we een groot retrospectief cohort van 268 TS-vrouwen bestudeerd met 
geavanceerde beeldvorming van de aorta. Hoofdstuk 7 gaat over aortadilatatie bij deze 
vrouwen met TS, een veelbesproken onderwerp in de TS-literatuur omdat het veel 
voorkomt en er veel factoren zijn, zoals groeihormoonbehandeling tijdens de kindertijd, die 
er mee in verband worden gebracht. In deze studie hebben we sommige van deze 
associaties bevestigd. Bovendien waren gelukkig aortadissectie en preventieve aorta-
chirurgie zeldzaam. 
 
Deel II    De Bicuspide Aorta Klep en Coarctatie van de Aorta  
 
Hoofdstuk 8 is gebaseerd op een boekhoofdstuk en dient als een inleiding tot ‘Deel II’ van 
dit proefschrift. In dit hoofdstuk wordt de-coarctatie van de aorta besproken, een vorm van 
aortapathologie die verweven is met zowel het syndroom van Turner dat in deel I is 
besproken als met de bicuspide aortaklep die in deel II wordt besproken. In hoofdstuk 9 
evalueerden we een nieuwe methode voor strainanalyse met behulp van 4D flow CMR. We 
tonen aan dat GLS-analyse mogelijk is met behulp van de magnitude datasets 
geproduceerd door 4D flow CMR met adequate beeldkwaliteit bij BAV-patiënten. GLS-
meting door CMR correleerde goed met CT en spikkelsporen 2D TTE. Hoofdstuk 10 richt 
zich op volumekwantificatie van de linker hartkamer met behulp van een nieuw algoritme 
op 3D echocardiografie datasets. In theorie maakt het gebruik van een volledig 
geautomatiseerde methode voor volumekwantificatie een gebruiker-onafhankelijke en 
daardoor zeer reproduceerbare meting mogelijk. Linker ventriculaire eind-diastolische en 
eind-systolische volumes en ejectiefractie berekend door de software en goed gecorreleerd 
met handmatige 2D en 3D echocardiografische metingen. Het linker atriumvolume 
correleerde significant, hoewel LHM het grotere linker atriumvolume schatte in vergelijking 
met zowel 2D- als 3D-echocardiografie. Dergelijke software kan helpen bij het overwinnen 
van enkele van de belangrijkste hindernissen bij het integreren van 3D-analyse in de 
dagelijkse praktijk, omdat het gebruikers-onafhankelijk is en zeer reproduceerbaar in een 
groep patiënten met BAV. Bicuspide aortaklep wordt vaak gezien samen met aorta-
coarctatie. Hoofdstuk 11 beschrijft de resultaten van 93 patiënten die stenting in de aorta-
coarctatie hebben ondergaan. Complicaties traden op bij negen (10%) patiënten, 




patiënten. De aortadissecties en -breuken werden met succes behandeld door een extra 
bedekte stent in te zetten. Twee patiënten stierven binnen 30 dagen na de indexprocedure. 
Na een gemiddelde follow-up van 3,2 ± 3,1 jaar waren bijna alle patiënten (98%) klinisch 
verbeterd en waren alle stents gepatenteerd. Herinterventie was nodig bij 10 (11%) 
patiënten. De vrijheid van herinterventie na 5 jaar was 85%. Twee extra patiënten stierven 
tijdens de follow-up van coarctatie-gerelateerde oorzaken, waaronder het scheuren van 
een geïnfecteerd transplantaat en viscerale ischemie. De overleving van de patiënt na 5 jaar 
was 89%. Deze studie toont aan dat endovasculair herstel van aorta-coarctatie effectief is 
en een acceptabel veiligheidsprofiel heeft bij de behandeling van nieuw gediagnosticeerd 
CoA en na eerste chirurgische reparatie. Het voegt eraan toe dat aortaruptuur een 
zeldzame (2%) maar verwoestende complicatie is met hoge mortaliteit. Het aantal 
herinterventies is acceptabel, met hoog procedureel en langdurig klinisch succes. 
Hoofdstuk 12 bouwt voort op het vorige hoofdstuk, waar stenten van een aorta coarctatie 
vaak veilig is kan dit bij vrouwen met TS (met een vasculopathie van de aorta), met een 
frailer aortawand als gevolg. Bij vrouwen is CoA een van de meest voorkomende 
aangeboren hartziekten (7-18%). Het oplossen van de aorta-vernauwing wordt in het 
algemeen beschouwd als een veilig alternatief voor de chirurgische aanpak in 
geselecteerde gevallen. De inherent zwakkere aortawand van TS-patiënten kan hen echter 
blootstellen aan een groter risico dan hun niet-TS-leeftijdsgenoten. Daarom was onze 
hypothese voor deze multicenter retrospectieve studie om de veiligheid van 
coarctatiestenting in een cohort van TS-patiënten te onderzoeken. TS is echter een relatief 
zeldzame ziekte en CoA bij deze patiënten is daarom nog zeldzamer. We hebben echt ons 
best gedaan om 19 patiënten met TS uit 10 centra te verzamelen die waren behandeld met 
percutane stent angioplastiek voor aorta-coarctatie. Drie (15,8%) bijwerkingen traden op 
binnen 30 dagen na de procedure, inclusief twee dissecties ondanks het gebruik van 
bedekte stents, waarvan één resulteerde in overlijden. Bij langdurige follow-up (6,5 jaar, 
min-max: 1-16) traden twee extra sterfgevallen op waarvan niet bekend was dat ze stent-
gerelateerd waren. Daarbij hebben we aangetoond dat, hoewel percutane behandeling van 
aorta-coarctatie bij TS-patiënten effectief is, dit gepaard gaat met ernstige morbiditeit en 
mortaliteit. Daarom suggereren deze risico's dat alternatieve behandelingsopties zorgvuldig 
moeten worden afgewogen tegen percutane stentstrategieën. Hoofdstuk 13 probeert een 
einde te maken aan de controverse over de vraag of het hebben van een CoA geassocieerd 
is met grotere aortadiameters en hogere complicaties. Deze studie beschrijft de uitkomst 
van 483 BAV-patiënten en evalueert of de coëxistentie van CoA geassocieerd is met aorta-
gebeurtenissen, aortadilatatie en aortadiametergroei. We concludeerden dat het naast 
elkaar bestaan van CoA niet was geassocieerd met een hoger percentage aorta-
gebeurtenissen, een hogere prevalentie van aortadilatatie of een sneller oplopende 
aortagroei. Daarom moet CoA niet worden gezien als een risicofactor die eerdere 




Deel III SMAD3  
In 2011 beschreef onze studiegroep voor het eerst het aneurysma-osteoartrose syndroom 
(AOS) veroorzaakt door een mutatie in het SMAD-3-gen. Hoofdstuk 14 beschrijft de lange 
termijn follow-up van uitkomst en aortadiameters bij deze patiënten. We tonen aan dat, 
hoewel deze patiënten nog steeds een hoog risico lopen, er geen sterfte was bij screening 
volgens het intensieve klinische follow-up protocol. Net als bij TS wordt de kwaliteit van 
leven bij deze patiënten aangetast. Hoofdstuk 15 onderzoekt voor het eerst bij 28 AOS-
patiënten hoe de subjectieve kwaliteit van leven en het onderzoeken van angst en 
depressie wordt beïnvloed door de last van deze ziekte. In vergelijking met de algemene 
bevolking scoorden AOS-patiënten aanzienlijk lager op de volgende SF-36-domeinen: fysiek 
functioneren, vitaliteit, sociaal functioneren, lichamelijke pijn en algemene gezondheid. 
Patiënten met AOS scoorden hoger op de HADS-depressieschaal, terwijl angst beleving 
geen significant verschil vertoonde in vergelijking met de algemene bevolking. Deze studie 
benadrukt dat de zorgen van patiënten voor hun toekomst en de erfelijkheid van hun ziekte 
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If you can force your heart and nerve and sinew 
To serve your turn long after they are gone, 
And so hold on when there is nothing in you 
Except the will which says to them: 'Hold on!' 
 
If you can fill the unforgiving minute 
With sixty seconds' worth of distance run, 
Yours is the Earth and everything that's in it, 
And - which is more - you'll be a Man, my 
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